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Chapter 1  Introduction 
 
The loss or failure of an organ or tissue is one of the most frequent, devastating, and 
costly problems in human health care. The cost of such failures to the US healthcare 
system is estimated at $400 billion annually (Langer and Vacanti, 1993).  Replacement 
of damaged organs has historically been carried out using either material from other 
non-damaged (and normally less sensitive) parts of the body such as with skin grafts, 
or using organs taken from either living or deceased donors. Both strategies give rise 
to issues. In the case of autologous material (self-donated), the removal of such 
material often brings greater complexity to an already highly traumatic procedure and 
can lead to risk of secondary infections. Autologous donation is also limited by the 
finite nature of the supply; only a limited number of blood vessels or skin may be 
donated without causing a problem of equal severity to that of the original trauma or 
disease. Allogeneic donation (donation from another individual) carries with it the risk 
that the organ will be rejected as the new host’s immune system recognises the 
material as foreign and attacks and destroys it. Immune suppressing drugs may be 
taking to limit the immune response and allow the organ to survive, such drugs 
however must be taken for life and carry a number of side effects such as a greater risk 
of infection due to the immune response being reduced. Additionally their non-
specificity cannot exert full control of the individual’s immune response and hence the 
graft will ultimately be rejected (Boyd et al, 2005).  Allogeneic vessels have an added 
disadvantage that demand normally hugely outstrips demand (Niklason and Langer, 
1997), with the waiting lists on most western nations  massively exceeding the number 
of available organs. 
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In recent years a variety of techniques have been explored as methods for either 
growing in-vitro replacement organs or by encouraging the regeneration of the 
damaged tissue through the use of growth factors and stem cells.  These would provide 
an attractive alternative if available as a clinical level treatment. 
 
Cardiovascular disease is a disease of the coronary arteries, those vessels that carry the 
blood supply to the heart. Symptoms consist of gradual accumulation of fatty plaque 
deposits within the cells forming the wall of the coronary arteries (Fig. 1.1).  If a 
plaque grows to a size where it occludes flow or becomes damaged and a section 
breaks off leading to an occlusion downstream then death of heart tissue may occur. If 
the blockage remains blocked and there is no alternative route for blood to reach the 
heart tissue then death will ultimately ensue. Normal causal and risk factors for such a 
disease and related to lifestyle with a genetic component.  
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Figure 1.1  Coronary Artery Bypass Graft (intensivecare.hsnet.nsw,gov.au) 
A cholesterol build up in one or more of the coronary arteries (as shown inset) reduces blood 
flow to the heart muscle. This reduced blood flow can result in damage and normally requires 
surgical intervention. Standard procedure is to bypass blockages using grafts created from 
veins in the leg (saphenous) or from arteries in the thorax (internal mammary artery). 
 
 
An artery is composed of three layers (Fig. 1.2). The intima, the section closest to the 
blood flow is formed of a single layer of endothelial cells, which are responsible for 
recognising chemical and physical signals and regulating vascular tone (Davies, 1995). 
The second layer, the media is composed of smooth muscle cells, which are 
specialised contractile cells that respond to endothelial cells and cause dilation or 
contraction of the artery (Owens, 1995). The third and final layer is composed of a 
support structure of collagen and fibroblasts and is called the adventis. Fibroblasts are 
dispersed throughout connective tissue within the body and can differentiate to form 
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smooth muscle cells. Their presence in the artery lends structural support and the 
ability to form new cells in the event of damage (Alberts et al, 1994). 
 
 
Figure 1.2  Human artery structure 
The artery is composed of three main layers. The innermost layer, the intima, is in contact 
with blood flow and is composed of a single layer of endothelial cells. These endothelial cells 
respond to physical stimuli (mechanotransduction) and chemical stimuli (chemotransduction). 
The media is the middle layer of the artery and is composed predominantly of smooth muscle 
cells (SMC). These SMC control the vasoconstriction (contracting) and the vasodilation 
(expanding) of the artery in response to stimuli from the endothelial cells. The final layer, the 
adventitia, consists of connective tissue interspersed with periodic fibriblasts.  
 
Within the United States alone 58 million people suffer cardiovascular disease. This 
has led to around 550,000 vascular bypass surgeries being carried out within the 
United States each year (Xue and Greisler, 2000).  In terms of all operations occurring 
where vascular conduits are required (includes Arterial-venous shunts for dialysis) and 
autologous, allogenic or synthetic small calibre conduit is required, the estimate is 1.4 
million per year (Langer and Vacanti, 1993). 
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The aim of this chapter is to provide an overview of the need for new treatments for 
cardiovascular disease, one of the largest causes of morbidity within western nations. 
This literature review will extend to current engineering and regenerative medicine 
strategies for treating cardiovascular diseases and the devices within which this takes 
place. Particular attention will be given to automation of these devices and the 
methods employed to maintain and control the environmental conditions required to 
sustain cellular growth. Consideration will also be given to the use of bioreactors and 
similar devices both within tissue engineering, for treatment of other conditions and 
within different but related fields such as industrial fermentation. These systems will 
be analysed to determine how existing technology may assist in advancing and 
improving automation in a device designed for producing a tissue engineered artery.  
1.1 Traditional treatment of coronary artery disease 
1.1.1 Autologous graft 
The usual treatment for coronary artery disease is an autologous therapy using veins 
from alternative parts of the patient’s own body to bypass the blockages. Surgeons 
remove a segment of a healthy and accessible blood vessel from a number of possible 
parts of the body and us it to make a detour of blood flow around the blocked part of 
the coronary artery. Most operations of this nature use vessels <5-6mm in diameter 
(Niklason and Langer, 1997; L’heureux, 1998). 
A piece of long vein from the patient’s leg (saphenous vein) may be taken. One end is 
sewn onto the large artery connecting the heart to the aorta. The other end of the vein 
is attached or "grafted" to the coronary artery below the blocked area. Alternatively 
and more unusually an artery may be detached from the chest wall and the open end 
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attached to the coronary artery below the blocked area. In both case the graft provides 
a new pathway by which blood may reach the heart muscle. Patients may receive one, 
two, three or an even greater number of such bypass grafts, depending on how many 
coronary arteries are blocked. 
The disadvantages of autologous transplants are significant. The procedure requires an 
additional operation to harvest the vessel, which may lead to further complications. 
The side branches of the extracted vein must be stitched closed which is an intricate 
procedure and often the pain arising from the extraction of such a vessel is generally 
excruciating and is often the greatest source of complaint from the recovering patient  
Harvested veins used are structurally adapted for a low-pressure environment and are 
being used to replace an artery carrying high-pressure blood flow a change that does 
not come without consequence (Cox et al, 1991). Problems relating to difference in 
vessel compliance between the graft and in-situ artery can occur, aneurysms can form 
where the lumen dilates due to the vein being insufficiently adapted to deal with 
arterial pressures (Teebken and Haverich, 2002) and even in extreme cases rupture 
(Nwasokwa, 1995). More gradual failures can also take place, ex-vivo experiments 
mimicking the early effects of native conditions compared with the environment 
experienced by vascular grafts were shown to lead to reduced matrix 
metalloproteinase by half and stimulate cell proliferation rates of 220-750% of normal 
leading to thicker vessel walls in response to the increased pressure. This may lead 
eventually to intimal hyperplasia (uncontrolled cell growth) that could contribute to an 
occlusion of the graft. (Mavromatis et al, 2000).  
Saphenous veins have been shown to have long-term limitations due to occlusion of 
the graft. The most common cause for this occlusion is a progression of 
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atherosclerosis. After 10-12 years 40% of vessels are blocked, 18.9% contain 
blockages obstructing at least half of the cross sectional area of the artery and 8.1% 
showed some evidence of atherosclerosis (Bourassa, 1984). These occlusions lead to 
further operations that carry increasing risk to the patient but also may result in a 
shortage of useful autologous vessels. Internal mammary arteries from the chest have 
been shown to have a significantly longer lifespan (Grodin et al, 1984). The 
disadvantage of using these vessels is that they are significantly shorter in length and 
thus they may only be used to bypass blockages arising at the initial (proximal) length 
of the coronary artery. Additionally a more complex operation is required to harvest an 
internal mammary artery and hence they are inappropriate for emergency surgery 
(Angelini and Newby, 1989, Markusen, 2005). In order to compensate for the finite 
supply of autologous vessels attempts to use vessels derived from animals (xenogenic) 
have been made (Rosenborg et al, 1966), although the use of animal products risks 
transmission of animal borne diseases (Fishman, 2006) and long term patency is poor 
due to rejection or formation of thromboses (Stock and Vacanti, 2001). Allogeneic 
vessels from cadavers have also been tested however unsuccessful results similar to 
xenografts have been attained with rejection and a higher risk of aneurysm than 
synthetic vessels (Madden et al, 2006).  
1.1.2 Synthetic graft 
Vorhees developed the first synthetic graft more than half a century ago in 1952, 
called Vinyon and composed of fabric (Vorhees et al, 1952). Currently the most 
widely used synthetic materials are poly-ethylene-terepthalate (Dacron) and expanded 
poly-tetra-fluoroethylene (e-PTFE). These materials although originally designed to be 
chemically inert are not capable of passively transporting blood flow without reaction. 
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Some of these reactions are beneficial, whilst others are damaging, however no 
reaction would be preferable (Xue and Griesler, 2000).  Synthetic grafts while 
demonstrating long term function for more than 10 years when used as large diameter 
grafts (Hoerstrup et al, 2001) have been shown to have particularly poor patency for 
smaller diameter grafts (<5-6mm). This is especially so for grafts used below the knee, 
where low blood flow and high resistances increase the risk of thromboses (Yeager, 
1982). Adaptations have been made to these vessels to try and make them more 
biologically compliant including coating the internal surfaces of the vessels with 
proteins, particularly components of the extra cellular matrix, usually containing the 
RGD tripeptide (Deutsch, 1999). Such vessels have even been coated with autologous 
endothelial cells (Lamm et al, 2001) which may potentially be obtained from 
peripheral flow within the patient (Mooney, 2001), although it appears that no surface 
treatment will entirely eliminate the low level immune response caused by recognising 
the graft as a foreign body (Greisler, 1990).   
1.2 Tissue engineering bypass grafts 
A major new initiative in the treatment of coronary artery disease is to grow grafts in-
vitro within an environmentally controlled device (bioreactor) from small quantities of 
biological material that may be harvested from the human body. Such a procedure is 
referred to as tissue engineering, the use of the biological material as a raw material to 
create necessary tissues and organs to replace those that are damaged or failing. 
The term “tissue engineering” is generally credited to the use by Y.C. Fung at the 
University California, San Diego in 1985 and was proposed at the National Science 
Foundation (NSF) meeting within the United States in 1987 for wider use. A further 6 
years were required before the term had entered the scientific zeitgeist sufficiently that 
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the first major review publication (Langer and Vacanti, 1993) occurred. Tissue 
engineering was defined as an interdisciplinary field involving the application of the 
principles of biology and engineering to the development of functional substitutes for 
damaged tissue. The usual interpretation involves placement of cells on or within 
scaffold matrices to encourage tissue growth into a suitable structure that may be 
implanted into the patient to fulfil either the same role or an analogous one as was 
carried out by the original in-vivo tissue or organ. 
  
The first attempt at developing a tissue-engineered artery or graft used a Dacron mesh 
as a support scaffold for seeded fibroblasts and smooth muscle cells. The lumen of this 
vessel was subsequently coated in endothelial cells. The graft produced by this 
method, although healthy did not posses sufficient strength to withstand arterial 
pressure, possessing a burst pressure of 318mmHg compared with approximately 
2000mmHg in a native artery (Weinberg and Bell, 1986). 
 
Recent attempts have considered burst pressure to be a key parameter within their 
work (L’heureux et al, 1998) and developed a vessel that could withstand arterial 
pressures by a “sheet based method” (L’heureux et al, 2007) without the use of a 
synthetic support. A sheet of vascular smooth muscle cells was formed into a sheet, 
rolled around a tubular support and subsequently wrapped with a second sheet 
consisting of fibroblasts. Following maturation and the removal of the central support 
scaffold, endothelial cells were seeded into the lumen to provide the third key 
component of an in-vivo artery (Fig. 1.3).  
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Figure 1.3 Engineered artery at 9 weeks maturation (L’heureux et al, 1998). 
L’heureux’s tissue engineered artery is composed of a fibroblast sheet rolled into a tube and 
coated in endothelial cells. L’heuruex et al, excluded smooth muscle cells (SMC) from their 
design due to the limited number of divisions such cells proved capable of performing. The 
presence of gradually increased amounts of smooth muscle actin (SMA), a marker of SMC, 
indicated that such cells may develop naturally through the differentiation of fibroblasts. 
           
           
     
L’heureux’s group recognised that the thickness of the fibroblast sheet and hence the 
culture time of this component was the key parameter in developing a vessel by this 
method that possessed a bursting pressure that compared favourably with in-vivo 
ateries (∼2000mmHg) and was superior to the saphenous vein (1680±307 mmHg). 
Subsequent work by this research group eliminated smooth muscle cells due to their 
low proliferative capacity and has led to improved vessel burst pressure of 
3468±500mmHg for vessels of 4.5mm diameter and 3688±1865mmHg for 1.5mm 
diameters. Despite the absence of this SMC layer, the presence of a SMA positive cell 
population indicates remodelling may be regenerating the vascular media. One 
disadvantage of such tissue engineered vessels is that a 28 week production time 
prevents the use of these vessels in an emergency situation. Work has demonstrated 
the effectiveness of such grafts as arteriovenous shunts for human patients receiving 
dialysis due to kidney failure. The first six patients in such a study at the time of 
publishing the results had been followed up for 13 months and were performing well 
(L’heureux et al, 2007). This work followed studies testing the vessels in rats as 
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abdominal interpositional graft, a study that also yielded successful results (L’heureux 
et al, 2006).  
 
(Niklason et al, 1999) were also able to grow arbitrary lengths of vascular graft from 
smooth muscles endothelial cells. These cells were obtained from bovine vascular 
biopsies and possessed a rupture strength >2000mmHg. Smooth muscle cells (SMC) 
were obtained from the medial layer and pipetted onto treated tubular biodegradable 
polystyrene scaffolds. Following thirty minutes to permit adhesion, pulsatile flow (165 
beats per second) was applied to the seeded scaffolds sited within a bioreactor system 
consisting of four parallel perfusion bioreactors containing the developing grafts. 
These bioreactors were sited on a hot plate maintained at 37oC with flow gradually 
being increased from 0.033 to 0.1 ml.s-1 (equivalent to a shear stress of 1x10-2 and 
3x10-2 N.m 2).  
 
The translation of this technique into humans posed problematic due to species and 
age differences, SMC from elderly people possess a limited proliferative capacity. 
Gong and Niklason (2008) explored the potential of human mesenchymal stem cells 
(hMSC) as a replacement for smooth muscle cells based upon their autologous nature, 
high proliferative capacity and a multipotent nature that allows differentiation into 
multiple cell lineages including fat, muscle, bone and connective tissue progenitors 
(Pittenger, 1999).  They showed that factors such as TGFβ1 could be used to induce 
these hMSC into early stage smooth muscle cells. It was also shown that while 
cyclical strain enhanced proliferation smooth muscle cells, it inhibited proliferation of 
hMSC although it did increase smooth muscle actin (SMA) expression in existing 
hMSC of in the presence of PDGF-BB, possibly indicating differentiation down a 
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SMC lineage. These results led Gong and Niklason (2008) to develop an optimised 
protocol of operating the bioreactor in two separate operational forms, four weeks for 
proliferation of cells throughout the scaffold and four weeks for differentiation of the 
cells into smooth muscle, followed by seeding the resulting smooth muscle tube with 
endothelial cells (EC). The successful proliferation of these seeded cells was taken as 
an indication that by deriving EC as well as SMC from hMSC, the goal of a marrow 
derived vascular replacement may soon be achieved.   
 
Shinoka’s group in Japan, initially used saphenous veins harvested from the leg. These 
veins were minced and seeded onto scaffolds to form grafts (Shinoka et al, 2001). 
Such an approach was discontinued as harvesting the cells could induce infection just 
as with standard bypass grafts and there was the possibility that the cells obtained 
would have insufficient proliferative capacity. Additionally these cells required animal 
serum to grow, which raises concerns about the use of the vessels in humans. These 
concerns led to the use of bone marrow cells, which in addition to not having many of 
the disadvantages listed above, require less cell culture media and other reagents 
which reduces the financial cost of the procedures. These cells were seeded into a 
tube-shaped biodegradable polymeric scaffold by pipetting and this scaffold was kept 
in culture for 2-4 hours until implantation into the patient. Four implantations into 
patients have been demonstrated to date – two using saphenous veins and two using 
bone marrow cells. In all instances the implanted vessels have demonstrated excellent 
post-operative flow (Matsumura, 2003).  
 
The successes of these groups indicate that the hope of developing tissue engineered 
arteries to solve many of the problems associated with more conventional treatments 
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based on autologous harvesting or use of synthetic materials may soon be a possibility. 
Many of these techniques are still at a very low scale, with small numbers of patients 
receiving treatment. Given the scale of the patient body, consideration of the potential 
for scale out to a manufacturing level is required, as this will be the ultimate goal. 
Such scale out requires detailed consideration of the process and the key stages that 
make up a tissue engineering process. 
  
1.3 Tissue Engineering Processes 
 
The process involved in engineering a graft has great relevance on the potential for 
scaling out. Any process has two key aspects, firstly the raw materials required (for a 
tissue engineered artery - cells, culture medium and support scaffold) and the steps 
that make up the process. 
 
1.3.1 Raw Materials 
 
The main raw material of cell culture is the cell themselves, the types used within the 
development of tissue engineered arteries range from mature cells (those with limited 
proliferative capacity present in the human body) to embryonic stem cells (cells 
derived from early stage embryos). Each cell type has varied culture conditions and 
that are commonly related to the conditions they would experience within the 
microenvironment within which they reside in-vivo. Cells will often react to different 
culture conditions in different ways that are not limited to the health of the cell. This is 
most noticeable with progenitor cells, which can often be driven down particular 
differentiation pathways by modifying chemical and physical conditions. 
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1.3.1.1 Mature Cells 
 
Mature cells used for engineering arteries tend to be those that are present natively in 
the mammalian artery and include endothelial, smooth muscle cells and fibroblasts in 
order of layer from the lumen outwards. Endothelial cells form the lining of all blood 
vessels within the mammalian body (Alberts et al, 1994). They are responsible for 
regulating vascular tone, arterial tone, arterial structure and remodelling through a 
process known as mechanotransduction (Davies, 1995). One of the responses to these 
transduced signals is the release of vasoactive substances such as nitric oxide synthase 
(NOS), which causes an increase in the synthesis and release of nitric oxide to produce 
vasodilatation or trophic changes in the artery (Burnstock, 1998). In addition to shear 
stress, endothelial cells respond to multiple chemical factors within the blood flow. 
Indeed the general health of the arterial wall is directly linked to the shear and 
chemical impulses experienced by the endothelium and the resulting 
mechanotansduction and linked responses (Davies, 2005).  
 
 Platelet endothelial cell adhesion molecule (PECAM-1 or CD-31) a surface 
glycoprotein represents a common method of identifying a cell as endothelial. It is 
known to regulate calcium signals (Ji et al, 2002), control the passage of materials and 
white blood cells (Alberts et al, 1994) as well as apparently being part of a 
mechanosensory complex (Tzima et al, 2005). This marker has the added advantage as 
an endothelial marker as it is not present on fibroblasts, muscle or other non-vascular 
cells (Newman, 1997). In a similar way endothelial cells may be identified by VE-
Cadherin (CD-144) a strictly endothelial specific adhesion moelecule that is found at 
 29 
junctions between endothelial cells. It is directly involved in regulating permeability 
through the endothelium and is implicated in the same mechanotransductory pathway 
as CD31 (Vestweber, 2008, Tzima et al, 2005). 
 
The dependence of the artery’s health upon the endothelium means that it must form a 
key part of any tissue engineered arterial graft that is intended to be truly analogous to 
the arteries found natively in-vivo. 
 
The second layer of the artery is formed from vascular smooth muscle cells (VSMC). 
VSMC are highly specialised cells with the primary function of contraction. The cell is 
so specifically designed once mature and fully differentiated that its proliferation rate 
is very low, as the majority of its energy and resources are reserved for contraction 
(Owens, 1995). The key markers for positive identification of VSMC are the SMA 
(Smooth Muscle Actin) Proteins which are directly associated with the cells’ 
contractile properties. Matrix GLA Protein is also expressed preferentially in late 
passage de-differentiated VSMC and is particularly strongly expressed in aortic 
VSMC but not in other smooth muscle cells (Shanahan et al, 1993). 
 
The final and outer layer of the artery is composed of fibroblasts within an extra-
cellular matrix. Fibroblasts are dispersed within connective tissue within the body, and 
are responsible for secreting a non-rigid extra cellular matrix that is rich in collagen. 
At injury these cell will migrate to the site of the wound and secrete this collagen to 
isolate and repair the wound (Alberts et al, 1994). 
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Mature cells, although an obvious source of material for forming tissue engineered 
arteries, have disadvantages, particularly in the case of smooth muscle cells, which 
possess a limited proliferative capacity, particularly when extracted from ageing 
donors (Owens, 1995, Gong and Niklason , 2008).  
 
1.3.1.2 Mesenchymal stem cells (MSC) 
Mesenchymal stem cells (MSC) are multipotent cells found within adult humans (and 
other mammalian species). Multipotent cells are stem cells, which are capable of 
differentiating (becoming after a number of cell divisions) to form a number of mature 
cells. In the case of MSC, which are normally located within the mammalian bone 
marrow at a proportion of between 1 in 10,000 and 100,000 (Deans and Moseley, 
2000, Galotto, 1999) this capability manifests itself as the potential to form into 
connective tissue, fat, muscle or bone (Pittinger et al, 1999). Such cell lines are often 
referred to as adult stem cells as they can be found in mature individuals of a species 
and are responsible for the continual regeneration and repair of the organism’s body.  
MSC have been shown to be capable of differentiating down a pathway towards 
smooth muscles cells and have been used in the growth of vascular grafts (Gong and 
Niklason, 2008). They have also been differentiated into endothelial cells in the 
presence of 2% fetal calf serum (FCS) and vascular endothelial growth factor (VEGF) 
(Oswald et al, 2004). Transplantation studies have even been performed and the results 
show that MSC appear to enter circulation from the bone marrow and engraft other 
tissues. It also appears that MSC may be normally present within arterial vessel walls. 
Such a presence indicates their role in vascular regeneration and regeneration may be 
extensive (Abedin et al, 2004). 
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As with many stem cells, there is no single test that identifies MSC with complete 
confidence and they tend to be identified using a panel of surface antigens including 
CD13, CD29, CD44, CD90, CD105, SH-3 and STRO-1 and by not possessing 
haemopoietic markers such as CD45, CD34, CD11 and CD14 (Koc and Lazarus, 
2001). The murine monoclonal antibody STRO-1 identifies a surface antigen 
expressed by stromal elements within the bone marrow and will not attach to 
committed progenitor cells (Simmons et al, 1991) however it still lacks specificity to 
MSC. The lack of a single marker to easily distinguish has led to techniques that 
involve selecting for MSC based upon rapid adherence to tissue culture plastic and 
their high proliferative potential in 10% fetal calf serum (FCS) (Koc and Lazarus, 
2001), although (Wan et al, 2006) showed that this method removes a non-adherent 
population of cells that possess mesenchymal characteristics. Despite this loss 
however the standard procedure remains rapid plastic adherence, a technique that has 
provided MSC that have ultimately been used to form grafts that have subsequently 
been implanted successfully into patients (Gong and Niklason, 2008, Matsumura, 
2003).  
1.3.1.3 Embryonic stem cells 
Embryonic stem cells are derived from the inner cell mass of an early embryo 
(Wolpert, 2006) the first human cell line was created in 1998 (Thomson et al, 1998). 
These cells are capable of dividing into any of the three germ layers (the developing 
regions in an embryo) (Donovan and Gearhart, 2001) and are referred to as 
pluripotent. In vivo, the three germ layers are the endoderm (including the 
gastrointestinal tract and stomach), ectoderm (including the nervous system) and 
mesoderm (including the muscle, bone and blood). The only cells that embryonic stem 
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cells are not capable of differentiating to form are those that become extra-embryonic 
material, such as the placenta. This inability prevents embryonic stem cells from 
developing into a living organism  (Alberts et al, 1994).  
There is also suspicion that many tumours contain a small central population of rogue 
stem cells reproducing uncontrollably (Andrews 2006). Teratocarcinomas which are 
often found in the reproductive organs of males and females are composed of cells that 
have been termed embryonic carcinoma stem cells as they seem able to produce all the 
cells found in an adult organism i.e. they are also pluripotent (Robertson ,1987). 
 
As with mesenchymal stem cells, several markers exist that seem to express strongly 
in cells that are pluripotent and these include the transcriptional regulators OCT-4 
(Nichols et al, 1998), Nanog (Chambers et al, 2003) and Sox 2 (Avilion et al, 2003). 
However at the current time many of these remain merely potentially useful as little or 
nothing is known about the role they play in maintenance of pluripotency and self 
renewal (Draper et al, 2007). 
 
Embryonic Stem Cells being pluripotent theoretically have the potential to form any of 
the more than 200 cell types found in the mammalian body, however much of this 
proliferative capacity has not yet been investigated.  
 
Despite this (Yamamoto et al, 2005) showed that Flk-1 (a receptor for VEGF – 
Vascular Endothelial Grown Factor) positive murine stem cells could be induced to 
form vascular endothelial cells in vitro by the application of shear stress. This 
differentiation was characterised by an increase in the expression of VE-cadherin and 
PECAM-1, and although there was an initial increase in smooth muscle actin (SMA), 
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this later decreased. This work was later continued (Shimizu et al, 2007) and it was 
shown that by seeding FlK-1 positive cells onto flexible silicone membranes and 
exposing them to controlled levels of cyclic strain (4-12% strain, 1Hz, 24 hours) 
expression of some endothelial markers such as Flk-1 decreased (others such as VE-
Cadherin did not) and led to dose –dependant increases in SMA and smooth muscle 
heavy chain (SMHC).  
 
 (Levenberg et al, 2002) derived endothelial cells from human embryonic stem cells 
expressing PECAM-1. These cells were able to differentiate and form tube structures 
and when transplanted in-vivo into severe combined immunodeficient (SCID) mice, 
were even able to form microvessels containing mouse blood vessels.  
 
These results indicate that although embryonic stem cells have great potential for use 
as a raw material in tissue engineering, there is still far too little understanding with 
regard to what effect a particular chemical or physical impulse will cause upon a cell.  
 
A more long-term problem with the use of embryonic stem cells to form mature cells 
for use in tissue-engineered blood vessels is the lack of specificity to the patient.  
 
Embryonic stem cells cannot be harvested autologously as they are formed from an 
embryo of which no cells remain at birth. Attempts have been made to create 
genetically matched stem cells using a process known as somatic cell nuclear transfer 
(SCNT). SCNT involves the removal of a nucleus from a cell belonging to the 
individual who will ultimately be treated and implanting it into an egg cell which has 
also had its nucleus removed. Such techniques using an established cell line rather 
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than cells either from or derived from embryos was first used to clone sheep 
(Campbell et al, 1996) and subsequently several other mammals (Wilmut and 
Peterson, 2002). Although the cloning of human beings is illegal in most jurisdictions 
the intent is to use such techniques to give rise to embryos that have the same genetic 
code as the target patient and harvest cells from the inner mass as with normal 
embryonic stem cells to create a matched line. To date SCNT in humans and many 
primates has been unsuccessful, although success was claimed by a group in South 
Korea (Hwang et al, 2005 Retracted) which was later proved false and has not led to 
the hoped for production of patient specific embryonic stem cells. 
 
A series of recent investigations have led to the formation of cells that possess 
embryonic characteristics from skin-derived fibroblasts by the addition of four genes 
Oct ¾, Sox 2, Kf4 and Myc in a murine animal model (Yamanaka, 2007) and repeated 
use of human fibroblasts (Takahashi et al, 2007). Subsequently (Junying et al, 2008) 
achieved similar successes without the use of Myc, which has been implicated in 
murine research as a potential cause of cancer, instead using the gene LIN28, which 
has been implicated in murine research as a potential cause of cancer. After up to 17 
months these four lines of induced pluripotent stem cells  (iPS) still possessed the 
morphology of typical embryonic stem cells and possessed a normal karyotype. These 
cells have not yet been conclusively proven to be embryonic stem cells and hence may 
behave in ways very different when placed under certain conditions. Mason (2008) 
points out that Yamanaka and Thomson are at pains to acknowledge introducing genes 
into cells using disabled viruses can introduce cancer as has happened in France by 
treating severe immunodeficiency diseases by the sufferers’ modified bone marrow 
cells (Fischer et al, 1990). This step does however at this time seem to provide more 
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hope of leading to cells that may be patient specific and be used to create tissue 
engineered blood vessels. 
 
In summary, with mature cells (particularly smooth muscle cells) suffering from a 
reduced proliferative capacity and embryonic stem cells being simply too recent a 
development to be sufficiently understood, the most viable cell type for use in the 
development of tissue engineered artery or bypass grafts that mimic the physiology of 
native vessels is the mesenchymal stem cell, harvested from the bone marrow. Despite 
the lack of development in purification techniques and a definite marker extensive the 
creation of blood vessels using this raw material have been achieved (Matsumura, 
2003, Gong and Niklason, 2008). 
 
1.3.2 Cell Culture Media 
 
The growth of adherent mammalian cell cultures requires a complex cocktail of 
essential amino acids, glucose and growth factors. Common procedure is for a defined 
medium base such as Dulbecco’s Modified Eagle Medium (DMEM) to have foetal 
calf serum (FCS) added to it. Serum is the liquid component of blood with fibrinogen 
and clotting factors removed and contains a rich mixture of proteins that allow cells to 
grow, divide and remain healthy (Freshney, 2000). The addition of FCS is undesirable 
as it ensures that the resulting medium is not fully defined and given the methods of 
FCS production and variety of source, experimental conditions cannot be deemed 
entirely consistent. The animal derived nature of FCS leads to the same concerns as 
those associated with the use of xenogeneic cells such as disease transmission (Griffith 
and Naughton, 2002). The DMEM base contains substrates such as glucose and 
glutamine that the cells can use in respiration to produce energy, grow and proliferate. 
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It will also often contain a visual pH indicator such as phenol red to indicate an excess 
concentration of waste product, either necessitating the exchange of the medium or in 
the case of a contamination, disposal of the flask. 
 
Some success has been achieved with developing fully defined culture medium. 
(Ludwig et al, 2006) demonstrated the growth of human embryonic stem cells in a 
defined media that still contained some animal derived components.  Despite an 
entirely animal free media not yet having been developed, the belief within the stem 
cell community is that this advance will take place soon (Hoffman, 2005). 
 
A major component of wound healing and normal maintenance of all organisms is 
tissue remodelling. This remodelling is dependant upon a set of growth factors and 
cytokines. Along with their receptors these factors dictate the type of cell or tissue that 
will respond and the expression level of their genes will dictate the length of the 
associated response (Deuel and Zhang, 2000). The most relevant growth factors in the 
development of blood vessels are endothelial cell growth factor (ECGF), vascular 
endothelial growth factor (VEGF), endothelin-1 (ET-1), platelet derived growth factor 
(PDGF) and basic fibroblast growth factor (bFGF).  
 
In terms of the relevance, these growth factors have for the tissue engineering of blood 
vessels, VEGF a regulator of angiogenesis (Ferrara et al, 2003) has been demonstrated 
to direct MSC down an endothelial path (Gong and Niklason, 2008, Riha et al, 2007) 
used cyclic strain to activate PDGF-β and drive murine embryonic stem cells toward 
forming vascular smooth muscle cells. Seruya (2004) achieved similar results to both 
of these works, maintaining smooth muscle progenitor cells from muscle as EC using 
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media containing VEGF and then causing them to differentiate down an SMC pathway 
by the addition of PDGF-β. bFGF has been shown to stimulate the growth of 
endothelial cells in denuded arteries and also stimulated growth in quiescent 
endothelium (in the left carotid denude six week prior to bFGF addition. (Lindner et 
al, 1990). 
 
These results indicate that growth factors could be highly relevant in the formation of 
tissue engineered arteries, particularly where progenitor cells such as MSC are 
involved. Although such factors can encourage division down particular routes, the 
ideal operation scenario in the long term should be to replicate in-vivo conditions to 
encourage cellular production, leading to the desired differentiation product. Methods 
such as controlled cyclical strain (Riha et al, 2007) could potentially lead to a much 
better quality of tissue than merely supplementing the medium with an arbitrary 
amount of a particular factor. 
 
1.3.3 Polymeric Scaffolds for Tissue Engineering 
 
To form a three-dimensional biological structure, the use of a scaffolding material is 
usually required. With the exception of the work of L’heureux (1998) most tissue 
engineering blood vessels have employed some sort of a support scaffold. This 
scaffold is normally formed from a polymeric or alginate material.  As stated by 
Hutmacher (2000) such a scaffold should possess the following characteristics. 
 
• It should encourage growth 
• It should encourage cell adhesion (most mammalian cells are adherent) 
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• It should ensure adequate distribution of supplied nutrients 
• It should be biocompatible 
• It should possess a structure that is coherent with the organ/tissue to be 
grown. 
• It should be degradable, i.e. bioresorbable or similar and in breaking 
down, should not lead to the formation of by-products that are 
cytotoxic. If the scaffold is not degradable it should not provoke an 
immune response. 
 
Williams (2003) in expanding upon the term biocompatibility, commented that 
materials should be selected on the basis of optimal mechanical or physical properties 
and optimal inertness and the chance of success is highest. 
 
A tissue scaffold can encourage growth by replicating aspects of the natural 
environment that the cells and developing tissue would experience in-vivo. Ensuring a 
homogenous distribution of cells when seeding encourages growth of cells throughout 
the scaffold body to produce a distinct three-dimensional structure. A high porosity 
and surface to area ratio will contribute to this proliferation through the scaffold and 
also allow the distribution of nutrients to the developing cells and the transport of 
waste products away (Li et al, 2002, Yang et al, 2001, Hutmacher, 2000). 
 
Aspects such as surface roughness and mechanical strength are examples of such 
properties that should be carefully controlled (Yaszemski M et al, 1995).  Mechanical 
strength is especially important for the development of hard load-bearing tissue. Often 
scaffolds for these tissues e.g. bone and other structures composed of softer tissue such 
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as arteries (Matsumura, 2003) can be dual purpose, allowing development of suitable 
tissue whilst simultaneously mimicking the tissue until it is fully developed. The 
mechanical strength of the scaffold and other physical properties should be as close to 
the original structure as possible and should remain at an appropriate level until the 
replacement tissue is completely developed (Yaszemski M et al, 1995, Hutmacher, 
2000). Strength should not be prioritised at the expense of biocompatibility. Any 
material intended for transplant in vivo must be biocompatible and non-toxic within 
the human body (Vande Vord et al, 2001).  
 
Ideally any scaffold would gradually break down without producing cytotoxic 
products (Griffith and Naughton, 2002) at a rate equivalent to the generation of the 
new tissue/organ. This would provide physical space for further growth and stimulate 
the formation of a tissue or organ of approximately the same shape as the original 
Hutmacher (2000). In the case of certain in-vivo transplants it is important that certain 
properties of the scaffold remain until it can be guaranteed that the new tissue has 
attained the required mechanical strength to carry the weight that will be placed upon 
it e.g. bone or joint tissue will require some degree of mechanical strength.  
 
It is essential that the cells initially seeded and those that subsequently develop attach 
strongly to the surface of the scaffold to avoid being displaced by shear effects from 
nutrient flow (Kim and Mooney, 1998).  The scaffold should possess suitable surface 
chemistry to encourage cell adhesion of appropriate strength. The majority of 
materials used to modify the surface of such scaffolds are those found within the in-
vivo ECM such as fibronectin and almost all contain a tripeptide chain (Arginine-
glycine-Aspartic acid - RGD) that is critical to binding within the ECM. Components 
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containing RGD may be either immobilised on the surface of scaffolds or when 
binding to hydrrogels by mixing with the monomers prior to polymerisation 
(Saltzman, 2000). 
 
Materials that have been used in the production of tissue-engineered arteries include 
collagen, a key part of the extracellular matrix forming blood vessels. Weinberg and 
Bell (1986) formed an artery structure from a series of collagen layers containing 
seeded fibroblast, SMC and EC. Such a structure had an insufficient burst pressure to 
withstand in-vivo stresses. Further improvements have subsequently been made in the 
design, including increasing collagen concentration (Hirai, 1994), adding sugars to the 
culture medium to chemically strengthen the collagen matrix (Girton, 2000) and using 
cyclic strain to encourage cellular led reorganisation of the collagen structure to 
increase the burst strength to in excess of physiological levels (Seliktar, 2000). 
 
Biodegradable polymers such as poly-L-lactic acid (PLLA), poly-glycolic acid (PGA) 
and poly-lactide-co-glycolide (PLGA) originated as implanted sutures that dissolved 
in-vivo and have been used for many years (Saltzman, 2000). Because of this use as 
sutures they are FDA approved and hence highly used in tissue engineering (Teebken 
and Haverich, 2002). Mooney et al (1995) formed a tube that could be seeded with 
bovine aortic smooth muscle, by wrapping PGA squares around a Teflon cyclinder of 
3mm diameter and spraying PLLA or PLGA onto the surface as it was rotated using 
an atomiser. PGA despite being a versatile material and highly porous will begin to 
degrade after one day in aquaeous solution (Hutmacher, 2000). Mooney et al (1995) 
found a combination of PGA and PLLA lasted 11 weeks in solution whilst PGA 
coated with PGLA had lost only 30% mass after 10 weeks. Hutmacher (2000) 
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comments that the use of such polymers is risky in areas with low vascularisation or 
blood flow as the build up of byproducts can lead to temporary disturbances where the 
removal rate is low. This does not affect the ability of such material to be used for 
tissue engineering blood vessels, as the constant blood transport will transport the 
degrading polymer to the kidneys at a high rate where it may be excreted. Greisler et 
al (1993) observed PGA residues leading to the dedifferentiation of SMCS into 
fibroblast like cells but despite this PGA based scaffolds have been used by several 
groups within bioreactors designed to produce tissue-engineered blood vessels 
(Niklason et al, 1999, Hoerstrup et al, 2001, Kim et al, 1999) which may suggest PGA 
byproduct build up was not the cause (McFetridge and Chaudhuri, 2005). 
 
Hydrogels such as sodium alginate have been used for a variety of biomedical 
applications (Kuo and Ma, 2001, Mongia et al, 1996). Alginate is a polysaccharide 
composed of repeating units of gluronic acid (G) and mannuronic acid (M), derived 
from seaweed and is cheap and abundant (Kuo and Ma, 2001) and biocompatible 
provided high molecular weight components are eliminated (Zimmerman, 2000). 
Alginate may be gelatinised by addition of calcium chloride, which causes cross-
linking of the polymers. This cross-linked gelatinised form provides a flexible material 
with which may be moulded to form a variety of 3- dimensional tissue engineering 
scaffolds. Alginate with covalently bonded RGD groups has been used to augment in-
vivo soft tissue by injection. When the injected material contained cells it was shown 
to grow stiffer over a 12-week period indicating cell growth and proliferation (Marler 
et al, 2000).  
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Semi-permeable gels have also been created that are intended to limit cell-cell 
communication and interaction with surrounding tissues; this ensures that the 
developing organ is contained within experiences the appropriate environmental 
conditions. It has also been possible to control supply of growth factors to the 
developing cells by encapsulating them within the hydrogel, ensuring their release as 
the scaffold breaks down. The intent is to directly link the breakdown of the hydrogel 
scaffold to the respiration rate of the contained cell (Pachence and Kohn, 2007). 
1.3.4 Key steps within a tissue engineering process 
Tissue engineering is a multi-stage process with a series of complex integrated steps. 
The potential scale of operation is very large as the number of patients that may be 
treated by many of the existing and future potential tissue engineering therapies is of 
the order of millions. Many of the current products within the market place are 
manufactured manually (by trained operators within laminar flow hoods) and have 
undergone limited automation that would permit truly high throughput, although 
current developments are taking place. The issues with commercialisation of tissue 
engineering products were highlighted by the bankruptcy of pioneering tissue-
engineering companies such as the two main producers of a tissue engineered skin-like 
substance: Organogenesis and Advanced Tissue Sciences (ATS) in 2002 (Mason, 
2003). The former ATS Vice-Chairman Gail Naughton was quoted as saying 
“Problems with automation and scaling-up the bioreactors is what has killed the 
products to date”. 
 
This observation was echoed in a commercial report published at the time exploring 
the potential for mass production of tissue engineering products “Tissue engineering 
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has yet to realise its full potential as a platform technology for a wide range of 
commercial products. This is mainly because current technologies do not allow cost-
effective, commercial production of replacement tissues and organs (Anon, 2003).   
 
Since then a number of companies have developed robotic cell culturing systems, 
which primarily seek to replicate the actions taken by human operators, through the 
use of automation. Such actions allow standardisation of experimental technique and 
can be operated without breaks.  
 
The SelecT is an automated robotic system developed for the automation of cell 
culture by TAP [The Automation Partnership, Cambridge, UK]. With a capacity of 90 
T175s or 210 plates (96 or 384 well), the system is capable of harvesting, counting and 
seeding cells.  The system is designed primarily for experimental work and is in no 
way adapted for tissue or organ growth. With suitable adaptation such a system could 
however be adapted to provide the steps prior to bioreactor seeding in a tissue 
engineering or regenerative medicine process. Tecan’s Cellerity ™ [Tecan Trading 
AG, Switzerland] is a similar system composed of modular systems such as pipetting, 
centrifugation that can be combined into an automated cell process. Although the 
Cellerity differs from the SelecT in its modularity, its application is equally limited to 
anything more than the initial preparatory steps prior to seeding into the bioreactor. 
 
The following section will discuss the key stages within tissue engineering a blood 
vessel and both existing and potential automation of the process shown in Fig. 1.4. 
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Figure 1.4 Tissue Engineering Process 
The growth of an artery by tissue engineering requires that appropriate cells be 
extracted from the human body by biopsy. Due to the lack of specificity in biopsy, 
these cells will require purification. Invariably the number of cells post-purification 
will be insufficient to provide an appropriate seeding volume for growth of tissue and 
thus in-vitro expansion in culture will be required before the replacement organ or 
tissue may be implanted into the patients. 
 
1.3.4.1 Biopsy 
The first stage of tissue engineering a blood vessel is obtaining the cells required. 
Mature cell types such as EC have been obtained for experimentation from umbilical 
cord (L’heureux et al, 1998), saphenous vein (Matsumura et al, 2006), or from human 
patients who have undergone bypass surgery, biopsies of their coronary arteries being 
taken at that time (L’heuruex et al, 2007). SMC have also been obtained from the 
saphenous vein on occasion (Matsumura et al, 2003) and from the medial layer of 
bovine aorta (Niklason et al, 1999) although this was not used for human implantation.  
 
More recently most research has moved towards using MSC as the raw material for 
tissue engineering an artery (Matsumura et al, 2003, Gong and Niklason, 2008). 
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The nature of the biopsy required to obtain MSC is a bone marrow aspiration or 
harvest. Bone marrow harvests for the collection of stem cells have taken place for 
over thirty years and have become routine procedures. The harvesting normally takes 
place under general anaesthetic in a surgical environment and involves the insertion of 
a large needle directly into the bone marrow cavity, usually around the hip or lower 
back area (superior iliac spine) after sterilisation (Matsumura et al, 2003). Bone 
marrow may then be aspirated from the bones. To collect sufficient material, a number 
of separate injections are required and the entire procedure normally takes around two 
hours and acquires a litre of undefined bone marrow material of which the stem cells 
form just one component. Such a procedure results in discomfort at the site of harvest 
and may results in complications such as bleeding, infections and in worst cases nerve 
damage (Bain et al, 2003). The collected material may then be sieved using a nylon 
cell strainer to remove fat and bone (Matsumura et al, 2003). 
 
An alternative method involving collection of stem cells from the peripheral blood 
involves the use of a catheter in one or several sites, unlike bone marrow harvesting 
which has been carried out for several decades (Thomas et al, 1957) this method only 
arose in the early 1980s (Korbling and Anderlini, 2001). 
 
Bone marrow biopsies carry a large variation in the quality of the product obtained, 
this variation arises from the doctor making separate injections in a relatively vague 
region and having little or no idea the location of the most appropriate regions for this 
patient. This variation in raw material composition translates to variation in process 
dynamics such as cellular growth rates (Phinney et al, 1999). 
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Two aspects could be improved to achieve greater standardisation; 
 
1. Improved mapping or modelling of the bone marrow region (Mantalaris et 
al, 1998). If a more specific location containing a high concentration of 
stem cells could be established then fewer injections would be required and 
a greater confidence could be established with regard to the quality of the 
starting material. A lower number of harvesting injections would also result 
in a lower risk to the patient.  
 
2. Improved collection of the stem cells. If improved mapping could be 
coupled with an automated bone marrow collection method possibly 
involving the use of robotics then the operation would be standardised to a 
far higher level and consistency would be far higher. Such methods have 
previously been explored by a number of companies e.g. Harvest 
Technologies Corporation, Plymouth, MA. (Bottino et al, 1995). 
 
A greater mapping of the region would result in an improved quality of raw 
material and an automated collection method would reduce human variation 
introduced into the procedure. 
 
1.3.4.2 Purification 
 
Although clinical trials have taken place using ill-defined cell mixtures such as those 
to treat coronary heart disease using bone marrow material (Strauer et al, 2002), it is 
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likely that regulatory and validation requirements will necessitate the separation and 
subsequent purification of an appropriate well defined cell type before it would receive 
approval for use in a clinical environment. For this reason cell sorting based upon key 
cell markers is required. Although MSC are normally selected for by rapid plastic 
adherence (Koc and Lazarus, 2001) when the markers of these cells are better 
understood a more formal method of separation would be required. 
 
There are several such separation methods. 
 
FACS (Fluorescence Activated Cell Sorting) is extensively used in immunology to 
determine the stage of proliferation, differentiation or activation of immuno-competent 
cell. It has also been used to purify variety of cell types (including neural stem cells) 
producing GFP (Green fluorescent Protein). Such purification methods would permit 
separation of an appropriate cell type within a population to allow it to be cultured in 
isolation (Sergent-Tanguy et al, 2003). 
 
Cells carrying the complementary marker will bind to these beads and concentration 
may also take place by applying a magnetic field to bring the beads together in a single 
area (Enroth and Engstrand, 1995). This technique has been applied to separating a 
type of Embryonic Carcinoma Cells (Embryonic-like stem cells derived from 
teratocarcinomas) called NTera2 to some effect (Przyborski, 2001). Sterility testing 
must also take place, the minimum tests required should include mycoplasma and 
pathogen testing (Stacey et al (2007).  Additionally whilst some bacterial 
contaminations will be clear to the naked eye at an earlier stage, some will be not so 
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apparent and could lead to cross-contamination with many lines before discovery, 
potentially risking huge quantities of research work. 
 
Impurity removal may be achieved by washing in Phosphate Buffered Saline (PBS) 
after separation and purification followed by centrifugation and re-suspension into 
fresh media (Freshney, 2000). 
 
1.3.4.3  Culture 
 
Before the isolated cells may be inserted into a bioreactor, they must be expanded until 
the seeding density of 1x106cell.ml-1 of alginate scaffold can be achieved. The first 
sub-culture or passaging represents an important transition for a culture. It implies that 
the original culture has expanded to occupy all available substrate and normally the 
population has become relatively uniform in its growth rate (Freshney, 2000). This 
expansion takes place in a laboratory setting and for any tissue intended for in-vivo 
implantation must obey current good manufacturing policy (GMP). Biological 
production processes are obliged to obey strict governmental regulations including the 
methods, facilities, labelling and storage of the product (Dorresteijn, 1996).  To this 
end each process requires a detailed standard operating protocol (SOP) on record for 
all steps (Dorresteijn, 1996). During the culture stage, cells from different patients 
require separate storage in different incubators, with predominantly disposable 
equipment used to avoid cross contamination during cell handling.  
 
Cells are grown within tissue culture flasks that contain treated bottom surface that 
encourage cell attachment. Depending upon the cell flask and the cell type required, a 
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more specific type of coating such as fibronectin or gelatine (Freshney, 2000). The 
media within these flasks requires constant exchange to limit reduction in substrate 
concentration and rise in waste concentration. This media exchange also provides an 
opportunity to determine the rate of metabolism for the growing cells, by measuring 
the concentration change of various substrates. 
 
 
1.3.4.4 Harvest and implantation 
 
Martin et al (2004) hypothesised a system that in addition to producing a vascular graft 
under controlled conditions would monitor the development of the graft and provide 
the surgical team with data on the development of the graft so that implantation could 
be scheduled. Although they commented a bioreactor of such complexity being 
developed to be economical in the near future was unlikely, they did believe this 
represented the ultimate development. In such a scenario, a coronary artery bypass 
graft could be performed just as it currently is with the exception that no vein 
harvesting would be required. 
 
1.4 Bioreactors in tissue engineering 
 
Within this section consideration will be given to the types of bioreactors used for 
tissue engineering other tissues and finally those within related industries and how 
such technology may be applied to developing a tissue engineered blood vessel and 
ultimately designing an integrated environmental control system As outlined by 
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(Portner et al, 2004) bioreactors are used for a number of different reasons within 
Tissue Engineering: 
 
a) Cell proliferation on a small scale, usually for research purposes 
b) Generation of three dimensional tissue constructs 
c) Direct organ support devices 
 
1.4.1 Small Scale cell proliferation 
 
Within this category fall micro-bioreactors for growing suspensions cultures such as 
those developed at MIT (Zanzotto et al, 2004) and subsequently multiplexed (Szita et 
al, 2005). These systems often contain at most minimal control systems and are 
operated in either incubators (which themselves control temperature, carbon dioxide 
and sometimes oxygen concentration) or bespoke made boxes that behave exactly as 
an incubator does.    
 
 Many incubator stages for viewing live material in real time under the microscope 
under environmentally controlled conditions can also be best characterised as small-
scaled bioreactors and include devices such as those developed by Linkam (Linkam, 
Surrey, UK) and Nikon (Nikon Instruments Europe B.V).  These devices often possess 
temperature and gas control but still suffer from the feed – starve cycle experienced by 
static cultures due to a lack of continuous media exchange.  
 
Continuous systems do exist for small-scale cell growth and include hollow fibre and 
airlift bioreactors (Safinia et al, 2005). Hollow fibre systems possess the advantage of 
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reducing shear but suffer from issues of scaling due to inconsistencies in gaps between 
fibres and as with most bioreactors when organ-like cell densities are reached (more 
than 10^8 cells.ml-1) will suffer from mass transfer limitations (Schonberg and Belfort, 
1987).  
 
An alternative system, the airlift bioreactor, although much more able to be scaled 
effectively suffers from the shear generated by bursting of the bubbles formed from 
the gas used to sparge the system with oxygen for the developing cells (Sardonini and 
Wu, 1993). This shear is responsible for cellular damage that impacts cell growth and 
proliferation. 
 
1.4.2 Generation of three dimensional tissue constructs 
 
Within tissue cultures a key problem is mass transfer through tissue masses as the 
thickness of biological matter increases (Nerem and Sambinis, 1995).  These mass 
transfer limitations in the right circumstances can lead to necrotic regions forming in 
tissue engineered materials due to lack of oxygen or nutrient supply (Wohlpart et al, 
1991). In-vivo such mass transfer limitations do not lead to the formation of necrotic 
regions due to the extensive vascularisation of the human body (Cassell et al, 2002) 
and mimicking this vascularisation in-vitro is currently one of the greatest challenges 
limiting the development of large or complex tissue and organs within bioreactors.  
 
It is because of these mass transfer issues that successful tissue engineering products 
have been limited to relatively simple structures such as skin (Eagelstein and Falanga, 
1997), blood vessels (L’Heureux et al, 1998) and the bladder (Atala et al, 2006), all 
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these possess relatively thin walls and can be developed successfully despite 
limitations of mass transfer. 
 
A number of bioreactors have been developed with the intent of producing a variety of 
these simple structures e.g. cartilage (Mahmoudifar, 2005), bone (Jannssen et al, 
2005), vascular material (Mironov et al, 2003) and even neural material (Sen et al, 
2002). These bioreactors are usually used in conjunction with some sort of support 
scaffold and attempt to mimic in-vivo processes such as nutrient supply and waste 
removal to encourage pockets of cells to proliferate and form three dimensional organ-
like structures (Hutmacher, 2000). 
 
Perfusion systems are common in the generation of such constructs as they allow both 
fresh feeding of medium containing growth factors and the removal of waste products 
that are often cytotoxic.  These perfusion systems tend to take a standard form and 
incorporate a bioreactor, some method of gas exchanges, media reservoirs and 
associated pumps.  
 
The majority of perfusion bioreactors that have been successfully employed in tissue 
engineering are bespoke systems that have been developed within university 
departments for growth of very specific tissue constructs including heart valves 
(Hoerstrup et al, 2000), small diameter arteries (Williams et al, 2004) and bone 
(Cartmell and El Haj, 2005). 
 
Several devices have been adapted to employ mechanical strain on the construct to 
assist in the development of specific cell structures (Kino-Oka and Taya, 2005), 
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Cartmell and El Haj, 2005), such devices incorporate the common components in 
tandem with some method of applying forces to the developing tissues.  
 
Limited development of complex systems for the control of biological parameters has 
taken place. Minuth et al (2005) identify the key variables as pO2, nutrients, 
electrolytes, ECM, temperature, pH, morphogens and mechanical load, while 
McFetridge and Chadhuri  (2005) specified Temperature, pCO2, pO2, nutrients and pH 
must be controlled within set parameters. The methods for achieving such control 
were respectively not identified and instead the solution was to place their device 
within a controlled incubator. Such a solution although effective is not useful in the 
long term as it does not readily lend itself to the scale out required by most market 
sizes. Additionally incubators experience gradients of temperature and gas 
concentrations that even at low levels could affect the development of undifferentiated 
cells such as MSC. (Ellis et al, 2005) stated that in-vitro creation of three-dimensional 
tissues will require well-controlled culture tools but provided no details on how this 
might be achieved. Kasyanov et al (2005) used a digital pump with a flow-rate range 
of 28-1700ml.min-1 to which was controlled by a PC connected to a pressure 
transducer to maintain static pressure at 150mmHg, but resorted to controlling other 
environmental parameters by designing the system to operate with a standard 
incubator. Kino-Oka and Taya (2005) showed the future aim of any tissue-engineered 
bioreactor with a schematic of a radial flow system used to produce antibodies by the 
Kirin brewery in Japan. This system used a series of continuous control feedback 
loops linked to invasive probes to maintain environmental properties. pH was 
measured and maintained by a carbon dioxide mass flow controller, likewise oxygen 
was measured and kept constant by the action of an oxygen mass flow controller, with 
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the two being balanced by a third linked mass controller attached to a nitrogen feed. 
The overall medium flow rate was also controlled to maintain glucose concentration 
within the system. Although such a system uses invasive probes, the design is very 
applicable to a tissue engineering system and represents a suitable potential model for 
a perfusion system such as the VTEB. The ideal long- term goal described by Martin 
et al (2004) is a system where the surgeon would remove a biopsy from the patient and 
introduce it to a bioreactor located on site. This bioreactor would contain all required 
reagents in separate compartments and would automatically isolate, expand, seed and 
culture the graft. Development would be monitored and surgery scheduled based on 
estimated delivery time. Although a system of this complexity does not yet exist and 
its design is based upon purely theoretical ideals, this work will provide a first step 
towards realising some aspects of this design. 
 
1.4.3 Direct Organ Support Devices 
 
Such devices are relevant to tissue engineering, as many of the control issues are 
similar to those within tissue culturing devices. Examples of such devices are those 
used to support Liver function in patients who have suffered failure of that organ 
referred to as BALs (Bio-Artificial Livers) (Allen et al, 2001). One of the more far-
sighted references on such work (Balis et al, 2002) suggested the use of a 
microcontroller for offline control of parameters such as DOT based upon predictive 
models. The potential such a system gives for scale-up is one that could be applied on 
a wider scale to tissue engineering with great effect. 
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1.4.4 Traditional bioprocessing 
 
The simplest form of cell growth vessel used within the bioprocess or biochemical 
engineering discipline is one within which there is no dynamic exchange of media 
contents, a static culture. The vessel for static culture is merely a sunken well in the 
case of suspension cells or a suitable chemically adapted surface for an adherent 
culture such as a tissue flask or gas permeable blood bags (Collins et al, 1998). Such 
systems do not have continuous media exchange and as a result of batch or semi-batch 
like re-feeding will constantly go through a feast-starve cycle that is in no way 
representative of in-vivo conditions. The absence of mixing in such static 2D systems, 
gives rise to heterogeneous environmental distributions throughout the system (Collins 
et al, 1998) and these environmental variations can lead to differences in cell 
behaviour within the system and reduce reproducibility (Ellis et al, 2005).  
Additionally, it has become apparent that two-dimensional systems do not necessarily 
translate to an equivalent three-dimensional cell culture (Weaver et al, 1997, Abbott, 
2003) and thus have limitations even as a diagnostic tool of likely behaviour of cells 
when forming into organs or complex tissues. It is for this reason that dynamic 
bioreactors are largely seen as the appropriate method of manufacturing any tissue 
engineered product. 
  
A bioreactor is the general name given to any closed culture environment (usually 
agitated) that is designed to control at least one environmental parameter of a physio-
chemical environment (Ellis et al, 2005) to achieve aseptic feeding and sampling and 
to automate the process and thus improve reproducibility (Doran, 1995). Some of the 
first industrial applications of bioreactors were in fermentation and although many 
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other systems do exist, it is fermentation that has been developed the furthest 
particularly in the area of process control. 
 
The traditional priorities of fermentations are fundamentally different from those of 
tissue engineering. Traditional fermentations use the cell as a production facility for a 
particular intra or extracellular factor (Belter et al, 1998). At the completion of 
fermentation, in the case of an intracellular product, the cells are disrupted (normally 
resulting in death) and in the case of extracellular products the cells tend to be filtered 
out downstream and disposed of as part of the filter cake (Belter et al, 1988). The 
priority in either case has always been to maximise yield of the desired product. 
Environmental conditions within the fermenter are optimised for the manufacture of 
these products and not for the cells, which will either be disrupted or filtered out and 
disposed of.  
 
It should not be assumed healthy unstressed cells and high product yields are mutually 
exclusive events during fermentation, indeed much research has taken place to avoid 
stress in such circumstances (Schweder et al, 2004). In many instances the production 
of stress products such as heat shock proteins, e.g. chaperones reduces yield of the 
desired product (Lindquist and Craig, 1988), however the fermenter is often operated 
in a manner that forces the cell to overproduce the desired factor at the expense of its 
own health. 
 
The adaptive capabilities of bacteria honed over many years of evolution allow them 
to respond and adapt to culture conditions in environments such as the laboratory, 
which are often radically different from the natural habitat (Roszak and Colwell, 
 57 
1987). Response to such an environmental shift may result in a large increase in 
desired product yield whilst limiting life span or health of vector. In traditional 
bioprocessing such a compromise, is deemed acceptable. 
 
Whilst in cell culture the aim is to operate within as tight a tolerance as possible close 
to the in-vivo environment of that cell, the standard approach when carrying out 
fermentations is to ensure by measurement that the controlled parameter does not fall 
below a specified minimal level (Stanbury et al, 1999). The extent of control, for 
example, of oxygen concentration, usually via a feedback loop and an invasive DOT 
electrode (Stanbury et al, 1999), is to operate above this critical value. Due to the high 
oxygen demand of bacteria and yeasts (Doran, 1995) and the interest being in the 
product rather than the cell, the problem of too much oxygen is not one that is likely to 
be prevalent for fermentation processes. Despite this however mass transfer limitations 
such as of oxygen and nutrients are an issue in all cell growth systems, in the case of 
fermentation due to the high growth rates and in the case of tissue engineering, due to 
the thickness required of living material for many organs. 
 
Mammalian cells are particularly vulnerable to bacterial contamination and the use of 
antibiotics is not permitted due to the potential for undesirable responses by the 
immune systems of the recipients due to allergy or idiosyncrasy. Whilst a fermenter is 
normally made of stainless steel and is sterilised using high-pressure steam (Doran 
1995), this level of sterility is not sufficient for a tissue engineering bioreactor and as a 
result disposable portions tend to be incorporated into the system for those parts that 
are in contact with the growing cells. 
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Despite these differences in purpose and strategy, many of the process control 
demands are the same and include maintaining desired environmental conditions and 
finding ways to measure cell growth online. In this area fermentation and other areas 
of bioprocessing are far more advanced than tissue engineering. Although many 
bioreactors implement simpler control systems, such as two-step and Proportional 
Integral and Derivative (PID), which respond based upon a set point or perform a 
mathematical calculation to determine the size of the response based upon the error, 
much more advanced systems have been theorised. 
 
Siimes and Linko (1995) developed a fuzzy-knowledge based system for the control of 
baker’s yeast production. Fuzzy logic, developed in 1965 (Zadeh, 1983), involves the 
linking of linguistic statements such as high, low to logical conditions such as ‘if’ and 
‘or’. A series of these statements may be formed and by weighting the various 
statements based on literature or expert knowledge and linking them to numerical 
ranges a control system may be formed (Konstantinov and Yoshida, 1991). Such a 
system allows complex systems to be reduced to ranges and combinations of events 
rather than specific equations and exact relationships, permitting prediction to be 
made, often with high accuracy. Implementing this approach Siimes and Linko, (1995) 
were able to identify which growth phase a culture was in and diagnose faults at an 
early stage. 
 
Kostantinov and Yoshida (1991) observed that fuzzy controllers could be either used 
to directly control the process, replacing standard controllers (e.g. PID) or in a higher 
level controller supervising the lower system level which is no different to a standard 
control system and informing it how to act and when, perhaps by changing the set 
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point of the controller. Flanagan (1980) used a supervisor to monitor and control the 
set points of a series of conventional controllers responsible for wastewater treatment. 
By modifying these set points the overall dissolved oxygen within the system could be 
controlled effectively.   
 
Intelligent systems using expert knowledge have also been applied to distributed 
control systems. Flores et al (2000) designed and implemented a system for remote 
monitoring of wastewater treatment at a number of different locations. This controller 
was based on an expert system that reduced the output parameters received by the 
operators to symbolic data that is more easily understood by them, improving the 
quality and rate of their response. Such a controller reduced start-up time and the 
attainment of stable conditions from three months to three weeks, a significant 
decrease. Recent advances have even extended to using neural networks as a tool to 
predict and control fed batch kinetics (Petrova et al, 1997). 
 
It is vitally important, as with any advancement within science, that the regenerative 
medicine and associated bioprocessing discipline [tissue engineering] must learn from 
the experience of other fields (Mason and Hoare, 2006) Many of these advanced 
control systems will in the future be very relevant to tissue engineering. Distributed 
control particularly holds great promise for the future scale-out of the bioreactors. 
Such advances in bioprocessing took place when the limits of controllers such as PID 
were reached and this is not yet the case in tissue engineering where little or no work 
in this are has been carried out. 
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1.5 Control Parameters within tissue engineering bioreactors 
 
Having examined the automation utilised in existing tissue engineering bioreactors and 
related disciplines such as bioprocessing, it is important to consider which variables 
require controlling in a biological system. 
 
Major improvements have been achieved in the control of biological production 
processes. Much of this improvement has been achieved through the development of 
computerised measurement and control units that have allowed the application of on-
line modelling of the process and in doing so improve yield and consistency 
(Dorrenstijn et al, 1996). Measurement outputs such as Dissolved Oxygen Tension, pH 
or metabolite concentration can be used to control physiological parameters and 
regulate substrate feed (Dorrenstijn et al, 1995, Dorrenstijn et al 1996).   
 
The basis of control is largely to produce a standard product through the use of a 
standard process at a predictable rate. Locher et al (1991) demonstrated that the 
reproducibility of a bioprocess is directly influenced by the reproducibility of 
environmental conditions within the bioreactor.  The exact parameters that should be 
measured have become relatively standard within bioprocessing and usually consist of 
the following: 
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pH or dissolved carbon dioxide concentration (see section 1.5.1) 
Temperature (see section 1.5.2) 
Substrates and metabolites (see section 1.5.3)  
Dissolved oxygen tension (see section 1.5.4)    
1.5.1 pH 
 
pH is a particularly important parameter in mammalian cell culture as it can affect the 
stability of proteins within the cells and hence the health of the cell. The current 
philosophy in terms of pH is to keep a culture as close to the physiological pH 6.8-7.5 
as possible. Standard medium for the culture of stem cells is normally a basal media 
such as Dulbecco’s modified eagle medium (MEM) or Mesencult (designed 
specifically for the culture of MSC), containing either a bicarbonate buffer or HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) an organic buffering agent to 
regulate pH within solution. Bicarbonate buffer is carbon dioxide assisted and requires 
a certain dissolved carbon dioxide content to maintain a physiologic range. HEPES 
has the advantage of being independent of such constraints but has a slightly less 
specific working pH range. 
 
Both of these buffers are used as they possess a pKa optimal for buffering effect 
around a physiological pH (in the case of bicarbonate this is only the case when 
physiological carbon dioxide levels are also replicated). Any excursion significantly 
outside of the stated physiological boundary is likely to indicate: 
 
i. The environment is no longer suitable for life. 
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ii. A contaminating agent may well be present; bacteria divide rapidly and 
produce large amounts of waste product such as lactate and ammonia – the 
presence of which is displayed through pH shift. 
iii. The product is likely to be ‘spolied’ i.e. no longer suitable for implantation. 
iv. Progenitor cells may well move down an inappropriate differential pathway 
(Bernard et al, 2006). 
 
The overriding assertion would seem to be that if a pH change is present that exceeds 
the range stated as physiological boundary, any sort of further chemical control is 
inappropriate as the product is no longer viable. Any pH change arising due to the 
production of waste products should be dealt with by employing some sort of media 
change system. 
 
A number of methods exist for the measurement of pH within a solution. pH is directly 
related to the concentration of hydrogen ions by the relationship pH = log10[H+].  
Methods such as measuring electrical conductivity and chemical behaviour of solution 
are thus, the most common methods used to determine pH.  
 
pH electrodes are sensitive to ions such as H+ as the electrodes voltage output is 
proportional to the local ion concentration in solution. A pH measurement system 
consists of such an electrode in tandem with a reference electrode (holds a constant 
voltage for comparison purposes), these electrodes provide output that may be 
processed by a pH meter that acts as a transducer; converting the signal from an 
electrical current, measured in mV to a reading of pH. Often a temperature sensor will 
be part of the system and also placed in the liquid to allow compensation for the effect 
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on pH of temperature changes. The disadvantage of such a system is that it is invasive; 
this can be problematic in environments where high sterility is required, such as those 
encountered in tissue engineering and regenerative medicine. An additional problem 
with such electrodes is that due to their size, their operation in small samples is often 
impossible, again a major issue in fields such as those considered within this body of 
work. 
 
Fluorescent Sensor spots such as those developed by PreSens (Precision Sensing 
GmbH, Germany) have a number of advantages over electrodes in being non-invasive, 
disposable and due to small size; capable of use in small sample volumes. pH mini 
sensors consist of a planar spot coated in two separate dyes; one, a pH indicator with a 
short decay, the second, an inert reference dye with a long decay time. When used 
with a fibre optic cable that acts both as transmitter of light signal and receiver of 
signals from the spots, the ratio of the emission from both dyes can be converted into a 
pH value of the solution. The disadvantages of such a system include, the small range 
of operation relative to an electrode (pH 5-9) although within a cell or tissue culture an 
excursion from a pH of 7 of a magnitude outside of this range in all likelihood would 
already be catastrophic and thus does not require accurate measurement.  Also the spot 
over a number of excitations will become bleached and lose sensitivity 
(www.presens.de) 
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1.5.2 Temperature 
 
As with similar environmental parameters, the temperature used for most stem cell 
culture is that experienced physiologically in the human body. Most cell culture takes 
place in incubators operating at or around 37oC (Freshney, 2000). Normal control 
methods for this, as stated previously, include operating the bioreactor in a heated 
chamber either of a bespoke design (Minuth et al, 2005, Balis et al, 2002) or a 
conventional incubator (Williams and Wick, 2004, Zhao and Ma, 2005, Kino-Oka et 
al, 2005) as found in cell culture laboratories. 
 
 Standard procedure for the measurement of temperature involves the use of 
thermocouple, which works by creating a circuit of two dissimilar metals. The 
magnitude and direction of the current within this circuit relates directly to the 
difference in temperature between the two junctions (Bolton, 2003). In terms of any 
bioreactor system large temperature fluctuations should ideally be avoided rather than 
merely controlled, the aim being to ensure the temperature is controlled within 
specification before it becomes an issue. The most appropriate method to avoid such 
problems is to operate the incubators within a temperature controlled facility (the 
standard lab operates at 19-23oC) to minimise fluctuations and for each bioreactor to 
be stored within a heavily insulated container such as those used in commercial 
thermally insulated boxes for transport of medical supplies. This box should then 
incorporate a heating device.  
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1.5.3 Substrates and metabolism 
 
Respiration represents the method by which energy is produced by cells. This energy 
is used to drive synthesis of ATP, the “energy currency” of cells. Respiration is 
predominantly the reaction of oxygen with glucose to form water and carbon dioxide 
although, other metabolites and waste products are also very relevant thus cell culture 
typically involves a liquid broth consisting of substrates, metabolites and growth 
factors. Such a broth is generally referred to as cell culture medium. 
 
These substrates and metabolites consist of glucose (and its waste product lactate) and 
glutamine (and its waste product ammonia) both of which are key components of cell 
media. Low concentration components of culture media such as Bone Morphogenic 
Protein (BMP) are generally ignored in a tissue engineering system, as there is 
currently no effective method to measure such concentrations rapidly either online or 
off-line, so their inclusion in the initial medium is normally of a sufficient level to 
maintain culture for significant periods of time. Pyruvate and glutamate, two cell 
culture components, are also generally neglected as they are present in much smaller 
concentrations in cell media. These compounds are produced and consumed at 
different steps of the Krebs (Citric Acid) Cycle; a key stage in aerobic respiration. Any 
final measured balance of these two components hence forms a ratio between 
consumption and production and monitoring such a value and relating it to respiration 
rate is not practical (Follmer et al, 2006). 
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1.5.4 Dissolved oxygen tension 
 
Dissolved oxygen tension (DOT) in solution represents one of the key environmental 
parameters involved in the culture of cells and directly affects their physiological 
properties. Within any tissue engineering device it is essential that its variation is  
monitored and, where appropriate, controlled.  
 
Standard policy for most experiments involving mammalian cells is to replicate 
normal in-vivo conditions and use oxygen concentrations comparable to those 
measured within the relevant part of the human or animal body using invasive 
techniques such as oxygen electrodes. Within in-vitro culture non-invasive measures 
exist just as with pH (see section 1.5.1) that use a small spot that will fluoresce when 
excited by a fibre optic cable. This responding fluorescence is retarded by oxygen in 
solution (Lakowicz and Weber, 1973) between the spot and the fibre optic cable, 
which also acts as a signal receiver. This signal can then be converted into an oxygen 
concentration (Precision Sensing GmbH, Germany). 
 
In the case of arteries the appropriate physiological DOT depends upon the location 
within the body, the further downstream from the lungs the lower the DOT will be.  It 
has been demonstrated that oxygen gradients within the bone marrow may be at least 
partially responsible for controlling haematopoiesis (the creation of blood cellular 
components) (Hevehan et al, 2000, Mostafa et al, 2000). Other cell types have also 
been shown to be affected by oxygen tensions, including adipocytes, the 
differentiation of which is inhibited under hypoxic conditions (Yun et al, 2002) and 
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MSCs, the osteogenesis of which is promoted by low oxygen conditions (Lennon et al, 
2001).  
 
1.5.5. Representing acceptable ranges of environmental parameters 
 
For a set of multiple related variables, some method must be used to determine what 
range control variables may operate within for each to allow an overall range to be 
established.  
A useful tool has been developed for representing complex bioprocess design 
multivariate problems by a graphical representation involving plotting the operational 
space defined by the system (chemical, physical and biological) and engineering 
constraints and correlations governing a particular process of operation under 
consideration (Woodley and Titchener-Hooker, 1996) (Fig. 1.5). 
 
Figure 1.5 Qualitative operating boundaries for an aerobic bacterial 
fermentation (adapted from Woodley and Titchener-Hooker, 1996). 
The window of operation (WOO) is a graphical method of relating two variables together, 
such as aeration and agitation in a fermenter, and determining the maximum and minimum 
extents of operation of these two variables. In the examples these extents are determined by 
parameters such as the maximum amount of aeration that can take place without foaming 
problems becoming prohibitive.  
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These windows of operation can be used to determine appropriate compromises where 
trade-offs must be made between two or more variables and provide an easy method 
for sensitivity analysis to be performed in this pursuit. Such a method was 
demonstrated effectively for a range of yeast growth rates within a fermentation and  
their relation to a set of operating conditions (Zhou and Titchener-Hooker, 1999).  
 
Windows of operation will be used within this thesis to determine appropriate ranges 
of the control variable and its effect upon parameters such as temperature, pH, oxygen, 
substrate and metabolite concentration. 
 
1.6 Existing Manufacture of Tissue Engineering Products 
 
The remaining consideration with regard to the creation of a tissue engineered blood 
vessel is how production may be scaled up from the bench to a level where a demand 
in the order of millions of patients can be satisfied (Xue and Greisler, 2000). 
 
Within the tissue-engineering field a variety of issues mostly relating to limits of basic 
scientific knowledge and engineering challenges, are yet to be overcome. For this 
reason existing tissue engineering products available on the market, have been limited 
to relatively simple structures that form simple geometric shapes such as skin (thin 
layer) (Eagelstein and Falanga, 1997), blood vessels (thin walled tube) (L’Heureux, 
2007) and bladder (thin walled sac) (Atala et al, 2006). 
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1.6.1 Blood Vessels  
 
As of 2007 an American company Cytograft following animal testing (L’Heureux et 
al, 2006) with a product named LifelineTM based on the rolled sheet technology 
(section 2.1) has entered human clinical trials in Buenos Aires (AV Shunt) and 
Cambridge, UK (Coronary Artery Bypass Grafts – CABG). Early reports indicate that 
six patients having undergone dialysis treatment have had cytograft vessels implanted 
and have been followed for up to 13 months. Of these patients, only one suffered from 
a non-functional vessel after 12 weeks, due to a thrombogenic failure (forming of a 
clot within the graft), one died from unrelated causes with a fully functional graft on 
day 39 and the remaining four at the time of reporting were benefiting from successful 
implants at between 3 and 13 months post operative monitoring (L’Heureux and 
McAllister, 2007). It appears that due to autologous nature of the therapy and the small 
scale of the trials Cytograft is currently still operating a heavily manual process. There 
is no evidence at the current time that a truly automated production method for 
creating tissue engineered blood vessels is in operation. 
 
1.6.2 Skin 
 
With several products having successfully proceeded through clinical trials, FDA 
approval and subsequently establishing positions with the market, bio-artificial skin is 
commonly regarded as the most successful of all tissue engineered therapies. The 
development of tissue engineered skin has allowed the wound management process to 
advance from the passive approach of removing impediments, debriding the wound 
and allowing natural regeneration (often unsuccessfully) to a more active approach. 
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Despite this success, these products continue to be limited by their inability to 
completely mimic the structure and function of skin, and scar formation and wound 
contraction remain prevalent issues. 
 
Initial success with tissue engineered skin involved its use on burn victims (Eagelstein 
and Falanga, 1997). As clinicians witnessed success on such patients, treatment for 
other purposes, such as in the treatment of chronic wounds, was explored (Bello et al, 
2001). 
 
The purpose of tissue engineered skin is to restore the structure and function of skin. 
This requires the presence of an outer karatinocyte layer (major cell type of the dermis 
to maintain/restore the barrier function, e.g. for water regulation in combination with 
appropriate dermal components to provide strength, flexibility and function 
comparable to naturally developed skin.  
 
The major differences between current engineered skin products and the natural 
substance it is intended to mimic are the absence of structures such as hair follicles 
and sweat glands (Jahoda and Reynolds, 2001). Such structures are ignored due to 
arguments that they are not essential to effective healing (an issue contended by 
Jahoda and Reynolds, 2001) and their inclusion would require a more complex 
manufacturing process which companies are keen to avoid so that commercial 
viability can be maintained. A secondary issue with the use of synthetically grown 
skin is that it can lead to the formation of abnormal scar tissue between the substitute 
and the patient’s own undamaged skin. Particularly in concealed areas such as diabetic 
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foot ulcers, cosmetic issues are minor compared to a chronic ulcer failing to heal over 
a period of several years. 
 
The manufacturing techniques used for the production of tissue engineered skin are in 
large part manual processes. The techniques tend to involve the culture of cells and 
tissue by trained individuals within clean room laboratories. Dermagraft ®, previously 
produced by Advanced Tissue Sciences [www.advancedtissue.com]  and now owned 
by Advanced Biohealing Inc. [www.AdvancedBioHealing.com] and Apligraf ®, 
produced by Organogenesis [www.organogenesis.com], are both for the treatment of 
foot and leg ulcers and pressure sores. Both allogeneic therapies involve human cells 
and animal products such as bovine collagen. Both Organogenesis and Advanced 
Tissue Sciences suffered extreme financial difficulties in the early 21st century (Tissue 
Sciences, SEC 8K, 2002) mainly due to difficulties in scalability of the process mainly 
due to its manual nature (Kemp, 2006, Mason, 2007). Apligraf involved a highly 
manual process spread over 4 distinct locations (Banks, 2006) Whilst ATS was sold 
off to Smith and Nephew and has subsequently been bought by ABH, Organogenesis 
ultimately exited chapter 11 bankruptcy successfully (Organogenesis, SEC 8K, 2003) 
and has gone on to become a successful company selling around 30,000 units of 
Apligraf per year and has currently entered clinical trials to determine its efficacy in 
treating pressure ulcers and Epidermolysis Bullosa  (Banks, 2006). At the time of 
bankruptcy it was reported up to one third of all manufactured discs of skin were 
contaminated and disposal was required and in 2007 Organogenesis began to roll out 
an automated process for the production of Apligraf using controlled robotic trays to 
combat these issues. This process has been designed specifically with the 
improvement of consistency and waste reduction in mind rather than to increase 
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product output (Banks, 2006). Other companies such as Ortec (Manufacturs of 
Orcel®) and Intercytex (launching ICX-pro in 2008) have also only used limited 
automation to date, an issue which they continue to explore and implement at a slow 
and controlled rate (Kemp, 2006). Both the owners of bankrupt and currently 
operating companies within the sector as well as analysts (Anon, 2003) are clear that 
automation and scalability are essential for the success of a tissue engineered or 
regenerative medicine product. 
 
1.6.3 Cartilage 
 
Every year around 2 million Americans injure the cartilage in their knees 
(www.cartiel.com). A number of autologous therapies exist for the treatment of such 
injuries using the patient’s own cells.  
 
The most successful therapy to date has been Carticel® which was the first FDA 
approved product to reach market within the United States (Wood et al, 2006). The 
autologous nature of the product has led to a manual process being employed for 
manufacture. A biopsy of healthy cartilage cells are taken from the patient expanded 
by manual cell culture and then returned to the surgeon and injected into the knee 
under a periosteal patch that is stitched over the damaged area. 
 
Such a procedure has a number of concerns including the risk of an uneven 
distribution of cells within the damaged region and even the unsupported cells leaking 
from underneath the covered surface. The manual nature of the overall process will 
affect the consistency and reliability of the material and treatment the patient receives. 
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The relatively high failure rate of the treatment (Wood et al, 2006) may be related to 
this aspect. 
 
Attempts have previously been made to develop automated technologies for the 
treatment of cartilage injuries. Milenium Biologix incorporated aspects of the 
OSTEO™ bioreactor into their ACTES™ system. The intended function of the 
ACTES systems was to process a patient’s biopsy, culture and expand the cells before 
seeding them onto an appropriate scaffold and culture the tissue until it was at a 
suitable stage for implantation, all under automation. This system could be placed and 
used in a hospital by suitably trained operators (Martin et al, 2004). At the time of 
writing, unfortunately it appears that Millenium Biologix are no longer operating and 
their website is no longer active (www.millenium-biologix.com).  Despite this failure, 
the ACTES system has proved to form the basis of a potential long term strategy for 
the role of bioreactors in tissue engineering (Martin et al, 2004). 
 
1.6.4 Summary 
 
Many tissue-engineering companies have succumbed either to bankruptcy or severe 
financial difficulties at some point of their operation. This has been in large part due to 
inadequacies in their largely manual processes, either related to output or consistency 
of product. The automation of tissue engineering processes subsequent to market 
launch is a slow and costly procedure, thus the obvious conclusion seems to be that 
automation must be considered as a key part of product development rather than an 
afterthought. Mason (2007) characterises this transition in ideology as being analogous 
to the development of successful Internet companies following multiple bankruptcies 
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and financial difficulties and christens the current situation as Regenerative Medicine 
2.0. Allogeneic products lend themselves much more readily to automation as they 
bring a consistency of raw material that translates to a consistency in process and 
product that cannot be as easily achieved with autologous products. For these reasons, 
it seems likely that, in the long term, provided a suitable method of mitigating the 
immune response rather than immunosuppressant drugs can be discovered allogeneic 
materials are likely to become the industry standard. In the short term however 
autologous products will continue to represent a viable product to deal with a variety 
of diseases and injuries. The advantage of tissue engineered products is that although 
they carry a high initial economic cost by solving the underlying injury or problem, in 
some cases permanently, and reducing the high costs of follow up treatment often 
directly related to the labour of the treatment they become an attractive alternative to 
current methods. 
 
1.7 Conclusions 
 
The aim of this chapter was to present a survey of literature that would demonstrate at 
what stage current technology was with regard to the production of a tissue engineered 
blood vessel. An overview was given of the underlying biology, existing attempts at 
producing such vessels and automation of bioreactors within both tissue engineering 
and related fields. There have been notable successes in both producing a tissue-
derived structure from mature cells and creating a structure that mimics the native 
vessel through the use of mesenchymal stem cells (MSC). The results with tissue 
engineered skin have shown that the more successful products are those that most 
closely match the tissue or organ for which they are acting as a replacement. 
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Mesenchymal stem cells may be the more plausible solution in the short term, as 
mature cells have limited proliferative capacity, particularly from ageing donors. In 
the much longer term embryonic stem cells may provide an excellent raw material, 
however the biology of such cells is little understood and requires much further work 
before they will provide a viable alternative. 
 
Despite the successes at the bench and small-scale clinical trial level, little or no 
advance has been made in truly automating the process of creating tissue engineered 
blood vessels. The progress that has been made, to date, has either neglected the 
effects of control and the impact subtle changes in local environment may have on 
immature cells such as MSC or has been applied as applied inappropriate control 
strategies that have little or no potential for being scaled up. This has severely limited 
the potential of tissue engineering and regenerative medicine. 
 
1.8 Project aims 
 
The aim of this project was to take the first steps in developing control systems for a 
developing tissue engineered blood vessel created from mesenchymal stem cells 
within an alginate scaffold situated in a perfusion bioreactor. Key parameters 
considered were oxygen concentration, substrate concentration, metabolite 
concentration and pH, which were required to be maintained within specified ranges. 
Possible strategies were considered on the basis that the system would ultimately be 
scaled out and hence any large or expensive pieces of equipment would be 
inappropriate for use. 
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Random disturbances can be introduced to test control systems. However it is difficult 
to implement disturbances that are representative of the type likely to be experienced 
in normal operation. The solution implemented in this work is to use a surrogate yeast 
cell line as a diagnostic tool. Yeast is an excellent eukaryotic model and at least 40% 
of single gene determinants of human heritable diseases find homologues in yeast. It 
has been used extensively in drug discovery (Hughes, 2002) and particularly in cancer 
research (Lui and Simon, 2007). In this case yeast’s metabolic similarity to human 
cells can be exploited. Yeast grows and divides at a much higher rate than most human 
cells and thus if the oxygen and substrate consumption and metabolic waste 
production of yeast can be effectively controlled, then the system will be sufficient for 
a bioreactor designed to control the development of a tissue engineered artery. 
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Chapter 2  Materials and Methods 
 
The aim of this chapter is to describe in detail, techniques, materials and reagents used 
within the practical work and software packages and solver methods used within the 
theoretical work.  
 
2.1 Mesenchymal stem cell culture 
 
2.1.1 Cell isolation 
 
Adult human Mesenchymal Stem Cells (MSCs) were provided at stage 2-4 passage  
(P2-P4) from colleagues working within the Regenerative Medicine Bioprocessing 
Unit, Dept. Biochemical Engineering. The use of human clinical samples has been 
approved by the joint University College London and University College London 
(UCL) Hospital (UCLH) Hospital Ethics Committee of Human Research. These cells 
were obtained from colleagues working within the Regenerative Medicine 
Bioprocessing Unit (ReMeBio), Dept. Biochemical Engineering, University College 
London. The method of isolation of these cells is described below; 
 
A sample size of 10ml (typically 5-10ml was used) of freshly harvested bone marrow 
was filtered using a 40µm nylon cell strainer (Falcon, Bibby Sterlin, Stone, UK) and 
then rinsed with an amount equal to the size of the sample of Dulbecco’s phosphate 
buffer solution (DPBS) without calcium and magnesium (Biowhittaker). A 20ml of 
ficoll of density 1.077g.ml-1 was added to a 50ml centrifuge tube (Corning, NY. USA) 
and the tube orientated at an angle so that the surface area on the top of the liquid was 
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maximised. This tube was placed in a suitably balanced centrifuge (5801R Centrifuge, 
Eppendorf AG, Hamburg, Germany) at 652g for 30 minutes at room temperature with 
no break applied. This centrifugation caused the desired fraction, the mononuclear 
cells, to remain at the surface whilst undesirable material, such as red blood cells, was 
forced to the bottom. The layer of mononuclear cells at the surface were gently 
aspirated using a pipette (Fisher Scientific, Loughborough, UK) and placed into a 
second centrifuge tube, rinsed with 40ml of DPBS and centrifuged at 290g for 10 
minutes at room temperature with a low brake setting. The supernatant was aspirated 
off of the resulting cell pellet and discarded and the pellet was resuspended with 5ml 
of complete MSC media, removed by pipette and injected into a T75 tissue culture 
flask (Corning, NY. USA). At this point, a further 5ml of complete medium was 
added. This flask was placed in a humidified incubator at 370C and 5% Carbon 
Dioxide concentration (HeraCell 150, Kendro Laboratory Products GmBH, 
Langenslbold, Germany or Galaxy S, RS Biotech Laboratory Equipment Ltd, Irvine, 
Scotland). Fresh medium was added every 2-3 days and after 2-3 weeks the MSC were 
sufficiently confluent (ca. 75%) within the T Flask that they were passaged. 
 
2.1.2 Culture Vessel 
 
The stem cells prior to insertion into the bioreactor were grown in polystyrene tissue 
flasks (Corning, NY, USA). These tissue culture flasks contained a negatively 
charged, hydrophobic surface to encourage cell attachment. Sizes of these flasks 
varied from T25 – T150 (25-150cm2). 
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2.1.3 Culture medium 
 
MSC growth medium was composed of MesenCult (Stem Cell Technologies Inc, 
Vancouver, British Columbia, Canada) combined with appropriate antibodies, 100U/ 
penicillin.ml-1 of media (Sigma) and 100µl of streptomycin.ml-1 (Sigma) and 1ng.ml-1  
recombinant human fibroblast growth factor (rhFGF) (R&D systems, Minneapolis, 
Minnesota, USA).  
 
2.1.4 Passaging MSCs 
 
MSCs provided by ReMeBio were passaged every 6-7 days with the cells in the flask 
being divided into three new flasks, when ca. 90% confluency was achieved in T150 
culture flasks. Prior to performing cell passaging, the culture medium was examined 
for colour of pH indicator, presence of cell debris, confluence of cells and 
morphology.  
 
As a first step, spent medium was aspirated for analysis using the Bioprofile Analyser 
(Nova Biomedical, UK) to determine glucose, glutamine and lactate and ammonium 
concentration as an indication of cell health. The bioprofile analyser permits these 
tests to be carried out in series within a single unit for ca. 300µl of media feed and 
generates a printout showing the levels of all these metabolites.  
 
Following the media aspiration, the adherent surface was washed with phosphate 
buffered solution (PBS) to remove any remaining factors such as those from foetal 
bovine serum (FBS) that can interfere with enzyme activity, 
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After washing 5ml trypsin-EDTA (0.25%:0.02%) was infused into the culture flask 
which was then turned horizontally so that it coated the adherent surface and was 
incubated for 5 minutes in a 37oC 5% CO2 environment. After 7 minutes hMSC were 
detached from the base of the flask by tapping it against the open palm of the hand. 
 
Subsequently, enzyme activity was quenched using 10ml media within a 50ml 
universal flask and centrifuged at 100g for 6 minutes, following which, the supernatant 
was aspirated off to leave the cell pellet, which was then resuspended in 3ml of media 
and agitated by pipette. Of this resuspension, Iml was pipetted into each of three 
flasks, with 14ml of fresh media subsequently added to each.  Finally, these newly 
seeded flasks were transferred to a 37oC and 5% CO2 controlled Incubator (HeraCell 
150, Thermo Scientific, MA, USA). 
 
2.1.5 Refeeding of MSCs 
 
MSCs were passaged every 6-7 days and cell cultures were also refed in the interim at 
3-day intervals. Refeeding is a simple operation and merely involves aspirating spent 
media (keeping a sample for chemical analysis e.g. glucose, lactate and glutamine) and 
replacing it with an equivalent amount of fresh media. This refeeding is necessary to 
replace depleted substrates, consumed by the cells or broken down by thermal 
degradation at 37oC (glutamine). A build-up of waste products of cellular respiration 
can prove toxic to the cells and may also lead to a pH shift, which is in itself harmful 
to the growing cells and such build-ups are also mitigated by media exchange. 
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2.1.6 Cell Counting and Viability – Trypan Blue Assay 
 
200µl of cell suspension was placed in a 20ml universal tube, with an equivalent 
amount of 0.4% trypan blue solution. This solution was mixed gently by pipette and 
allowed to stand for 5 minutes to permit staining. 10 µl of the resulting solution was 
pipetted into a haemocytometer where stained and unstained cells were counted to 
form the viable and non-viable cell populations respectively. Multiplying the average 
number of cells within the quadrants of the haemocytometer by 2*104 converts the 
viable and non-viable cell counts into a concentration per ml. 
 
2.2 Yeast Culture 
2.2.1 Yeast extract peptone dextrose (YEPD) broth 
 
Yeast extract peptone dextrose (YEPD) broth is a complete media for yeast culture 
and contains yeast extract, peptone and dextrose (glucose) and distilled water. 10g of 
Difco peptone (Sigma) and 5g of yeast extract (Sigma) were added to 450ml of 
distilled water and autoclaved. 10mg of glucose was added to distilled water and 
sterile filtered through a 0.2µm cellulose acetate Nalgene filter flask to ensure sterility. 
This was then added to the autoclaved broth. 
  
2.2.2 Initial Culture 
 
Live baker’s yeast was obtained from a master baker (J.Sainsbury and Son, UK) in 
1kg units. A 0.5ml pipette tip was used to harvest a small amount of yeast cells, which 
were cultured in suspension within a 1L shake flask, containing 50ml of yeast extract 
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peptone dextrose (YEPD) broth, and agitated within an incubated orbital shaker over 
night (12-16 hours) at 250rpm and then harvested. 50ml volume and 250rpm were 
selected as operating conditions to ensure oxygen concentration did not fall to zero 
during cell growth (Talosa et al, 2002). 
 
2.3 Bioreactor System 
 
This system was inherited from previous research (Mason and Town, 2002; Chau, 
PhD Thesis, UCL, 2008). The general layout is shown in Fig. 2.1 and is of a perfusion 
design. Fresh feed is pumped into the system to maintain concentration of substrates 
within the recycle loop and an associate purge ensures the concentration of waste 
products does not rise indefinitely. An oxygenator within the recycle loop oxygenates 
the media, which is transported into the bioreactor containing the growing cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 General layout of the bioreactor system 
The system incorporates a bioreactor, containing the alginate scaffold within which the artery 
will develop, a membrane oxygenator and a feed and bleed system for providing fresh media 
and removing build up of waste products. 
 
 
Bioreactor
Oxygenator
Feed Purge
Recycle Loop 
1 
Recycle Loop 
2 
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2.3.1 System fluid transfer (pumps) 
 
The system design necessitates the use of two pumps, one responsible for perfusing 
fresh feed into the system and one responsible for the movement of media within the 
recycle loop. 
 
The type of pump selected in both cases was a peristaltic pump. Such a pump was 
chosen as it is particularly appropriate where the materials being transferred are 
vulnerable to contamination, such as cell culture medium, and must be kept isolated 
from the pump housing. 
 
The use of peristalsis as the method of propulsion has an impact upon the type of 
tubing, which must possess sufficient flexibility to ensure that an appropriate 
displacement can be created in the tube to force the media forwards. Common 
materials for such tubing include amongst others Poly Vinyl Chloride (PVC) and 
silicone rubber. In addition to flexibility the tube must possess sufficient strength to 
last around six weeks of constant displacement by the peristaltic pump. 
 
Pumps were purchased from Instech laboratories Inc (Plymouth Meeting PA, USA). 
The Instech P625/900 was selected due to its low flow rates, coupled with accuracy, 
small size (provides portability which is a pre-requisite for potential future scale-out), 
and low power demand. Such a pump is especially well suited to battery powered 
systems which could be useful for future scaling of the bioreactor especially during 
transport. Although it is likely that this system will go through many iterations of 
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development before it is suitable for use at a manufacturing scale. However, it is 
desirable to consider future requirements, even at an early stage. 
 
The feed pump (P625/900, Instech, PA, USA) is designed for operation at moderately 
low flow rates, as it was anticipated the feed rates would be much lower than the 
recycle rates. This pump was capable of flow rates of between 1.2ml.hr-1 and 24ml.hr-1 
when used with a 0.031” diameter tube (Instech, Set-up instructions; P625 Peristaltic 
Pumps).  
 
The recycle pump (P625/141, Instech, PA, USA) operates at higher flow rates than the 
feed pump within a range of 0.9ml.min-1 and 18ml.min-1 when used with a 0.093” 
diameter tube (Instech, Set-up instructions; P625 Peristaltic Pumps).  
 
2.3.2 Tubing 
 
In addition to being appropriately flexible whilst still possessing the inherent structural 
integrity to be used in tandem with a peristaltic pump there are a number of properties 
the tubing requires to be used within this body of work. 
 
Given that the gas concentration within the flow will be closely controlled it is vitally 
important that the tube is as impermeable to gases as possible. Additionally given the 
biological nature of the material being produced within the bioreactor, it is vital that 
the tubing does not leech chemicals as plastics commonly do. 
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The tubing selected to perform this work was the Tygon S-50-HL tubing (Saint-
Gobain Performance Plastics Corporation, MA, USA). In addition to meeting the 
aforementioned criteria Tygon S-50-HL is designed for use in medical and surgical 
procedures and more specifically for the perfusion of blood in peristaltic systems and 
meets all requirements of ISO 10993 a standard set relating to biocompatibility of a 
medical device prior to clinical study. 
 
The values for the pump duties provided by Instech were for silicone tubing, although 
when tested with the Tygon S-50-HL tubing, they also held true. 
 
2.3.3 Oxygenator 
 
Living cells require oxygen to respire, live and grow. In the case of stem cells the 
concentration of oxygen carries a separate importance as a signalling molecule. 
To enable such control the oxygen must thus be introduced into the system in a 
regulated manner and the device used to achieve this is a membrane oxygenator 
(Living Systems Inc., Burlington, VT, USA). This oxygenator is of a membrane 
bundle design and contains 162 polypropylene fibres of 7.5 centimetres in length with 
a polycarbonate case. This oxygenator was selected because it had proved successful 
in previous perfusion bioreactor systems developed within the Department of 
Biochemical Engineering at University College London. This device contains four 
fittings (as shown in Fig. 2.2) and oxygen diffuses from the chamber of the device into 
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the cell culture media as it is pumped through the membrane bundle. 
  
 
2.3.4 Media and Waste Storage 
 
Media and waste were stored in 3L Flexboy clinical bags with Luer locks (Sartorius), 
which were supplied in sterile condition. 
  
2.3.5 Bioreactor 
 
The perfusion bioreactor design contains a tubular alginate scaffold, containing the 
cells and created by a reverse coating method (see section 2.3.5.3). The alginate tube is 
contained within one section of a partitioned insulating container separated from 
cooled fresh media and waste awaiting disposal (see section 2.3.6). Oxygen sensors 
within flow chambers form part of the perfusion system (see section 2.3.8) and are 
positioned between the oxygenator and the alginate tube bioreactor.   
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2.3.5.1 Alginate Preparation 
 
Manugel DMB high G alginate (ISP Alginate (UK) Ltd Tadworth, UK) was mixed 
with sterile cell culture grade PBS at a concentration range of 0.5-2.5%w/v. This 
mixture within a 50ml universal tube was rolled for around 12 hours on a roller mixer 
(Bibby Stuart Scientific, Stove, UK) to ensure homogeneity.   
 
2.3.5.2 Preparation of cells for mixing with alginate 
 
Mesenchymal stem cells were harvested from tissue culture flasks using the same 
protocol as for passaging (see section 2.1.4).  Post trypsinisation, the resulting 
suspension was removed to determine cell concentration and then centrifuged in a 
50ml centrifuge tube at 100g for 10 minutes. The resulting supernatant was discarded 
to remove trypsin, which could interfere with cell attachment, and EDTA, which 
chelates calcium ions and would cause breakdown of the cross-linked alginate 
scaffold. The cell pellet was resuspended in the required amount of culture medium to 
achieve a   2x106cell.ml-1 and the same amount of alginate solution to give a final 
solution of cell concentration 106cell.ml-1 of 50:50 culture -medium and alginate 
solution.  This solution was always used within 30 minutes to form an extruded 
scaffold. 
 
The same procedure was used to produce alginate scaffolds containing yeast cells, 
however due to the yeast’s higher growth rate seeding concentration was 105 cell.ml-1 
of 50:50 culture medium and alginate solution. 
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2.3.5.3 Hydrogel Perfusion Media Preparation 
 
Alginate in solution is normally water-soluble, to cross-link it and form a solid 
structure that may be used to form a tissue engineering scaffold, a solution containing 
divalent cations is required. The cross linking solution; CaCl2 was mixed with sterile 
cell culture grade PBS at a 2%w/v ratio and sterile filtered through a 0.2µm cellulose 
acetate Nalgene filter flask. 
 
2.3.5.4 Alginate Tube Extrusion 
 
The extrusion method developed by Mason and Town (2002) and utilised and 
modified by Markusen (2005) and Chau (2008) involves reverse coating a precision 
bore glass cylinder (Glass Precision Engineering, Bedfordshire, UK). 
 
The process involves two steps (see Fig. 2.3).  
 
Step One 
Fluid containing a mixture of cells and alginate is injected into a reservoir within the 
dual inject unit developed by Mason and Town (2002) using a 1ml syringe (Becton 
Dickinson). The original dual injection unit was a bung with two injection ports, one 
for the alginate mix and one for the propelling CaCl2. A reservoir was created by 
placing a glass tube over the perfusion inlet in contact with the top surface of the 
device. The current dual injection unit involves a three way valve connected to a 
reservoir at the base of glass tube fixed in position on a steel support board with 
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permanent tubing and three way valves to incorporate quick fitting into the perfusion 
system. Using a mixture of cells and alginate as the priming solution ensures a 
homogenous distribution of cells within the scaffold from the beginning. This 
reservoir surrounds a small plastic sphere (Precision Plastic Ball Company) supported 
on a central metal cylindrical support. 
 
Step Two 
The central metal cylindrical support is a tube connected directly to a 100ml glass 
syringe (Samco, CA, USA). Following the injection of cells/alginate mixture, the 
small plastic sphere is propelled on a stream of CaCl2 at 20ml.min-1. 
 
This stream of CaCl2 forces the ball and the cell/alginate mix upwards coating the 
inside of the glass tube as it does so, with the presence of the ball creating the lumen 
of the tube. CaCl2 is chosen as the propelling fluid as when it comes into contact with 
the alginate, it causes the polymer strands to become cross-linked and solidify into a 
hydrogel scaffold tube containing ready-seeded cells. After cross-linking was 
complete (ca. 15 minutes) cell culture medium was injected to reduce the CaCl2 
concentration. The resulting cell-alginate tube was matured within the incubator for 
twelve hours before being placed in series within the bioreactor system. 
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Figure 2.3 Extrusion of alginate scaffold tube 
The extrusion of the alginate scaffold takes place by propelling a small ball up the centre of a 
hollow glass rod on a stream of calcium chloride. When this stream of calcium chloride is 
propelled through a reservoir of alginate solution, the two liquids will mix together and 
solidify, progressively coating the inside of the glass rod. 
 
 
2.3.6 Bioreactor containment and thermal insulation  
 
The VTEB system is contained within an insulating box that is partitioned into a 
number of separate sections as shown in Fig. 2.4. The walls of the box are dual 
layered, layer 1 is composed of Ultra High Density (UHD) polystyrene and layer 2 
from Normal Density polystyrene. Both layers are of approx 2” giving a total 
thickness of 4” between the system and the external environment. 
 
Within this insulating container the bioreactor is compartmentalised into three distinct 
sections. The 4oC section contains the nutrient feed-bag, the waste bag is contained 
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separately from the cold and warm sections as although temperature control is 
unnecessary, if it was incorporated into the section controlled at a physiological 
temperatures, it is likely it would begin to rot due to high bacterial proliferation rates, 
which is highly undesirable. The bioreactor itself is within the 37oC section so as to 
match the normal environment an artery would experience when grown in-vivo. 
 
 
 
Figure 2.4 Partitioned bioreactor system container 
The different sections of the system are partitioned into different regions of a thermally 
controlled and insulated contained. The alginate scaffold containing the developing artery is 
controlled at 37 degrees Celsius, human body temperature. Fresh media is controlled at 4 
degrees Celsius to limit degration of active components while waste although stored in a 
separate compartment is not temperature controlled. 
 
 
2.3.7 Cooling of fresh feed 
 
Cell Culture media contains a number of components that are thermally unstable. To 
ensure media remains of suitable composition for the life of the experiments, the 
bioreactor incorporates a facility for cooling the store of fresh media prior to injection 
into the system. This required cooling is provided by a thermoelectric assembly that 
allows heat to be absorbed by a series of heat exchangers equipped with fans 
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(Supercool, Sweden). This assembly is placed in the external wall of the insulated 
media chamber of the bioreactor container (see Fig. 2.4). 
 
2.3.8 Oxygen Measurement 
 
Oxygen measurement takes place using fluorescent oxygen spots (see section 1.5.4) 
that are excited by 2mm polymer optical fibres (Presens), which are also responsible 
for transmitting fluorescence measurements. Provided the vessel containing the liquid 
is transluscent and non-fluorescent this process can take place non-invasively and will 
not affect sterility.Mesaurements from these fibre optic cables are converted into a 
digital signal by a Fibox-3 system (Presens) that may be processed with a personal 
computer. A flow chamber was developed by Alfred Ding and Martin Town within the 
department of biochemical engineering at UCL to allow the media within the recycle 
loop to flow directly over either one or two oxygen sensitive spots in series. A 
schematic of this flow chamber is shown in Fig. 2.5. 
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Figure 2.5 Flow chamber for oxygen spots designed by Ding and Town. 
The flow chamber allows media flow in and out to be spread evenly over a contained oxygen 
fluorescent spot. This permits oxygen concentration to be measured. 
 
 
2.4 Computer modelling 
 
2.4.1 MATLAB 
 
MATLAB (Mathworks, MA, USA) is a numerical software package designed 
primarily for mathematical analysis. Its name, a portmanteau of Matrix and Lab, 
relates to the fact that it is most effective when writing programs based upon the 
manipulation of sets of matrices and tensors.  
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MATLAB’s greatest strength, and one that made it appropriate for use in this work, 
was its large user population (in excess of 1 million [Mathworks]). MATLAB is 
capable of forming an interface with most common mathematical software packages 
used in both industry and academia. For this work these packages included Microsoft 
Excel (Microsoft Corporation, WA, USA) and Comsol Mutliphysics (Comsol AB, 
Stockholm, Sweden). Additionally, a number of toolboxes expanding the number of 
available functions have been designed by users and are supplied commercially or 
without charge online. The most useful and most extensive of these of these, which is 
supplied as part of the standard MATLB package, is Simulink. Simulink, which was 
used extensively to model the bioreactor, is designed specifically for simulating 
dynamic systems such as the VTEB. Systems to be modelled can be constructed from 
a number of pre-programmed blocks, each of which provides a graphical 
representation of a portion of MATLAB code to form the overall model.  A screenshot 
of a simple Simulink program can be seen in Fig 2.6 and in the case of the example 
permits the use to view and generate a sine wave signal and view the integration of 
that sine wave signal over a specified time range. 
 
 
Figure 2.6  A screenshot of a simple simulink program (www.mathworks.com) 
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2.4.3 Comsol Multiphysics  
 
Comsol Multiphysics 3a (Comsol AB, Stockholm, Sweden) is a finite-element 
modelling (FEM) package and was used to model the effect of cells growing within 
the bioreactor. Due to symmetry around the centre line of the tube within the 
bioreactor it was possible to reduce it to one half of a two-dimensional slice as shown 
in Fig. 2.7. FEM is a technique for finding approximate solutions to series of partial 
differential equations (PDEs). Complex, non-linear are broken into smaller regions 
(finite elements), These regions are solved individually with each solution considering 
only immediately adjacent regions. This division of a structure into finite elements is 
referred to as the mesh, with each intersection, a node. A finer mesh yields a more 
accurate solution. However this accuracy comes at the cost of complexity, computer 
power and thus greater time to solution. A simple finite element system is shown in 
Fig. 2.8. 
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Figure 2.7 Reduction of Comsol Model from 3D to 2D 
The three-dimensional alginate scaffold can be reduced into a two dimensional slice due to 
symmetry in the 3600 angle and also down the central axis. 
 
 
Figure 2.8. A simple example of Finite Element Modelling (FEM) 
Finite element modelling allows the division of a non-linear system into a number of finite 
elements. The mesh dividing up this system is composed of a number of nodes, labelled Nx in 
the diagram above. Individual finite elements are labelled Ex. 
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Given the non-linear nature of a number of parameters in the system, the solver 
method was transient and non-linear, the mesh was refined up to 1800 elements as a 
balance between accuracy and speed of solution and at each time step Newton 
iterations were used as the solution method.  
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Chapter 3  Modelling the Vascular Tissue Engineering 
Bioreactor (VTEB) 
 
 
3.1 Introduction 
 
 
The aim of this chapter is to demonstrate how the tissue engineering system under 
consideration may be abstracted into a set of discrete components and how each of 
these components may in turn be represented by a set of equations. Finally it is shown 
how these equation sets can be used to create a process model suitable for testing 
control strategies for a number of variables in subsequent chapters. 
 
A process model represents an abstraction of a real system and is by nature simplified 
to exclude extraneous information. Assumptions are used to achieve such 
simplification and although the intention is to minimise error and to keep it within 
acceptable tolerances, it is of vital importance that the limitations of any model are 
well understood so that is only used to represent appropriately prescribed systems. 
 
The primary step in the development of any model representing a system or a process 
is to determine the important parameters; constants and variables and equations that 
characterise the system. Marshall (PhD Thesis, UCL, 1992) whilst exploring the use of 
comparative reasoning tools and their application to fermentation studies divided the 
required information into sub-groups as shown in Fig 3.1. 
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Figure 3.1 Sub-Division of Fermentation Data [Marshall (1992)] 
Marshall, 1992 demonstrated that fermentation, a biological process can be divided into time 
variant and invariant data. The same type of approach can be taken for the tissue engineered 
artery process. 
 
Fermentation although similar to the operation of a tissue engineering bioreactor is 
still different in some key respects, as a result both the constituents of each of the 
subgroups shown in Fig. 3.1 and their values must be determined specifically for the 
VTEB.  The models used in this work have been built using Simulink. Simulink 
programs are built using time dependant and independent variables, thus a 
complementary approach to that taken in Fig 3.1 has been adopted for this work. 
 
3.2 Model Variables 
 
The primary grouping of required data is into time variant and time invariant. Time 
variant data are values that will largely be determined by the model and in an 
experimental setting will be those parameters that are unknown at outset and are either 
estimated, monitored or controlled. Such parameters will be specified but will not be 
assigned a value and are shown in Table 3.1. Time invariant data is usually known or 
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can be estimated prior to model development or experimentation. It can be subdivided 
into three categories: batch sheet data i.e. equipment and raw materials used, 
descriptive data i.e. user imposed conditions and expert comments such as noting that 
the cells on visual inspection appeared smaller than normal and other factors that may 
not be recorded under a fully automated analysis. 
 
Table 3.1 Time Variant Data for the VTEB 
 
Temperature 
Air flow rate 
Oxygen transfer coefficient 
pH 
Dissolved Oxygen Tension 
Dissolved Carbon Dioxide 
Concentration 
Oxygen uptake rate 
Cell concentration 
Substrate concentration 
Waste product concentration 
Cell growth rate 
Waste production rate 
Substrate consumption rate 
Substrate breakdown rate 
Waste product breakdown rate 
Oxygen diffusivity in alginate 
Feed flow rate 
Recycle flow rate 
Shear stress on alginate 
Cell viability 
Cell physiological state 
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3.2.1 Batch sheet data 
 
 
Batch sheets consist of the parameters that would be recorded as standard within a 
research laboratory book or batch/process logbook. These are normally noted down 
according to a framework that is generally standard to the institution or company 
within which the work takes place. For the VTEB the parameters shown in table 3.2 
have been chosen. These parameters will have a slight variation depending upon cell 
source selected as shown in note 2 below. All these parameters are user controlled and 
will have a known magnitude or value prior to experiment commencement or model 
development. 
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Table 3.2 Batch sheet data items 
 
Parameter Sub Parameters 
  
Batch Number  
Cell Type  
Start date and time  
End date and time  
Medium Composition 
Supplier 
Batch Number 
Bioreactor number1  
Sterilisation 
procedure of 
bioreactor 
 
Starting Conditions Temperature, pH, 
Feed Composition 
Inoculation Source2 
Cell Seeding 
Density 
Passage Number 
 
Notes 
1. It is assumed that many VTEBs are operating simultaneously with each 
carrying a unique identification number 
2. If autologous, this will require a full patient history, including age, sex, health, 
race and medical treatment to date. Additionally a full data trail will be 
required from cell harvest onwards. If allogeneic, this will require a supplier, 
batch number and history of storage conditions to date. 
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3.2.2 Descriptive data (constants)  
 
 
Descriptive data represents the constants relevant for the dynamic systems within the 
bioreactor. Such data include maximum possible values for different variables and will 
assist in both forming equations (as boundary conditions) to model the VTEB and may 
also be used for assembling diagrams that graphically represent the various operating 
tolerances of the system (Woodley et al, 1996, Zhou et al, 1999).  Several variables 
have to be estimated using averages from literature such as MSC growth rates which 
vary between donors. Various attempts have been made to produce the biochemical 
equivalents of stoichiometric equations for cellular processes and the use of ranges has 
been required to incorporate this uncertainty. This model has used a similar approach. 
Table 3.3 Descriptive Data items 
 
Maximum cell growth rate 
Maximum specific cell growth rate 
Maximum substrate consumption rate 
Maximum substrate degradation rate 
Maximum waste production rate 
Chemistry of substrate degradation 
Maximum waste degradation rate 
Chemistry of waste degradation 
Yield of cells on substrate 
Yield of waste on substrate 
Maintenance consumption rates 
Maximum cell number 
Alginate concentration 
Alginate scaffold dimensions 
Oxygen diffusivity in medium 
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3.2.3 Expert comments 
 
 
Although the temptation due to cost and efficiency is to completely replace human 
operators with automated machine driven alternatives, the user must not be considered 
incompetent and instead should be encouraged to apply their knowledge to a system 
designed to complement rather than replace and allow the user to exercise their 
expertise more effectively (Marshall, 1992, Dreyfus and Dreyfus, 1986). The 
weakness of automation lies in its inability to anticipate and although knowledge 
based learning algorithms (Trilea et al, 2001) and neural network based systems 
(Zulkeflee, 2007) are being developed for fermentation and other bioprocesses these 
still struggle to anticipate unusual problems for which the human brain is better suited. 
An additional risk of excessive reliance upon automation is that in the event of some 
sort of failure, understanding of how the equipment operates is limited to such a small 
number of people that potential catastrophes may be impossible to avert (Kletz, 1999). 
Various human interactions can be incorporated into the control system such as 
identifying contaminations by the presence of fungal flocks in the outlet stream. These 
can be useful to identify failure at a pilot stage but are impractical for scaled-out 
systems as manufacturing scales. 
 
 
3.2.4 Forming equations 
 
 
Table 3.3 represents a comprehensive list of unknowns that are required to form an 
effective and robust model of the VTEB. A list of such values although an essential 
first step, will in isolation be ineffective without being placed in context through the 
use of series of equations. The VTEB is a dynamic system within which time variant 
parameters are constantly changing, often several of these parameters are inter-related 
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and it is vital that such relationships are defined through the use of appropriate 
mathematical formulae. The derivation of such formulae requires a logical approach to 
be taken and the method implemented here is to consider each unit operation within 
the system as a distinct model. This represents an attempt to simplify the problem by 
abstracting it into smaller constituent parts that may be solved sequentially and then 
recombined.  
 
The key control variables within the VTEB are those relevant for cell culture and 
include: pH, metabolite concentration, waste concentration, and dissolved oxygen 
tension (DOT). Using the relevant parameters listed in table 3.3, series of equations 
have been formulated to describe how these variables change in time to form a model.  
 
The VTEB system is a relatively simple process to deconstruct, as it is composed of 
distinct unit operations (see Fig. 2.1), based around a perfusion bioreactor. Media is 
pumped through the lumen of the developing artery to supply nutrients and 
metabolites to the cells contained within.  
 
This media is subsequently passed through a 162-fibre bundle membrane oxygenator 
where oxygen will diffuse into the media so that this too may be transported through 
the lumen allowing diffusion into the alginate scaffold, which contains the cells. 
 
The system is of a ‘feed and bleed’ design, the intent of such a design being to reduce 
toxic waste product build up through a purge stream and gradually infuse the system 
with fresh media. The suggested flow rates of the feed and purge streams are relatively 
small as the cell growth rates are slow hence build up of waste is a gradual process. 
The various ratios of the purge to the recycle (a function of cell type and bioreactor 
 106 
operation) can be determined through simulation and will be discussed later in more 
detail, however it should be noted that a small purge rate relative to the recycle rate 
has the added benefit that cell factors responsible for encouraging cell growth are 
permitted to accumulate within the system. However, this also allows toxic waste 
products to build up, necessitating optimisation of all flow rates. 
 
The VTEB System has been deconstructed into 6 separate parts for analysis; 
 
These six component parts are listed below and illustrated in Fig, 3.7. 
 
i. Bioreactor  
ii. Oxygenator 
iii. Purge 
iv. Feed 
v. Recycle Part 1 
vi. Recycle Part 2 
 
Each of these sections has been modelled discretely and then incorporated into a final 
overall model of the VTEB System. Knowing that the main control variables will be 
dissolved oxygen and metabolic component concentrations, emphasis will be given to 
deriving equations representing the change of these parameters in relation to other 
factors such as cell number and flow rate. 
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3.3 Modelling the oxygenator 
 
The oxygenator is responsible for adding oxygen to the media passing through it at a 
rate that may be derived from plug flow equations (Metcalfe, I.S.  1998). The rate of 
oxygenation is directly related to; temperature of media, area of exchange to volume 
ratio, the media flow rate through the system and both the saturation concentration of 
the media and the existing concentration of oxygen with the media on entry; the 
difference between these latter two values represents the concentration driving force 
for mass transfer. The Oxygen Transfer Rate into the media flowing through the 
oxygenator follows the standard mass transfer equation (3.1, Doran, 1995).  
 
OTR = kLa(CL-C*)    (3.1) 
 
(OTR is oxygen transfer rate, kLa is the overall oxygen transfer coefficient, CL is the 
concentration of dissolved oxygen in the bulk and C* is the saturation constant of 
oxygen in cell culture medium. (Doran, 1995) 
    
kLa= f(T,pH,F1,a)    (3.2) 
 
(T is temperature of cell culture medium, F1 is the flow rate of the bulk liquid through 
the oxygenator, a is the ratio between surface area and volume). 
 
No cells or living material is present within the oxygenator, thus it is assumed that 
with the exception of causing a change in oxygen tension it has no further impact upon 
the composition of the media e.g. metabolic components such as glutamine, glucose or 
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waste products. Additionally it is assumed that oxygenation of the media is isothermal 
and hence has no impact upon temperature. 
 
To calculate the oxygen transported into the system in a single pass through the 
oxygenator the uptake rate between the inlet and outlet of the oxygenator must be 
determined as outlined in equations 3.3-3.7. 
 
€ 
dCL
dt =OTR    (3.3) 
 
€ 
dCL
dt = kLa(CL −C*)   (3.4) 
 
€ 
dCL
CL −C *
= kLa dt   (3.5) 
 
€ 
lnCL ,new −C *CL −C *
= kLa* t  (3.6) 
where,  
€ 
t = VRF     (3.7) 
 
The only unknown value within these equations is the overall coefficient of oxygen 
transfer; the kLa. Experiments have been performed relating this to the bulk flow of the 
liquid.  For these experiments media temperature was assumed to be 37oC as the 
oxygenator was within a temperature controlled environment and media was perfused 
through the oxygenator at a variety of flow rates in the absence of cells. By measuring 
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oxygen accumulation within the system and through the use of equations 3.3-3.7 a 
relationship between kLa and the flow rate through the oxygenator (recycle rate) was 
determined as shown in Fig. 3.2.  
 
 
Figure 3.2 Relationship between bulk flow through the oxygenator and the 
oxygen transfer coefficient. 
The oxygen transfer coefficient kLa varies with the rate of flow through the oxygenator. 
Varying the flow rate through the oxygenator and determining the change in oxygen 
concentration between input and output for each flow rate allowed determination of this 
relationship.  
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By fitting a curve to the empirical data as in Fig, 3.3, an equation can be formed for 
the relationship between recycle flow rate and oxygen transfer coefficient. 
 
3.4 Modelling the bioreactor 
 
The VTEB is of a bespoke design (Mason and Town, 2002) and is intended to produce 
a tube like structure approximating to a tissue engineered CABG graft. This structure 
extrudes a cell-alginate mixture into a polymeric scaffold seeded at inoculation density 
of cells. The properties of this scaffold such as density and length are of key 
importance to the modelling of the bioreactor as they affect the porosity of the 
hydrogel (and thus mass transfer properties and total cell number). These properties 
are explored in section 3.4.1.  
 
The cells within the scaffold will consume substrates such as oxygen and glucose for 
use in respiration to allow growth and proliferation. This consumption will vary with 
the number of cells present in the scaffold. Respiration in addition to producing energy 
and leading to the production of biomass will also result in waste by-products that are 
often cytotoxic. This consumption is the prevalent driving force for mass transfer into 
the scaffold and diffusion is much smaller by comparison. Equations describing the 
dynamics of the growth and respiration by the encapsulated cells are derived in 3.4.2 
and 3.4.3 respectively. 
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3.4.1 Modelling the alginate scaffold 
 
As outlined in section 2.3.5, cells are grown in the bioreactor within an extruded 
alginate scaffold. A relationship between the volume and concentration of alginate 
used in the priming solutions and the scaffold length can be used to determine the 
density of the scaffold and hence the total cell number present in a scaffold for a given 
cell number and other properties such as porosity. 
 
Chau (2009) has previously determined a relationship between various alginate 
properties and the length of the scaffold. In an attempt to replicate results obtained by 
Chau, the data shown in Fig. 3.3 was obtained relating alginate tube length to initial 
volume of 1% alginate solution. 
 
 
 
Figure 3.3 Length of alginate tube based upon the priming volume of 1% 
alginate solution 
The length of the alginate scaffold varies with the volume of priming solution. Higher 
volumes lead to greater lengths.  
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Clearly this shows a discrepancy and as a result the experiments were repeated several 
further times, the results still fall within the error bars shown on the Scutcher (2011) 
data in Fig. 3.3. The variation could be due to a number of factors including variations 
of alginate source or batch and possibly technique. Despite a satisfactory explanation 
for the difference not being obtained this thesis is based upon the results obtained by 
the author of this work.  
 
The alginate concentration within solution will also have an impact upon various 
parameters of the tube but most ostensibly the length due to increased viscosity 
increasing resistance to the propelled ball. Fig. 3.4 shows how the length of scaffold is 
affected by the concentration of the alginate solution used to prime the extrusion 
device and unsurprisingly the effects of resistance caused by an increased alginate 
concentration leads to a shorter tube being formed. Scutcher (2011) relates to data 
obtained during this work. 
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Figure 3.4 Length of alginate tube based upon priming volumes of 1% and 2% 
alginate solution 
Use of the higher concentration alginate, 2%, leads to a shorter scaffold tube length, than use 
of the 1% concentration alginate. This is due to increased resistances from the higher 
concentration alginate on the internal wall of the glass rod used in the inverse coating 
procedure. 
 
 
The remaining issue regards selection criteria for the concentration of the scaffold. For 
these experiments a series of scaffolds were formed from alginate of various 
concentrations. These scaffolds were perfused within the bioreactor for five-day 
periods and it was found that while the 1% concentration scaffold degraded over time 
and appeared to erode away, the 2% scaffold was sufficiently robust as to remain 
intact at the end of the experiment. Interestingly a 3% scaffold appeared to be 
excessively brittle as it broke in half after two days rather than eroding away. This 
may be because higher alginate concentrations of alginate result in less homogenous 
tube formation. This lack of homogeneity means that certain areas of the tube are 
significantly stronger than others and manifests itself as brittleness. Table 3.4 
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summarises the parameters determined in this section to allow modelling of the 
alginate scaffold. 
 
 
Table 3.4 Alginate scaffold parameters for modelling 
 
 
Parameter Value Source 
Alginate scaffold length 0.33m Assumed 
Alginate scaffold conc. 2%w/v Experimentation 
Priming solution volume 1.2ml Experimentation 
 
 
 
 
3.4.2 Modelling cell growth in the bioreactor 
 
 
The next stage after determining the properties of the scaffold and prior to establishing 
the relationship of the various substrate uptake rates to the cell number, a method of 
modelling the cell growth must be established. 
 
The cell number is determined by the growth rate, which varies with cell type. This 
growth rate is related to the concentration of the different substrates and directly to 
whichever of those is limiting (Doran, 1995). Equation 3.8, chosen for modelling cell 
growth is a standard one used for many types of population growth. One of the most 
developed areas of modelling that can be considered analogous to the growth of tissue 
engineered organs is tumour growth.  Tumour growth can be modelled using the 
Verhulst equation (Forys and Marciniak-Czochra, 2003). The Verhulst equation was 
originally developed for modelling population growth were the growth rate is related 
to existing population and the amount of available resources (equation 3.8).   
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€ 
dP
dt = rP 1−
P
K
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟     (3.8) 
 
P is the population, r is the growth rate and K is the carrying capacity i.e. maximum 
population. 
 
Equation 3.8 can be solved to give equation 3.9 showing population at any time as a 
function of time. 
 
€ 
P(t) = KP0e
rt
K + P0 ert −1( )
    (3.9) 
 
Where P0 is initial population. 
 
Substituting the general terms for population growth with cell growth variables 
provides equation 3.10. 
 
€ 
X(t) = XMAX X0e
µt
XMAX + X0 eµt −1( )
   (3.10) 
 
Where X(t) is the cell growth at time t, XMAX is the maximum cell number with the 
scaffold, X0  is the seeding cell number and µ is the specific cell growth rate. 
 
The specific cell growth rate is unique to cell type and may be obtained from the 
Monod equation (equation 3.11). This equation incorporates terms for the maximum 
 116 
specific growth rate when all substrates are in excess and terms for the limiting 
substrate. 
 
€ 
µ =
µmaxS
S + KS
     (3.11) 
 
Where µmax is the maximum specific growth rate, S is the concentration of limiting 
substrate e.g. glucose, sugar, KS is the Monod coefficient for S, i.e. concentration of S 
at which µ is one half of its maximum. 
 
For the purposes of this chapter and the relation of the cell growth rate to substrate 
uptake, the limiting substrate will be assumed to be dissolved oxygen concentration 
with other substances in excess. 
 
3.4.3 Modelling substrate uptake in the bioreactor 
 
The uptake of the various substrates is directly related as the limiting substance 
dictates the overall rate of respiration. Equation 3.12 indicates how oxygen and 
glucose uptake are directly related through the basic equation of respiration: 
 
€ 
C6H12O6 + 6O2⇒ 6H2O+ 6CO2   (3.12) 
or 
Glucose + Oxygen  Water + Carbon Dioxide 
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For this reason the relationship between substrate uptake rate (SUR) and cell growth 
rate is illustrated using oxygen uptake rate (qO2) in place of SUR; the assumption 
being that dissolved oxygen concentration is the limiting factor. A similar relationship 
may be assumed to hold for any substrate that is limiting. 
 
 
 
Figure 3.6  Phases of the cell cycle [Adapted from Alberts et al (1994)] 
Cell division is composed of four key stages; S – the synthesis phase, G2  - A gap between S & 
M phases, M – the mitosis phases and G1 – A gap between M & S phases. Cells that have 
ceased dividing and become senescent are often referred to as being in a G0 phase. 
 
Within a random population of cells, division is almost never synchronous, at any 
given time a proportion will be operating within a part of the cell cycle and 
undergoing divisions and the remainder will have left the cycle and have ceased 
dividing (see Fig. 3.6). It appears that cells undergoing division consume a greater 
amount of oxygen (Zhao et al, 2005; Gosmann et al, 1988) this is possibly because the 
energy required to produce the components of a new cell is significantly larger than 
that required to merely sustain a cell through its normal operation. This greater energy 
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demand requires a greater level of aerobic respiration to generate it and thus a larger 
qO2 by the cell is observed. 
 
In the case of the bioreactor, one of the key limiting factors to division will be the 
available space for the cells as they proliferate. As the maximum cell concentration is 
reached the proportion of cells dividing will reduce and as such the average qO2 per 
cell will reduce (Gosmann et al, 1988).  qO2 dependant upon cell number and as such 
must be related to cell growth.  
 
A number of assumptions are made as follows and an equation representing this 
relationship may be derived (see equation 3.13). 
 
1. Dividing cells consume more oxygen than senescent cells. 
2.  At any given time, a proportion of cells within a population will be 
dividing, whilst another proportion are senescent 
3. Space limited cells will no longer divide hence cells at high 
concentration within the alginate scaffold will show a lower 
average oxygen consumption rate as the senescent proportion 
begins to dominate. 
 
The single pass oxygen consumption balance between the inlet and outlet of bioreactor 
can be determined by equation 3.13 
 
€ 
qO2 = qO2MAXCELL *
dX
dt + qO2MAINTENANCE
CELL * X   (3.13) 
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Where qO2 is the oxygen uptake rate (mmol.s-1), qO2,MAX is the oxygen uptake rate per 
dividing cell per second (mmol.cell-1s-1), qO2,MAINTENANCE is the oxygen uptake rate per 
senescent cell per second (mmol.cell-1s-1) and X is the cell number. 
 
For a volume of the bioreactor VR, equation 3.7 gives the residence time τ, the time 
required for a single pass. 
 
€ 
d([O2]*VR
dt = −OUR     (3.14) 
 
Where; VR is the volume of the bioreactor, t is the time, [O2] is the oxygen 
concentration in the bulk liquid flow. This equation may be rearranged and solved to 
give equation 3.20. 
 
€ 
d O2[ ]
dt =
−OUR
VR
    (3.15) 
 
€ 
d[O2] =
−OUR
VR
dt     (3.16) 
 
€ 
d[O2][o2 , final ]
[o2 ,initial ]∫ = −OURVR
dt
0
τ
∫    (3.17) 
 
€ 
[O2] final − [O2]initial = Coutlet −Cinlet =
−OUR
VR
τ  (3.18) 
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Therefore the single pass oxygen consumption as a total is given by equation 3.18 * 
VR . 
 
ΔO2, SP = - OURτ    (3.19) 
 
This single pass oxygen consumption may be applied to any limiting substrate and 
together with equations 3.11 and 3.13 provide the relationships necessary to model 
cellular growth and the associated consumption of metabolites. These relationships 
characterise the bioreactor and along with the earlier model derived for the oxygenator 
constitute a large part of the information required to create a model suitable for testing 
control strategies. The only remaning requirements to form such a model are equations 
representing the recycle loop, feed and purge streams and the impact these flows will 
have upon bulk concentrations within the system. 
 
3.5 Modelling system flows 
 
The major system flows are labelled in Fig. 3.7. The recycle loop represents those 
portions of the system where the media is transported between the key parts of the 
system already considered. The only equation required to represent the recycle loop is 
the residence time or time delay between the media moving between two points 
(equation 3.20) 
 
€ 
τD =
VRLS
F     (3.20) 
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(τD is transport delay (s), VRLS is the volume of the recycle loop section between the 
two points under consideration (ml), F is the recycle rate flow rate (ml.min-1). 
 
To determine the impact the purge and feed flows have upon the bulk concentrations 
of oxygen and other metabolites within the system a series of mass balances 
(Equations 3.21-3.25) have been derived. 
 
Figure 3.7 Flows within the VTEB system 
 
 
Feed overall flow rate 
F2 = F1 + F6     (3.21) 
 
Feed substrate component balance 
xF2 = xF1+xF6      (3.22) 
Where x represents the concentration of a component within the flow (mM) 
 
Purge overall balance 
F4 = F5 – F3     (3.23) 
 
Purge substrate component balance 
xF4 = xF5 – xF3    (3.24) 
 
Overall system balance 
F1 = F4      (3.25) 
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These mass balances may be combined with the generation and consumption terms 
developed in previous sections characterising the oxygenator and the bioreactor to 
give overall equations for substrate concentration changes in the overall system.  
 
3.6 Overall Model 
 
By combining the separate models that have been developed within this chapter, a set 
of equations may be collated that represent the overall system. Equations 3.26 to 3.38 
represent the necessary information to determine oxygen and other substrate changes 
within the system (see Fig. 3.8). 
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The following series of equations (3.26 to 3.38) and starting conditions, derived within 
the body of this chapter characterises the variables shown in Fig 3.8. All the terms for 
these equations have been defined previously. 
 
€ 
dCL
dt = kov (C −C*)    (3.26) 
€ 
kOV = −10−6F 2 + 6 ×10−5 + 5 ×10−6   (3.27) 
€ 
dCL
dt =
−OUR
VR
     (3.28) 
€ 
OUR = A dXdt + BX     (3.29) 
€ 
dX
dt = µX 1−
X
XMAX
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟     (3.30) 
€ 
C = CL −
OUR
VR
τ     (3.31) 
€ 
τOxy =
VOxy
F      (3.32) 
€ 
τBio =
VBio
F      (3.33) 
€ 
τRL1 =
VRL1
F      (3.34) 
€ 
τRL1 =
VRL 2
F      (3.35) 
 
The required starting conditions are given by equations 3.36 to 3.38. 
CL (t =0)      (3.36) 
C (t=0)      (3.37) 
X (t=0)       (3.38) 
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The values for the constant variables contained within these equations are listed in 
Table 3.5.  
Table 3.5 Constants within the overall model for MSC 
Constant Value Source 
VR,1 12.26 ml n/a 
VR,2 12.26 ml n/a 
VO.2 0.549ml Manufacturer 
VBIO 1.151ml n/a 
µ 0.022hr-1 Bruder S.P. et al, 1997 
A Derived in next section Zhao et al, 2005 
B Derived in next section Zhao et al, 2005 
X (t=0) 106 cells.ml-1 n/a 
C (t=0) 0.079mM.L-1 n/a 
CL (t=0) 0.079mM.L-1 n/a 
XMAX Derived in next section n/a 
Monod Constant for 
oxygen 
10-6mol.L-1 Peng and Palsson, 1996 
 
A similar set of equations can be used to determine the concentration of other 
substrates or metabolites throughout the system but will exclude the terms relating to 
the oxygenator as this unit has no effect upon the system except in terms of the oxygen 
concentration. 
 
3.7 Conclusions 
 
This basic VTEB model outlined in this chapter provides a starting point for the 
development of a control system to maintain environmental conditions within the 
system. Simultaneously solving the set of differential equations (3.26-3.35) using 
specified boundary conditions will provide oxygen and substrate curves against time 
and location in the system. Altering variables within the model allows for control 
strategies to be tested, using the variation in the oxygen and substrate outputs from the 
bioreactor to measure success.  
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Using the model developed in this chapter each control parameter has had a distinct 
control system designed separately in isolation from the others, DOT (Chapter 4), pH 
(Chapter 5), and respiratory substrates and waste (Chapter 6). These control systems 
are ultimately combined into an overall control model (Chapter 7).  
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Chapter 4  The control of oxygen tension within the VTEB 
 
 
In this chapter the model developed in the previous section is implemented to 
determine an appropriate process control strategy for maintaining dissolved oxygen 
tension (DOT) within appropriate ranges within the vascular tissue engineering 
bioreactor (VTEB). A strategy is provided for maintaining DOT to allow the 
proliferation of mesenchymal stem cells (MSC) with the ultimate goal of forming a 
healthy tissue engineered arterial graft. Methods are also provided for estimating 
health and developmental state of these grafts non-invasively. 
 
4.1 Introduction 
 
 
 DOT in solution represents a key parameter involved in cell culture, being a key 
respiratory substrate as well as a signalling molecule. It is thus vital that its variation is 
both monitored and where appropriate controlled within the VTEB. 
 
Most experiments involving mammalian cells seek to replicate normal in-vivo 
conditions and in the case of DOT, use concentrations comparable to those measured 
within the relevant part of the body. 
 
For arteries the appropriate physiological DOT depends upon the location within the 
body, the further downstream from the lungs the lower the DOT will be. In fact the 
consideration of the in-vivo value experienced within an artery is of little importance 
for this work, rather the in-vivo conditions within the source of the progenitor cells and 
during angiogenesis has been deemed to be of primary concern; i.e. the oxygen tension 
within the micro-environment of the bone marrow where mesenchymal stem cells are 
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located and may be harvested from. This is because the work within this thesis will 
seek to effectively control a bioreactor during the preliminary stages of tissue 
engineering an artery. This first stage considers the proliferation of MSC throughout a 
tubular scaffold and attempts to limit differentiation. The second stage that will not be 
considered within this work will incorporate controlling conditions so as to encourage 
the differentiation of these MSC into the three layers of a mature artery. 
 
4.1.1 Human mesenchymal stem cells (hMSC) 
 
Low oxygen tension has been shown to be an integral component of the 
microenvironment of the human mesenchymal stem cell (hMSC), with low 
concentrations such as 2% leading to higher protein levels and expression of markers 
such as those of osteoblast and adipocyte cells when compared with culture at 20% O2 
(Grayson et al, 2006). 
 
As the bone marrow is a complex, relatively large structure, the pO2 is not 
homogeneous although the average has been measured as 5% (Pennathur-Das and 
Levitt, 1987) with the maximum concentrations found at the edge of the sinus wall 
where a venous partial pressure is experienced (Mostafa et al, 2000) It is within the 
lower pO2 environment that Mesenchymal Stem Cells (MSCs) exist, along with other 
progenitor cells, grow and proliferate (Mostafa et al, 2000). Ishikawa and Ito (1988) 
reported the range of oxygen concentrations within the region of the bone marrow 
where these undifferentiated progenitor cells reside to be 52.0mm±11.2mmHg 
(0.069±0.020mmol.L-1). It is this range that provides the boundaries of the oxygen 
control window. 
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4.1.2     Yeast 
 
Yeast is a flexible organism with regard to cell metabolsm. It does however 
fundamentally differ from the mammalian cell lines for which it acts as a surrogate, as 
it produces a diauxic growth curve. When oxygen is limited, yeast cells may switch 
from an aerobic method of respiration to an anaerobic form, requiring less oxygen and 
hence causing oxygen to cease to limit growth rate.   
 
In anaerobic cultivation yeast forms ethanol as a by-product. The intention is to 
operate at a value of DOT that leads to the highest oxygen consumption possible, to 
represent an effective test of the proposed VTEB control system with the caveat that 
some value comparable to physiological conditions will be used wherever possible. 
Baumberger (1939) demonstrated that yeast cells possess a constant respiration rate 
from 160 mmHg to at least as low as 0.24 mmHg, a similar assertion was made by 
Winzler (1941) who showed that in the presence of appropriate substrate, the oxygen 
uptake rate would remain constant to an oxygen concentration of 0.2mmHg. Any 
operation within this range should not affect the respiration rate of the yeast cells 
provided substrate concentration is sufficient. 
 
4.1.2 Measurement of dissolved oxygen tension (DOT) 
 
Measurement of DOT was performed non-invasively using PreSens microspots 
[PreSens GmBH, Germany]. These spots decay with a fluorescence life span 
proportional to the oxygen concentration within liquid local to the position of the 
microspot (see Chapter 2). These spots were positioned to measure the DOT at the exit 
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of the bioreactor as this minimises the delay between the unknown oxygen 
concentration at that point and any responding control action. 
 
4.2 Methods of controlling DOT within the VTEB 
 
Using the model developed in chapter 3 it is possible to test various control strategies, 
this section outlines possible methods by which this control can take place and the 
selection criteria used to determine the most appropriate. 
 
4.2.1 Control mechanism and manipulation of variables 
 
Oxygen transfer across the oxygenator membrane obeys the standard mass transfer 
equation 4.1. 
€ 
dCL
dt = kLa(C *−CL )     (4.1) 
The mass transfer coefficient (kLa) of the oxygenator is a function of the flow rate of 
the gas or the liquid stream flowing through it. Modifying the gaseous side, would 
involve using a set of gas mass controllers regulating the flow of oxygen, carbon 
dioxide and a nitrogen balance stream. A feed back loop could be used to link DOT 
within the system to the mass transfer controllers (MTCs) via an appropriate controller 
to keep the oxygen within the system at an appropriate set point. A similar approach 
has been used in previous bioreactors (Altman et al, 2001, Zhao et al, 2005). 
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The disadvantage of implementing such a system is that it carries a high cost in terms 
of unit cost and also limits the potential to scale the system. The price of three gas 
mass controllers whilst not prohibitive is expensive and also adds to the overall 
complexity of the system – increasing the number of components of which any 
individual failure will be critical. 
 
The value of the kLa within the oxygenator may be changed in a second way, by 
altering the flow rate on the liquid side.  In a manner analogous to the physiology of a 
mammal, in the event of an increase in oxygen demand where the heart will work 
harder, when the oxygen demand of the cells within the alginate scaffold is greater, the 
pump will increase the flow rate of the culture media.  Such a method has the 
advantages of being relatively cost effective, as the entire required infrastructure 
already exists within the system. Small oxygen sensing spots [Presens GMBH, 
Regensburg Germany] are incorporated with the system and used to measure the DOT 
before and after the alginate scaffold. 
 
If the output from these sensors is processed to specify the speed at which the pump 
responsible for the recycle rate works, then control can be achieved. This has 
particular advantage in terms of scalability of the system, as it does not add to the 
complexity of the system or significantly to the basic unit cost. It is for these reasons, 
quantified in Table 4.1, that the control parameter for maintaining DOT is the flow 
rate of the recycle rate. 
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Table 4.1 Comparing methods of controlling DOT within the VTEB 
This table compares the merits of controlling the dissolved oxygen tension (DOT) 
within the vascular tissue engineered bioreactor (VTEB) by use of either the air-flow 
rate or the cell culture medium flow rate through the membrane oxygenator. 
 
Parameter Oxygen Control Recycle Control 
Cost ** (O£1000s) **** (O£10s) 
Complexity 
Added 
** *** 
Scale Out ** (Completely new system) **** (No new equipment) 
 
 
 
4.2.3 Types of Controller 
 
The first step in implementing any control strategy is to determine the method of 
control to be employed. The standard approach is to employ systems in increasing 
levels of complexity until an acceptable level of tolerance is achieved. 
 
In terms of controller type these are; 
 
1. Two-step Controller. A simple controller such as those attached to a 
thermostat that heats when the measured temperature is below the set point 
and turns off heating when it is above. 
 
2. Proportional Controller. The two-step control approach often leads to an 
oscillatory output, as the response of the controller when the system 
displays an output below the set point is simply to switch the controlling 
variable on without any concern for magnitude of response. Proportional 
control is so-called as it responds to any error in the system with an 
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increase in the control variable proportional to the size of the error as 
shown in equation 4.2.  
 
€ 
Pout = KPe(t)      (4.2) 
(Where: KP =Constant of proportional control, e(t) = error, Pout = Control output) 
 
3. Integral Controller. Proportional control although an improvement on two-
step control, will often result in an offset or steady state error whenever the 
set point is changed mid-process. This is because any change in the set 
point will mean that the steady state value, which was originally set at a 
ratio of 50% control action to 0 error will have to have an error value other 
than 0 to achieve the new set point i.e. an offset (Bolton, 2003). Integral 
control works so as to eliminate such offsets, by relating the rate of change 
of the control output to the size of the error as shown in equation 4.3 
(Seborg  et al, 1989). 
€ 
Iout = KI e(τ )dτ
0
t
∫     (4.3) 
Where: Iout = integral control, t = time, e(τ) = error, KI =integral gain 
 
4. Derivative controller. Derivative action anticipates the magnitude of the 
future error by measuring the rate of change of controlled variables, its 
derivative (see equation 4.4). Thus, derivative action can improve the 
dynamic response and achieve superior control. However, the presence of a 
noisy signal can actually result in inferior control (Willis, 1998). 
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€ 
Dout = KD
d
dt e(t)     (4.4) 
Where: Dout = derivative control, t = time, e(t) = error, KD =derivative gain 
 
5. Model Predictive Controller. Model reference adaption (Bolton, 2003) is 
possibly the gold standard of process control strategies. Such a method 
requires an accurate model of the system to be developed (this is often the 
barrier to its implementation). This model is run in tandem with the actual 
controlled system and control strategies can be tested in faster than real-
time on the model before being implemented. Such a method is rarely 
implemented due to the cost, time and immense complexity of developing a 
model sufficiently accurate. Intelligent and knowledge based systems are a 
variant of this type of control and have been theorised extensively in 
literature in diverse areas such as fermentation (Konstantinov and Yoshida, 
1991), waste water treatment (Flores et al, 2000) and bioprocesses 
generally (Guthke et al, 1998). 
 
In terms of the four possibilities this chapter will demonstrate both the effectiveness 
and weakness of each of the first three strategies using two-step control additionally, 
prior to implementing proportional and integral control in conjunction. Model 
Predictive control is beyond the scope of this work, which is a first attempt to 
determine if the system in its current design is capable of accurate control and if so, 
implement an initial solution. 
 
A process control diagram of the system is shown in Fig. 4.1 with the measured DOT 
being compared to the set point and the size of the error being translated by the 
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controller into a change in pump flow rate. The action of the controller depends both 
on its type and its set points. Feedback control has been selected in preference to feed 
forward due to the system’s complexity and dynamic nature. Feed forward control is 
only utilised in situations where the system is very well defined and understood 
(Seborg et al, 1989). 
 
 
 
Figure 4.1  Process control feedback loop for DOT 
This diagram demonstrates how a feedback control loop responsible for maintaining the 
dissolved oxygen tension (DOT) within the range 0.079-0.049mmol.L-1 can be deconstructed 
into a series of unit operations. Each of these unit operations represents a physical, temporal or 
mathematical aspect of the control loop. 
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4.3 Determining the capacity of the system and the acceptable 
range of flow rates 
 
The first stage of defining the control system is determining the acceptable range of 
rates the recycle loop pump may be operated at.  Parameters considered include shear 
stress, diffusivity of the alginate matrix and cell concentration. A window of 
operation, a visual tool for presenting acceptable ranges of operating variables, has 
been employed. This window of operation is created using the model developed in 
Chapter 3.  
 
4.3.1                        Oxygen uptake rate model  
 
The key unknown parameters required to utilise the model of the bioreactor outlined in 
chapter 3 are those that relate to the relationship between oxygen uptake rate and the 
cell number (see equation 3.13).  
 
Defining this relationship is of added importance as determining cell number within 
the bioreactor is essential to determine the health of the developing tissue material and 
to estimate the likely future delivery day and allow scheduling of surgery for 
implantation. 
 
The design of the VTEB containing alginate within a glass tube makes sampling to 
determine cell number almost impossible and continually scanning by some imaging 
method would prove complex and expensive.  The most viable alternative is to infer 
the cell number by measuring the variation in related parameters such as the 
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consumption of respiratory metabolites. As OUR is already being measured online in 
real time to allow its control and is directly related to the cell number it is a suitable 
candidate provided equations relating it to cell number may be derived. 
 
It has been demonstrated by Gosmann et al (1985) and Zhao et al (2005) that oxygen 
consumption rate of eukaryotic cells is not constant and reduces as cell concentration 
increases and space becomes a limiting factor when the cells are encapsulated. This 
non-constancy ensures that the equations relating OUR and cell number will not be a 
simple proportional relationship and requires the use of exploratory experimentation. 
For this work, yeast cells were used both for reasons of time and as they reach 
maximum cell number within the scaffold in less than 2 days. Scaffold tubes were 
formed as described in section 2.3.5.2 within the bioreactor and oxygen consumption 
was measured, when little or no change in oxygen consumption rate was observed 
between measurements (which were taken at three hour intervals) it was assumed that 
maximum cell number had been obtained within the scaffold, for each case this took 
between 33 and 39 hours. Final cell numbers (Fig. 4.2) were obtained by dissolving 
the scaffold in 1M sodium-citrate solution as the sodium ions interfere with the cross 
linking and cause the scaffold to dissolve. The resulting solution was neutralised with 
phosphate buffer solution (PBS) and a cell count was performed with a 
haemocytometer. The initial seeded concentration was 105 cell.ml-1 and the final cell 
concentration results are shown in Fig. 4.2. 
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Figure 4.2 Final Yeast Cell Number.ml-1 within Alginate Scaffold 
In a series of experiments the final yeast cell number (after 33-39 hours), determined by 
manual cell count was within the range of 4.3*107-5*107 cells.ml-1. 
  
 
To determine the relationship between cell number and the oxygen consumption rate, 
scaffolds were formed and oxygen concentration was measured. Sampling the alginate 
scaffold to determine cell number is difficult and determining cell number requires 
sacrifice of the tube. For this reason, Figs. 4.3 and 4.4 are composites of a number of 
separate experiments. Cell numbers were determined for three-hour intervals and were 
performed over 39 hour periods to generate growth curves (Fig. 4.3). The consumption 
rate of these cells was calculated by determining the measured difference in 
concentration in the bulk flow, between cell counts. This data provided sets for which 
curves could be fitted and equations derived to determine the necessary equations. 
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Figure 4.3 Yeast cell growth curves 
Cell growth curves for yeast grown in alginate tubular scaffolds undergoing perfusion within 
the vascular tissue engineering bioreactor were formed from a series of experiments. Due to 
cell counts requiring sacrifice of the alginate scaffold each point represents a distinct 
experiment.  
 
Figure 4.4 Yeast cell oxygen uptake rate curves 
Oxygen uptake rates corresponding the yeast growth curves in Fig. 4.3 were determined by the 
measurement of oxygen concentrations before and after the alginate scaffold. These 
measurements were obtained using non-invasive fluorescent spots that when excited decay 
predictably as a function of dissolved oxygen tension (DOT). 
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By studying Fig. 4.3 and Fig. 4.4 it is clear the relationship between cell number and 
oxygen uptake rate is not constant and as such equation 4.4 holds true. 
 
                    OUR/qO2(x) ≠ cell number    (4.4) 
 
OUR is the measured oxygen uptake rate across the bioreactor, mmol.hr-1, qO2 is the 
oxygen consumption rate, mmol.cell-1hr-1 and x is the cell concentration, cells.ml-1 
 
These figures demonstrate that as the cell concentration increases the consumption of 
oxygen per cell decreases. This is likely to be because as space becomes limiting the 
growth rate reduces more and more cells will enter the G0 phase of the cell cycle (i.e. 
cease to divide also referred to as being senescent). This will lead to a reduction in 
respiration rate and hence oxygen consumption per cell falls. 
 
It seems reasonable to assume that a cell uses more oxygen when dividing than when 
senescent due to the need to form all the required cellular structures to create the new 
daughter cell and hence more energy will be required with this coming from 
respiration. 
 
It is further reasonable to assume that a cell has two different respiration rates 
depending upon whether it is senescent (G0) or actively proliferating (Synthesis phase 
‘S’ or Mitosis phase ‘M’).  Thus, the overall oxygen uptake rate may be assumed to 
obey an equation composed of two parts; one incorporating oxygen uptake by cells 
actively producing new cellular material, respiring at a relatively high rate and a 
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second part representing senescent cells respiring at a relatively low rate. Such an 
equation is outlined in equation 4.5. 
 
€ 
OUR = A* dXdt + B X −
dX
dt
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟     (4.5) 
 
(Where OUR is oxygen uptake rate, A is oxygen consumption rate of proliferating 
cells, B is oxygen consumption rate of senescent cells, X is cell number and dX/dt is 
the proliferation rate) 
 
Determining A and B directly is impossible in real time and as such a theoretical 
method must be adopted so that these values may be inferred. If it is assumed that at 
the start of the exponential phase, the cells are all proliferating and consuming oxygen 
at rate A and during the stationary phase all cells are quiescent due to space limitation 
and thus consuming oxygen at rate B, then these values may be easily derived. 
 
Fig. 4.5 shows how this model compares to an experimentally derived trend with A 
and B determined to be 1.79*10-7mM.hr-1 and 1.30*10-8mM.hr-1 respectively. This is 
based upon Fig 4.5 taking the value at the commencement of the exponential phase 
and dividing it by the associated cell number to obtain A and repeating the exercise for 
the values at the end of the exponential phase to obtain B. 
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Figure 4.5 Theoretical Model determining cell number (ml-1) within the 
scaffold based upon oxygen uptake rate. 
Our theoretical model using the measured oxygen uptake rate to estimate yeast cell 
concentration within the alginate scaffold compares favourably with experimental results 
obtained over a twenty-hour period. 
 
Such a model provides a close fit and a reasonable estimation of the state of the 
developing graft, as indicated by the cell number and may ultimately be used to 
estimate the likely delivery time of any developed graft courtesy of curve fitting 
techniques.  
 
It is possible to estimate A and B for MSC (Mesenchymal Stem Cells) from data 
provided in Zhao et al (2005) who noted that cells immobilised in alginate consumed 
less oxygen at higher densities than at the time of seeding (The lower value was 
0.0017*10-9mmol.hr-1.cell-1, while the higher value recorded was 
0.012*109mmol.hr1.cell-1). This data coupled with the method used before provides a 
suitable estimation of cell number in developing arterial grafts and gives rise to 
equations 4.6 for yeast and 4.7 for mesenchymal stem cells. 
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€ 
OUR =1.79*10−7 dXdt +1.20*10
−8 X − dXdt
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟   (4.6) 
€ 
OUR = 0.012*10−9 dXdt + 0.0017*10
−9 X − dXdt
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟  (4.7) 
Where OUR, is oxygen uptake rate (mM.hr-1), dX/dt is the proliferating cell number 
and X is total cell number. 
 
4.3.2 Window of operation for dissolved oxygen tension 
 
In-vivo measurements from Ishikawa and Ito, 1998 indicate that the physiological 
oxygen concentration within the region of the bone marrow stem cells are most likely 
to be found is between 0.049 and 0.089mmol.L-1 of oxygen. To ensure that 
concentrations in excess of this value are not experienced the oxygen concentration of 
the perfused medium within the bioreactor was selected to be 0.079 mmol.L-1. Flow 
rates based upon this concentration must ensure a minimum concentration of 0.049 at 
any coordinate within the scaffold must be used. The oxygen concentration’s 
dependence upon mass transfer within the VTEB must be determined. As the oxygen 
must diffuse from the perfused medium into the alginate scaffold a concentration 
gradient will exist in two dimensions within the tube (radially and longitudinally). 
 
To determine the range of acceptable flow rates a number of simulations were 
performed using the Comsol Multiphysics Modeling Package (Comsol, Stockholm, 
Sweden). The technique used was closely related to that adopted by (Gerontas, PhD 
Thesis, University of London, 2008) where windows of operation were used to 
describe oxygen mass transfer within a prototype bioreactor. Gerontas uses standard 
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diffusion equations obeying Fick’s Law and a number of assumptions, as listed in 
Table 4.2, to obtain equations 4.8 and 4.9. 
 
Table 4.2  Assumptions of model to represent oxygen mass transfer in a 
prototype bioreactor (Gerontas, PhD Thesis, UCL, 2008). 
Gerontas (2008) previously demonstrated how flow could be modelled within a tubular 
alginate scaffold containing mesenchymal stem cells (MSC). Many of the assumptions used in 
that work are applicable for the model contained here. 
 
 
The scaffold is cylindrical so the diffusion equations were used in the form of polar 
cylindrical coordinates. Equation 4.8 is the continuity equation and represents the 
mass balance of oxygen within the lumen (zone 1) within the bioreactor while 
equation 4.9 represents then radial mass balance as oxygen diffuses from the bulk into 
the alginate scaffold. Diffusion is assumed to be radial only within the scaffold and the 
outer surface of the scaffold has no transport through it as it is encased within glass. 
 
€ 
∂CO2
lumen
∂t +VZ
∂CO2
lumen
∂z = DO2
LUMEN 1
r
∂
∂r (r
∂ 2cO2
lumen
∂r ) +
∂ 2cO2
lumen
∂z2
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟   (4.8) 
€ 
∂CO2
scaffold
∂t +VZ
∂CO2
scaffold
∂z = DO2
scaffold 1
r
∂
∂r (r
∂ 2cO2
scaffold
∂r ) +
∂ 2cO2
scaffold
∂z2
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ + q  (4.9) 
Lumen (Zone 1) Alginate Scaffold (Zone 2) 
  
Isothermal Homogenous Suspension 
Flow is Laminar, Parabolic and Developed Oxygen consumption obeys Monod kinetics 
No reaction within bulk No convective transport 
Diffusion Coefficient is Constant Diffusion coefficient is Constant 
Diffusion is Fickian Diffusion is Fickian 
Culture medium has equivalent physical 
properties to water 
Oxygen uptake rate by cells is constant 
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Although windows were developed here using a similar methodology, the underlying 
model used differed from that of Gerontas in that oxygen uptake rate (OUR) of 
encapsulated cells was not assumed to be constant based on Zhao et al (2005) for 
mesenchymal stem cells and Gosmann et al (1985) for yeast cells. In both instances it 
was demonstrated that as cell concentration rises and proliferation rate falls, the 
oxygen uptake rate per cell will reduce in all likelihood due to the number of cells 
switching out of the mitotic cycle into the G0 static phase increasing until it 
encompasses the entire encapsulated population.  This relationship within the model 
was defined using equation 4.7. 
 
Dahl et al, (2007) suggested that the minimum concentration of cells required to form 
a vascular graft would be 1.16*108 cells.ml-1. If this is assumed to be correct then the 
perfusion rate of cell culture media containing 0.079mmol.L-1 of oxygen on entry to 
the VTEB must be capable of supporting 1.16*108 cells.ml-1 with the concentration of 
oxygen no lower than 0.049 mmol.L-1 at any point within the scaffold. Such a 
parameter provides the first lines for the window.  Using Comsol Multiphysics, a 
commercial CFD package, the equations outlined in chapter 3 for cell growth and 
oxygen uptake were combined with equations 4.7 - 4.10 and solved simultaneously to 
determine the minimum flow rate permitted for a given cell number to ensure that if 
DOT is successfully controlled at 0.079mmol.L-1 at entry the minimum concentration 
at no point within the scaffold is below 0.049mmol.L-1 
 
The minimum flow rate capable of achieving adequate mass transfer to support a 
concentration of 1.16*108cells.ml-1 is 0.095ml.min-1 and the oxygen concentration 
throughout the system for this flow rate is shown graphically in Fig. 4.6.  
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Figure 4.6 Oxygen gradients within the alginate scaffold 
Oxygen gradients are shown for cells distributed at a concentration of 1.16*108 cells.ml-1 for a 
recycle flow rate of 0.095ml.min-1. This flow rate is the minimum possible while still ensuring 
that at no point within the scaffold is the oxygen concentration below 0.049mmol.L-1, the 
lower boundary of in-vivo conditions within the bone marrow. 
 
The same type of simulation was run for a range of flow rates up to 20ml.min-1 (the 
maximum flow rate of the pump) and a window of operation may be formed from the 
numerical outputs of these simulations and those corresponding to Fig. 4.6. This 
window is shown in Fig. 4.7 with the acceptable operating range being represented by 
the bounded region labelled WOO. 
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Figure 4.7  Initial window of operation (WOO) relating the flow rate of the 
recycle stream to the cell concentration within the scaffold. 
This WOO applies to maintain an oxygen range of 0.079mM to 0.049mM throughout the 
scaffold. 
 
Porter et al (2005) showed that mesenchymal stem cells (MSC) within a perfusion 
bioreactor demonstrated improved proliferation at flow rates exerting shear stresses up 
to and including 5 dynes. When cells were exposed to shear stresses in excess of this 
value they demonstrated increased osteogenic tendencies. Differentiation leading to 
bone lineage is clearly undesirable for cells intended to form blood vessels. Thus, the 
flow rate through the lumen of the alginate scaffold (recycle rate) should not exceed 
the value where the shear exerted upon the alginate scaffold wall is equivalent to 5 
dynes. 
 
Although alginate is not a rigid material, the scaffold is encased within a glass tube 
thus it can be assumed to be as such for the purposes of this model. The Reynolds 
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number for flow at the upper end of the pump’s duty (20ml.min-1) is 1.4x10-3 hence 
the flow can be confidently assumed to be of a laminar nature. Poiseuille’s equation 
(4.10) is valid for steady laminar flow of an incompressible Newtonian fluid through a 
long straight, rigid smooth, cylindrical tube. 
Q
a3
4
τ
µ
τ =                  (4.10) 
Where τ is shear stress, µ is the viscosity of cell culture medium (assumed to be 
equivalent to water), a is the cross sectional area and Q is the volumetric flow rate.  
 
Using equation 4.10 it is possible to determine a shear stress of 5 dynes will be exerted 
by a flow rate through the lumen of 9.4ml.min-1. Thus 9.4ml.min-1    represents a new 
extent of the window of operation. 
 
Figure 4.8  Enhanced window of operation (WOO) incorporating shear stress 
When shear stress is considered an upper limit is placed on the recycle rate of 9.4ml.ml-1. This 
constricts the WOO to the bounded region shown. 
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Fig 4.8 shows the final window of operation for the growth of MSC within the VTEB 
with permitted recycle loop flow-rates within the range 0.02 - 9.4ml.min-1 (depending 
upon cell number). This window although informative is only valid where the entrance 
concentration of oxygen is effectively controlled at 0.079 mmol.L-1 and as such 
discounts the impact of other steps within the process and effectively considers the 
VTEB in isolation. The oxygen concentration within the system also depends upon the 
rate of transport into the system by the oxygenator and also flow in from the feed and 
out in the purge. 
 
The form these equations take will depend upon the strategy used to achieve the 
required DOT from the oxygen concentration at the start, for this there are two 
possible options. 
 
1. The media should be sparged with nitrogen to remove all dissolved oxygen and 
then re-oxygenated to the desired concentration prior to being fed into the 
bioreactor.  
 
2. Sparge the oxygen from the media using nitrogen and re-oxygenate by flowing 
it around the system very rapidly to raise the oxygen tension to the desired 
value after the start up of the bioreactor with a fresh feed and purge flow rate 
of zero. 
 
The second of these two alternatives has been selected with the intention being to 
circulate prior to introducing the seeded bioreactor. This method ensures the correct 
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oxygen concentration of 0.079mmol.L-1. The implementation of this sparging strategy 
means that the oxygen concentration of the fresh feed is 0mmol.L-1. 
 
A mass balance on oxygen around the system (equation 4.11) includes terms for 
oxygen flow in, oxygen flow out, oxygen consumption in the bioreactor, and a term 
for transport in the oxygenator. 
 
€ 
xinFF − xexitFF −OUR + kOV (xexit −C*) = 0   (4.11) 
Where, FF is the fresh feed rate, xin is the concentration of oxygen on entry to the 
oxygenator, xout is the concentration of oxygen on exit from the oxygenator, kOV is the 
mass transfer coefficient for oxygen within the oxygenator, OUR is the oxygen uptake 
rate of the cells within the bioreactor, C* is the saturation constant of oxygen in cell 
culture medium. 
 
€ 
0 − xexitFF −OUR + kLa(xexit −C*) = 0               (4.12) 
 
€ 
OUR = 0.012*10−9 dXdt + 0.0017*10
−9 X − dXdt
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟   (4.13) 
The oxygen transfer coefficient, kLa, for the oxygenator obeys equation 4.14 as shown 
in Fig. 3.2. 
€ 
kLa = −1e − 06FR2 + 6e − 05FR + 5e − 06     (4.14) 
Substituting equation 4.14 into equation 4.12 gives equation 4.15. 
€ 
kLa(xexit −C*) = (−1e − 06FR2 + 6e − 05FR + 5e − 06)(xexit −C*) (4.15) 
Finally, combining equation 4.13 and 4.15 gives the overall oxygen mass balance (see 
equation 4.16). 
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€ 
−xexitFF − 0.012*10−9
dX
dt + 0.0017*10
−9 X − dXdt
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ + (−10−7FR2 + 6*10−6FR
+5*10−7)(xexit −C*) = 0
 (4.16) 
This overall mass balance (equation 4.16) shows that the oxygen concentration within 
the system is a function of both the fresh feed ‘FF’ and recycle rate ‘FR’ as well as the 
cell concentration and the proportion of cells that are proliferating versus those that are 
senescent.  
 
Having already determined the theoretical range of the recycle rate, it is now possible 
to calculate an equivalent range for the fresh feed rate. This range can be determined 
using equation 4.16. The lower boundary is determined by substituting the minimum 
recycle rate (0.1ml.min-1), the minimum cell concentration (106cells.ml-1) and the 
lower oxygen consumption rate (0.0017mmol.cell-1.s-1) into equation 4.16. The upper 
boundary may be determined similarly by substituting the maximum recycle rate 
(9.4ml.min-1), the maximum cell concentration (1.16*108cells.ml-1) and the higher 
oxygen consumption rate (0.012mmol.cell-1.s-1) into equation 4.16. The results for the 
evaluation of these equations can be used to form a window of operation as shown in 
Fig 4.9. 
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Figure 4.9 Window of Operation relating cell concentration and feed rate 
The range of possible fresh feed rates is a function of cell concentration within the alginate 
scaffold and the recycle rate within the bioreactor system. This window of operation 
demonstrates that the range of acceptable fresh feed rates varies between 0.19ml.hr-1 (A) and 
8.08ml.hr-1 (B). 
  
4.4 Designing process controllers 
 
Using the windows of operation shown in Figs. 4.8 and 4.9 it is possible to design 
process controllers. The simplest form of a process controller is the two-step 
controller where the recycle rate pump is instructed to work at a different flow rate 
depending upon whether the measured DOT falls above or below a set value.  
 
The position of the sensor for measuring the DOT is most sensibly at the exit of the 
bioreactor (Fig. 4.10) as this is the point closest to the region where control of 
oxygen concentration is most important. It is placed near the exit rather than the inlet 
as the control system chosen is a feedback loop due to the complexity and dynamic 
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nature of the system. The set point for the exit of the bioreactor flow within the bulk 
has been set at 0.079mmol.L-1 and at low flow rates the time delay through the 
system to any other point of the system further from the cell scaffold will affect the 
rate of control response unfavourably.  
 
 
 
  
 
 
 
 
Figure 4.10  Location of DOT sensor within the system 
The sensor responsible for measurement of the dissolved oxygen tension (DOT) shall be 
located at the exit of the bioreactor containing the alginate scaffold and the developing cells. 
 
 
4.4.1 Two-step controller 
 
A two-step controller is the simplest form of controller. It is designed to overact when 
the system is operating at a value below a user-specified set point and under-act when 
the system is below the same set point. Two-step controllers are not sophisticated and 
generally lend themselves to simple processes where gradual changes take place and 
the inconvenience of oscillations and relatively large time delays are insignificant 
compared with keeping the system simple and cost effective. 
 
To illustrate this case, a two-step controller for the VTEB has been designed. For this 
model, the system normally operates at 0.1ml.min-1 and is only activated when the 
Bioreactor
Oxygenator
Feed Purge
Measurement of 
DOT 
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concentration falls below 0.074mmol.L-1, at which point the controller changes the 
flow rate of the recycle loop to 9.4ml.min-1. This flow rate is maintained until a 
concentration of 0.079mmol.L-1 is attained. At this time the controller is deactivated 
and the flow rate returns to 1ml.min-1. 9.4ml.min-1 and 1ml.min-1 were selected as the 
two steps of the controller. These values were selected as it has already been 
determined that 0.1ml.min-1 and 9.4ml.min-1 represent the range of acceptable recycle 
flow rates. A two-step controller takes no account of error magnitude so thus it is 
common for such controllers to over-react and become unstable. 
 
Such a control strategy is illustrated in Fig. 4.11 and Fig. 4.12. These figures present a 
two-step flow rate change and the associated oxygen concentration trend, respectively. 
These trends are symptomatic of a two-step controller, oscillating around the set point 
of the controller, 0.079mmol.L-1. 
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Given the relative ineffectiveness of such a controller in a system such as the VTEB 
where much closer control is desirable, more sophisticated controllers such as 
Proportional-Integral (PI) are required. 
 
4.4.2 Proportional-Integral (PI) controller 
 
The PI controller is widely used in industrial application. Before designing the PI 
controller, the transfer of the function will be given as follows. Equations 4.17 - 4.26 
represent the derivation of a transfer function relating DOT concentration at the exit of 
the bioreactor to recycle loop flow rate. Equation 4.17 represents a mass balance 
neglecting cell growth terms. For the purposes of determining the transfer function cell 
growth and the associated oxygen uptake has been treated as a disturbance entering the 
system to modify the oxygen concentration undesirably.  
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€ 
V dxdt = Fin xin − Fout xout + kLa(C *−xout )  (4.17) 
Where: V is the system volume, Fin is the fresh feed flow rate, Fout is the purge flow rate, xin is 
the concentration of oxygen in the feed, xout is the concentration of oxygen in the purge, kLa is 
the overall mass transfer coefficient in the oxygenator, C* is the saturation constant of oxygen 
within cell culture medium, x is the concentration of oxygen within the system and t is time. 
 
Knowing that the fresh feed flow rate is equal to the purge flow rate (4.18) and that the 
concentration of oxygen within the feed is 0 (4.19)  gives  equation 4.20. 
€ 
Fin = Fout = F       (4.18) 
 
€ 
V
F
dx
dt = xin − xout +
kLa(C *−xout )
F    (4.19)  
€ 
V
F
dx
dt + xout =
kLa(C *−xout )
F     (4.20) 
Assuming that the controller is effective and the exit concentration from the bioreactor 
is at a steady state allows equation 4.21 to be formed. 
 
€ 
€ 
V
F
dx
dt + xout =
(C *−xoutss )
F kLa    (4.21) 
Where: xoitss = the steady state concentration on exit from the bioreactor 
 
kLa is a non-linear term and has the potential to complicate the system, however on 
examination, the relationship between kLa and recycle rate (See Fig. 3.3) has the 
potential to be linearised. It has already been determined that the maximum recycle 
flow rate cannot exceed 9.4ml and the curve relating to kLa will approximate to a 
linear relationship within this range. This linearisation is shown in Fig. 4.13.  
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Figure 4.13 Linearization of the relationship between overall oxygen transfer 
coefficient, kLa, within the oxygenator and the recycle rate. 
 
Substituting this linearised term of kLa = 5x10-5 FR into equation 4.22 gives the 
overall relationship between change in oxygen concentration, recycle rate and feed 
rate.  
 
€ 
V
F
dx
dt + xout =
(C *−xoutss )
F (5 ×10
−5)FR    (4.22) 
€ 
 
Assuming the feed rate is constant performing a Laplace Transform on equation 4.22 
generates a transfer function that characterises the dynamic nature of the system. 
 
€ 
δx(s) =
(C *−xoutss )
F (5*10
−5)
V
F
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ s+1
δFR (s)     (4.23) 
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Assuming a feed rate of 0.1ml.hr-1 and a steady state exit concentration of 0.079 mmol-
1 allows this transfer function to be used to calculate the gain of a proportional 
controller. The gain of this transfer function is thus 0.1098 and relates a change in 
recycle rate to a change in oxygen concentration. Given this transfer function has been 
determined without giving consideration to cell growth significant tuning is required.  
 
Proportional controllers work by multiplying the error between a set point and the 
measured value by this gain. A Simulink program was used to model the system and is 
outlined in Appendix 1. Using 0.10 as the initial gain and using trial and error to 
minimise the offset that is inherent in the use of a proportional controller the most 
effective value was determined to be 15. To eliminate noise within the system and 
prevent excessive control the mean average of the oxygen concentration over five 
minute intervals was used to determine the error rather than a point value. This served 
to smooth the data and eliminate any random outlying values arising for some reason 
and having a negative effect on the control of the system. The controlled recycle rate is 
shown in Fig. 4.14, the associated oxygen concentration, at the exit from the 
bioreactor, is shown in Fig. 4.15 and the cell growth rate curve, within the bioreactor, 
is shown in Fig. 4.16.  
 
Fig. 4.16 demonstrates the disadvantage of using a proportional controller, which 
generates a response directly related to the magnitude of the measured error. Such a 
controller will always have an offset from the desired set point as the generated 
response falls away to 0 linearly as the error falls to 0. It can also result in both  
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overshoot and undershoot of the desired set point, as the controller does not respond 
effectively to the rate at which the error increases or reduces. A proportional integral 
(PI) controller generates a response equal to the integral of the error over time and thus 
even when the measured error approaches zero, the PI controller will still have a 
response output to eliminate the offset generated by a proportional controller in 
isolation.  Given the large delays and slow response inherent in the VTEB system, it is 
not surprising to find the integral time is a large value. After using an initial value 
equivalent to 0.1*Gain, the optimum value was determined, by tuning to be 1e-3 and 
generated controlled recycled rate and dissolved oxygen tension trends as shown in 
Figs. 4.17 and 4.18, respectively. 
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These results serve to indicate that the oxygen concentration within the bioreactor 
system may be controlled successfully by a control loop incorporating a sensor at the 
bioreactor’s exit and a proportional and integral controller linked to a pump 
responsible for the flow of media within the recycle loop.  Many of the values 
incorporated into the model used to determine this control loop are not certain and 
have been assumed or taken from literature. For this reason sensitivity analysis should 
be carried out to determine the effect a change on these parameters will have upon the 
proportional integral (PI) controller’s effectiveness. 
 
4.4.3 Testing the control system 
 
Two assumed values within the model have had sensitivity analysis performed on 
them, the growth rate of the cells and the oxygen uptake rate. For a growth rate of 
+10% of the specified value and oxygen uptake of +10%, for both senescent and 
proliferating cells, the controlled DOT trend is shown in Fig. 4.19.  This trend 
demonstrates that the control system developed is capable of maintaining the dissolved 
oxygen tension at the bioreactor exit even if there are 10% errors in both the assumed 
cell growth rate and the assumed oxygen consumption rate.  
 
4.5 Conclusions 
 
This chapter has shown that it is possible to derive windows of operation for the 
vascular tissue engineered bioreactor (VTEB) within which oxygen concentration may 
feasibly be controlled. These windows have been used in conjunction with the model 
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developed in chapter 3 to demonstrate that it is possible to control 
 
the dissolved oxygen within the VTEB. PI controllers simulated within a relevant 
software package have been demonstrated to provide superior maintenance of DOT 
when compared with two-step or proportional control and provide sufficient control to 
grow a graft within currently estimated in-vivo tolerances, even when some parameters 
are modified. More complex control techniques are discussed in Chapter 7 when 
oxygen control is considered not in isolation as it has been here but as part of a more 
complex strategy along with metabolite concentrations and variables such as pH and 
full integration between feed and recycle loop controllers. 
 
Additionally, methods have been developed that allow the use of the oxygen 
consumption rate by the cells within the bioreactor to estimate the cell number online. 
This estimation of cell number may be used both to estimate the health of the culture 
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and also estimate likely delivery time by fitting the generated growth curve to the 
expected trend.  
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Chapter 5  pH within the VTEB system 
 
 
5.0 Introduction 
 
 
Most mammalian cell lines grow at a pH of 7.2-7.4. The consumption of glucose and 
other substrates coupled with waste production such as lactic acid can influence this 
pH, which necessitates constant media change when cells are grown in static culture. 
In a perfusion system where media exchange continuously takes place this is less of an 
issue provided the system is operated within a suitable range of flow rates that ensure 
pH does not fall below 7.2 or exceed 7.4.  
 
5.1 Cell Media Buffers 
 
 
The by-products of cellular metabolism are not exclusively cytotoxic and include 
growth factors that are beneficial to cell division and stimulate proliferation, for this 
reason constant media change is not ideal and most cell media contain buffers that are 
capable of keeping pH constant in the presence of small amounts of acidic or basic 
chemicals.  
 
Chemical buffers work upon the principal of a reversible chemical reaction between a 
compound and its conjugate ion such as ammonia and ammonium chloride (see 
equation 5.1) 
 
NH4+ ⇔ NH3 +H+   (5.1) 
 
 
In the presence of an increased concentration of H+ ions the reaction balance will 
move to the left hand side (see equation 5.2). 
 
NH4+ ⇐ NH3 +H+   (5.2) 
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In the presence of an increased number of OH- ions the balance of the reaction will 
move to the right (see equation 5.3). 
 
NH4+ + OH- ⇒ NH3 +H2O  (5.3) 
 
 
Different buffers are effective within different ranges of pH, this is dictated by the 
dissociation constant of the acid KA, i.e. the equilibrium ratio between the compound 
and it’s conjugate (see equation 5.4). 
 
€ 
KA =
H +[ ]eq A
−[ ]eq
HA[ ]eq
   (5.4) 
 
 
The pH of a solution is directly related to the KA value of a solution by the Henderson-
Hasselbach equation (Atkins, 1998), (see equations 5.5-5.6). 
 
€ 
pH = pKA + log10
A−[ ]
HA[ ]
  (5.5) 
 
 
 
€ 
pKA = −log10 KA[ ]  (5.6) 
 
 
A buffer is most effective at a pH equivalent to its pKA and its effective range under 
normal conditions is generally considered to be its pKA ± 1. 
 
There are two common chemical buffers used in mammalian cell culture the sodium 
bicarbonate (NaHCO3) and HEPES systems. 
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5.2 Bicarbonate Buffer 
 
 
The bicarbonate buffer system is analogous to one of the main buffering systems 
present in the blood. Its prevalence in use within cell culture media stems from its 
advantages of being cheap, non-cytotoxic and being a physiological system. There is 
even some possibility it may have some nutritional benefit (Freshney, 2000).  
 
€ 
H2CO3⇔HCO3− + H +   (5.7) 
 
 
Despite these benefits the bicarbonate buffer has a pKA of 6.1 and as such is not an 
effective buffer at the required physiological pH required by mammalian cells of 7.2-
7.4. 
 
To achieve such a pH bicarbonate buffered media must be used within an environment 
where the carbon dioxide is controlled at a concentration up to 100 times higher than 
that found in the air (normally 5% within an environmentally controlled incubator). 
Such a situation is similar to that experienced in the human body where carbon dioxide 
is a waste product of respiration and is carried in solution within the blood to the lungs 
where it may be excreted. 
 
The presence of this carbon dioxide moves the equilibrium of the reaction towards the 
left hand side and increases the pH of the solution to a less acidic value i.e. the 
required physiological value of 7.4. 
 
Due to the relative weakness of the bicarbonate buffer and also the risk of 
contamination, medium incorporating this buffer often contains the visual indicator, 
phenol red, which appears a distinct colour depending upon the pH of the solution. 
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Table 5.1 Phenol red colour variation with solution pH 
 
 
pH Colour 
>7.8 Purple 
7.6 Pink 
7.4 Red 
7.0 Orange 
6.5 Yellow 
<6.5 Lemon Yellow 
 
 
 
5.3 HEPES buffering system 
 
 
A common alternative to the bicarbonate buffering system is HEPES. HEPES in 
comparison to bicarbonate buffer is a very strong buffer within the physiological range 
7.2 – 7.4. The reason that HEPES has not become the prevalent buffer in cell culture is 
because it is much more cytotoxic especially for certain cell lines which may not be 
grown in solutions containing it. An additional disadvantage of HEPES is that in 
comparison to bicarbonate it is far more expensive. For these reasons DMEM 
containing bicarbonate is commonly used in static cell culture, being changed at 1-2 
day intervals, and it is selected for tissue engineering arteries within the VTEB. 
Although bicarbonate is a weaker buffer than HEPES, given it is sufficient to ensure 
buffering capacity for 48 hours within a static culture it is deemed acceptable for a 
perfusion system with continuous media exchange.  
 
5.4 Calculating the window of operation for pH versus lactic acid 
concentration 
  
The bicarbonate buffer, within the cell culture medium, is capable of ensuring the pH 
in solution is constant for low levels of acid or base, but cannot achieve this 
indefinitely. 
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The standard concentration of bicarbonate buffer within Dulbecco’s Modified Eagle 
Medium (DMEM), a common basal media, is 44mM, however to determine pH of the 
buffer it is necessary to know the ratio of bicarbonate ion to carbonic acid.  Under 
normal conditions the pH of bicarbonate buffer is 6.1, equivalent to its pKA, however 
in a carbon dioxide controlled environment the pH is 7.4. 
 
To determine the ratio H2CO3/HCO3- at a pH of 7.4 the Henderson-Hasselbach 
equation can be used; 
 
€ 
7.4 = 6.1+ log10
HCO3−[ ]
H2CO3[ ]
   (5.8) 
 
 
€ 
H2CO3[ ] + HCO3−[ ] = 44mM    (5.9) 
 
 
From these two equations it is possible to form equation 5.10 and determine the 
concentration [HCO3-] as 41.88mM and then from substitution into equation 5.9 
[H2CO3] as 2.11mM. 
€ 
7.4 = 6.1+ log10
44 − H2CO3[ ]
H2CO3[ ]
  (5.10) 
 
Glycolysis is the first stage of respiration within a mammalian cell. Respiration is the 
process by which glucose is broken down to release energy for the cell to use. Glucose 
is initially broken down into pyruvate, which is ultimately converted into lactate. The 
lactate, which forms lactic acid on passing into solution, is one of the agents primarily 
responsible for pH shifts in cell culture medium. With the values determined using 
 170 
equations 5.8-5.10 it is possible to determine the amount of lactic acid that will 
produce a change in pH of undesirable magnitude. 
 
The physiological pH range is generally considered to be between 7.2 and 7.4 and it is 
this range that determines the limits of the pH window of operation. 
 
Again using the Henderson-Hasselbach equation it is possible to determine the amount 
of lactic acid that would be required to shift the pH beyond this acceptable range. For 
a system at the lower limit of the pH range 7.2; we have. 
 
€ 
7.2 = 6.1+ log HCO3
−[ ]
H2CO3[ ]
   (5.11) 
 
 
€ 
H2CO3[ ] + HCO3−[ ] = 44mM     (5.12) 
 
 
Using the same approach as employed previously it can be shown that the presence of 
lactic acid causes the buffer equilibrium to move to the left hand side with  [H2CO3] 
now equal to 3.24mM and [HCO3-] 40.76mM. 
 
For a pH shift from 7.4 to 7.2, the concentration of H2CO3 has changed by 3.24mM-
2.09mM = 1.13mM due to an addition of a stoichiometrically equivalent amount of 
protons from lactic acid, this relationship is shown visually in Fig. 5.1, forming a 
window of operation for pH versus lactic acid concentration. 
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Figure 5.1 Window of operation for pH versus lactic acid concentration 
 
 
To determine an operating window of pH versus control variable the method of 
control must first be established. Given that media exchange will provide fresh buffer 
for controlling pH, the most appropriate method of control is regulating the rate of the 
fresh feed/purge both to provide fresh buffer and remove the responsible chemicals 
from the system. 
 
The operating window can thus be formed by plotting pH against the feed flow rate 
(the control variable). This requires a value for the lactic acid production rate for each 
cell type of interest. 
 
To obtain appropriate values for embryonic stem cells and mesenchymal stem cells, a 
set of data obtained from literature has been used and is outlined in Table 5.2. 
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Table 5.2 Data required for calculating lactate production rate by cells 
 
 MSC Reference 
Glucose 
consumption 
rate 
1.46±0.92x10-10 
g.cell-1.hr-1 
Markusen 
JF (2005) 
Lactate yield 
on glucose 
2mol.mol-1 Zeng A et al 
(1998) 
 
 
As stated in the previous chapter on the control of oxygen within the VTEB (Chapter 
4), it is known that a cell density of between 1x108 cells.ml-1 and 5x108 cells.ml-1 are 
required for a functional tissue engineered artery. 
 
With a cell population of 5x108 cells.ml-1 the total cell number within the tissue-
engineering scaffold (volume 1.2ml [2s.f.]) will be 5.8x108cells [2s.f]. The production 
rate of lactic acid per mesenchymal stem cell (MSC) is 2.79*10-13mmol.s-1.cell-1 based 
on the glucose consumption provided by Markusen (2008) and the lactate yield on 
glucose from Zeng A, et al (1998) (See table 5.2). Thus the lactate production rate of 
5.8x108 MSC can be determined to be 2.6x10-4 mmol.s-1 (2s.f.). Given 5x108 cells.ml-1 
is the maximum concentration for an arterial graft 2.6x10-4 mmol.s-1 (2s.f.) represents 
the maximum likely production rate of lactic acid within the alginate scaffold (even 
though as stated in chapter 4 as cell density increases, respiration rate falls and an 
increasing number of cells become senescent, the lactate production is likely to fall 
dramatically). 
 
  
 173 
5.5 Single pass pH window of operation 
 
As there are two controlled flow rates within the vascular tissue engineering bioreactor 
(VTEB) two separate windows of operation are required. The first and simplest of 
these relates the flow rate within the recycle loop i.e. the flow through the bioreactor 
with the pH drop between the points shown in Fig. 5.2. The window in this case 
designates flow rates required to ensure that the pH drop across the bioreactor does not 
exceed 0.2 (7.4-7.2). 
 
 
Figure 5.2  Single pass pH change across the alginate scaffold containing 
mesenchymal stem cells (MSC).  
 
The minimum single pass flow rate through the bioreactor can be determined by 
relating the lactate production rate of the cells to the amount of lactate required to 
cause a pH change that falls outside of the acceptable range. i.e. <7.2 and determining 
the amount of time such a change would occur in. This relationship is shown in 
equation 5.13. This time can then be related to flow rate using equation 5.14. 
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€ 
concentration _of _ lactate_ to_cause_ pH < 7.2
rate_of _concentration _change_ from _cells = τ  (5.13) 
 
 
€ 
τ =
VR
υ t
      (5.14) 
 
(τ is residence time (s), VR is reactor volume (ml) and υt is the flow rate within the 
recycle loop (ml.s-1)) 
 
The size of the single pass window of operation relating pH to the recycle rate is 
dependent upon both the cell type and the number of cells present. As the number of 
cells increase during arterial growth and development the required flow rate will 
increase. This required flow rate can be determined from equation 5.15, formed by 
combining equations 5.13 and 5.14 and this equation can be used to relate cell number 
to recycle rate as shown in Fig. 5.3 on a logarithmic plot. 
 
€ 
VR * n *LPR
concentration _of _ lactate_causing_ pH < 7.2 =υT   (5.15) 
(VR = reactor volume (ml), n = cell number,  
LPR=lactate production rate (mmol.cell-1s-1)) 
 
Equation 5.15 can be used to relate cell number to the minimum recycle rate as shown 
in Fig. 5.3. The minimum required recycle flow rates are less than 0.1ml.min-1 for all 
cell concentrations below the target required for a tissue engineered blood vessel 
(1.16*108 cells.ml-1) as discussed in chapter 3. These minimum flow rates can be 
readily achieved in conjunction with the window of operation derived in chapter 3 for 
the control of dissolved oxygen tension (DOT). This DOT window permitted recycle 
rates of between 0.1 and 9.33 ml.min-1. This range will ensure pH remains within an 
acceptable range. 
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Figure 5.3  Logarithmic plot of mesenchymal stem cell number present in 
scaffold and minimum recycle rate flow rate required to ensure pH 
change across the bioreactor falls within an acceptable range 
 
5.6 Continuous pH window of operation 
 
The second controlled flow rate within the VTEB is that responsible for the fresh feed 
of media into the recycle loop. The relationship between the two windows within the 
system is shown in Fig. 5.4. 
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Figure 5.4 Controlled flow rates within the VTEB System 
 
 
The concentration of lactate within the feed to the system can be considered to be 0. 
For the purposes of calculating the window the concentration within the exit stream 
must be large enough to ensure the pH remains above 7.2. Such a concentration has 
already been determined as 1.13mM of lactate. Knowing this value a conventional 
mass balance (equation 5.16) may be used to create a window of operation relating 
cell number to fresh feed flow rate. 
€ 
x1F1 − x4F4 + LPR* n = 0   (5.16) 
(x1 = inlet concentration of lactate, F1 = fresh feed rate of cell culture medium, x4 = 
outlet concentration of lactate, LPR = lactate production rate per cell, n = cell number) 
 
It can be assumed that the concentration of lactate within the fresh feed is zero, hence 
equation 5.16 becomes equation 5.17. 
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€ 
LPR* n = x4F4     (5.17) 
 
Using equation 5.17, it is possible to develop a window of operation for MSCs relating 
fresh feed flow rate to cell number. Plotting equation 5.18 allows the formation of 
such a window as shown in Fig. 5.6 
 
€ 
2.79*10−13 * n
1.13*10−3 = F2    (5.18) 
 
 
 
Figure 5.6 Continuous window of operation for pH for mesenchymal stem 
cells. 
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5.6 Conclusions 
The purpose of this chapter was to determine if the pH of the cell culture medium 
should play a role within any control strategy employed to maintain metabolite and 
dissolved oxygen concentration within the bulk flow of a perfusion vascular tissue 
engineering bioreactor (VTEB). 
 
Equations have been derived in this chapter that allow the creation of two windows of 
operation. The first of these windows relates the flow rate of the recycle stream and 
cell number to pH. The second of these windows relates the flow rate of the fresh feed 
stream and cell number to pH. It has been demonstrated no account need be taken of 
the effect changes in the flow rate of the recycle stream will have on pH even at 
maximum cell number. However, changes in fresh feed flow rate have been shown to 
have an impact on pH within the system. Ultimately, the overall control strategy will 
need to take account of pH when using the fresh feed flow rate as a control variable. 
 
A further point is that these equations have not taken account of ammonia production 
and the effect this may have in balancing the pH. In addition to the production rate of 
ammonia being low in comparison to that of lactate, these equations were derived to 
indicate the most extreme example of pH changes that could arise within the system. 
Such an assumption does of course provide a future opportunity for further 
optimisation of any final control system. 
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Chapter 6  Process Control of Respiratory Substrates 
 
The aim of this chapter is to investigate how to control the inlet flow rate to achieve 
various requirements on two key substrates: glucose and glutamine; and on two key 
waste products lactate and ammonia. Feasible flow rates will be defined based on 
components’ mass balance in the system. 
 
6.1 Glucose 
As stated previously respiration is predominantly based around the reaction of glucose 
with oxygen (6.1), as such its concentration in cell culture media is highly relevant to 
respiration rate.  
 
6O2 + C6H12O6  6CO2 + 6H2O    (6. 1) 
i.e. 
oxygen + glucose  carbon dioxide + water 
 
The fresh media used to culture mesenchymal stem cells contains 6 mmol.L-1 and a 
maximum acceptable drop of 2 mmol.L-1 to give a concentration of 4 mmol.L-1 has 
been chosen as a reasonable range. The flow rates required to achieve this will vary 
depending upon the cell number present in the alginate scaffold. (Markusen, 2005) 
provides a value of 1.46±0.92*10-10 g.cell-1.h-1 (2.25 x 10-13 mmol.cell-1s-1) for the 
glucose consumption rate of mesenchymal stem cells (MSCs). Using this value a 
series of equations may be formed that can be used to derive the flow limits required 
to ensure glucose stays in the range 4x10-2 – 6x10-2   mmol.ml-1. A mass balance 
across the system gives equation 6.2. 
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€ 
F1x1Δt − F4x4Δt −UTR*NΔt = 0     (6.2) 
 
Where cell number is calculated by; 
N = n*VS        (6.3) 
Where F1 is inlet flow rate (ml.h-1), F4 is outlet flow rate (ml.h-1), x1 is medium glucose 
concentration (mmol.ml-1), x4 is exit glucose concentration (mmol.ml-1), N is total cell number, 
n is cell concentration (cell.ml-1), VS is volume of alginate scaffold, UTR is glucose 
uptake/consumption rate (mmol.cell-1.s-1). 
 
The volume of the bioreactor is 1.151x10-6 m3 given by equation 6.4. 
€ 
VS = π (R22 − R12)L        (6.4) 
Where R2 is the external radius of the alginate scaffold and R1 is the internal radius of the 
alginate scaffold 
 
€ 
VS = π ((2*10−3m)2 − (1.7*10−3m)2) *0.33m =1.151*10−6m3   (6.5) 
Implementing the condition that the concentration within the purge stream cannot be 
less than 4x10-2mmol.ml-1 gives equation 6.6 which may be rearranged as shown in 
equations 6.7 and 6.8 to form 6.9. 
 
€ 
x2 =
Fx1 −UTR*N
F ≥ xmin ≥ 4 *10
−2mM.ml−1   (6.6) 
 
€ 
Fx1 −UTR*N ≥ xminF       (6.7) 
 
€ 
F(x1 − xmin ) ≥UTR*N       (6.8) 
 
€ 
F ≥ UTR*Nx1 − xmin
        (6.9) 
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Where x1 is 6*10-2mmol.ml-1, xmin is 4*10-2mmol.ml-1, UTR is 2.25 *10-13 mmol.cell-1s-1, n is 
106−108 and VS is 1.15ml 
 
Equation 6.9 may be used to determine a window of operation for glucose that ensures 
that glucose concentration within the bulk flow remains within 0.04 - 0.06mmol.ml-1. 
This window is shown in Fig. 6.1 and the flow rate must be equal or above the plotted 
line to achieve the appropriate glucose concentration. 
 
 
Figure 6.1  Window of operation for glucose concentration 4-6mmol.L-1 
The minimum flow rate required is directly proportional to the cell number within the alginate 
scaffold. This log graph demonstrates the possible feed flow rates for a given cell number. 
Control action must take place at a value equal to or exceeding the curve. 
 
 
The required flow rates to maintain glucose within the range 4-6mmol.L-1 range from 
0.5 to 47 ml.h-1 depending upon cell number, thus as the  graft develops, the required 
feed rate of media will need to increase to maintain glucose concentration within  
acceptable limits. 
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6.2 Lactate 
 
Lactic acid is the primary product arising from the breakdown of glucose. Normal 
blood lactate concentrations fall in the range 1-3mM providing an appropriate range 
for the window of operation. Zeng el al (1998) provided a conversion ratio of 1: 2 for 
glucose to lactate meaning that one mole of glucose consumed gives rise to 2 mole of 
lactate. This information allows an estimate of the lactate production rate to be made 
giving a value of 2xUTR = 4.56 mmol.cell-1s-1. The lactate concentration in the fresh 
feed and the system at time zero is assumed to be 0 mmol.ml-1 and will increase and 
change over time. The lactate concentration over time must be determined and the 
appropriate flow rate selected to keep the concentration less than 3 mmol.ml-1. 
 
Based on the mass balance across the system for a given Δt 
€ 
x1F1Δt − x4F4Δt + kLNΔt = 0     (6.10) 
Where it is known that feed rate is equal to purge rate and assumed that lactate concentration 
in the feed is 0. F1 is the fresh feed flow rate, F4 is the purge stream flow rate, x1 is the 
concentration of lactate in the feed stream, x4 is the concentration of lactate in the purge 
stream, kL is the production rate of lactate (mmol.cell-1.s-1), 
 
€ 
x4F = kLN        (6.11) 
Where F = F1 = F4 
 
€ 
x4 =
kLN
F ≤ 3       (6.12) 
 
€ 
F ≥ kLN3 =
2
3 (−UTR)N      (6.13) 
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Using equation 6.13 the flow rates required to ensure a lactate concentration equal to 
or below 3x10-2mmol.L-1 can be determined. The production rate of lactate, which 
varies with cell concentration provides figure 6.2, a window of operation for lactate. 
€ 
  
Figure 6.2 Window of operation for lactate concentration 0-3mmol.L-1 
The minimum feed flow rate required is directly proportional to the cell number within the 
alginate scaffold. This log graph demonstrates the possible feed flow rates for a given cell 
number. Control action must take place at a value equal to or exceeding the curve. 
 
 
The required flow rates to ensure lactate concentration does not exceed 3mM are 
lower (0.21 ml.h-1 to 20.7 ml.h-1) than those required to maintain glucose 
concentration (0.5 to 47 ml.h-1). This indicates that it is likely that lactate will not need 
to be considered in the overall model. For a given cell number the flow rate required to 
maintain glucose concentration will always be higher than that required to maintain 
lactate concentration. 
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6.3 Glutamine 
 
Cell culture medium typically contains glutamine; a major energy and nitrogen source 
for mammalian cells in culture (Thilly, 1986, Ozturk and Palsson, 1990). 
 
Of the four chemicals under consideration (glutamine, glucose, lactate and ammonia), 
glutamine is arguably the most interesting as unlike the others, it is not thermally 
stable in cell culture medium (Glacken, 1986, Ozturk and Palsson, 1990). This thermal 
instability means that unlike glucose, even in the absence of significant cellular growth 
glutamine concentration will fall considerably over time. The difference between 
actual glutamine uptake rate (including thermal degradation) and apparent glutamine 
uptake rate can be up to 200% (Ozturk and Palsson, 1990). 
 
This instability is linked to temperature and is the major justification for storing cell 
culture medium within a refrigerated environment and for providing it with a finite 
shelf life. 
 
This thermal instability is of concern as the design of the Vascular Tissue Engineering 
Bioreactor (VTEB) as the circulating media is kept at a controlled temperature of 
37oC. This fact alone ensures that degradation kinetics form a key variable in any 
system being designed to control metabolic concentrations. Ozturk and Palsson (1990) 
demonstrated that a number of factors influenced such breakdown kinetics in-vitro and 
included temperature, media type, presence of foetal bovine serum (FBS) (although 
not in Dulbecco’s Modified Eagle Medium; DMEM). 
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The relevance of media type relates to the presence of phosphate ions and bovine 
serum contains enzymes such as glutimases. Unsurprisingly as glutamine is an amino 
acid the pH the cell culture is stored at will also play a role in its breakdown.  
 
Ozturk and Palsson (1990) using curve fitting stated the relationship between the 
degradation constant of glutamine and pH (see equation 6.14). 
 
€ 
lnkG = a + b* pH        (6.14) 
 
Where kG is the  coefficient of degradation (s-1), b is the specified constant, a is the specified 
constant) 
 
Based upon DMEM maintained at 37oC the degradation constant is equivalent to;    k-
G=6.03*10-7s-1. 
 
To determine the change of glutamine concentration, the thermal degradation must be 
combined with the consumption of glutamine by the cells present as part of a mass 
balance around the system. Zeng et al (1998) showed that the ratio of glutamine 
consumption to glucose consumption falls between 0.2 and 0.5 mol.mol-1. 
 
Based on the mass balance for a given Δt, 
 
€ 
F1x1Δt − F4x4Δt −UTR*GGR*NΔt − kGx4VsΔt = 0  (6.15) 
Where F1 is the fresh feed rate, F4 is the purge rate, UTR is the glucose uptake rate, GGR is 
the ratio of glucose uptake to glutamine uptake, N is the cell number in the scaffold, kG is the 
degradation coefficient for glutamine, x1 is the fresh feed concentration of glutamine, x4 is the 
purge stream concentration of glutamine, V is the volume of the entire system and t is time 
 
As feed rate is equal to purge rate (F1 = F4 = F) this equation may be simplified to; 
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€ 
F + kGvs( )x4 = Fx1 −UTR*GGR*N     (6.16) 
 
€ 
x4 =
Fx1 −UTR*GGR*N
F + kGvs
≥ xmin     (6.17) 
€ 
Fx1 −UTR*GGR*N ≥ Fxmin + kGvsxmin    (6.18) 
 
€ 
F(x1 − xmin ) ≥UTR*GGR*N + kGvsxmin    (6.19) 
 
€ 
F ≥ UTR*GGR*N + kGvsxminx1 − xmin
    (6.20) 
 
Equation 6.20 can be used to plot flow rate ranges that may be implemented to ensure 
glutamine concentration remains between a chosen range of 3mmol.L-1 and 4mmol.L-1 
for all ratios of glucose conversion to glutamine conversion. This window is shown in 
Fig. 6.3.  
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Figure 6.3 Window of operation for glutamine concentration 3-4mmol.L-1 
The minimum feed flow rate required is directly proportional to the cell number within the 
alginate scaffold. This log graph demonstrates the possible feed flow rates for a given cell 
number and for a range of theoretical ratios of glucose uptake to glutamine uptake. Control 
action must take place at a value equal to or exceeding the curve. 
 
 
These results indicate that except at low cell densities the required flow rates do not 
exceed those required to maintain glucose. This indicates that with the exception of 
when the cell number is low, provided glucose is controlled, glutamine will also 
remain within specification. 
 
6.4 Ammonia 
 
The main product of glutamine breakdown is ammonia (the other being pyrrolidone 
carboxylic acid). The presence of ammonia can inhibit cell growth and cause cell 
death or morphological chances due to toxicity. Mirabel et al, 1987 showed that 72 
hours culture in ammonia concentrations of 6 mmol.L-1 reduced cell numbers 
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significantly when compared with control populations. For the purposes of this study a 
value of 6mM was used as a control set point. 
 
Zeng et al (1998) provided a conversion rate for ammonia to glutamine of 0.8, using 
this value and the 6 mmol.L-1 limit for ammonia production allows the formation of a 
window of operation in a similar fashion to the other metabolites. A mass balance 
(6.21) over the system allows derivation of equations (6.22 – 6.27) that may be used to 
create such a window (Figure 6.4). 
 
Based upon the mass balance for a given Δt 
€ 
x1FΔt − x4FΔt + kaNΔt = 0      (6.21) 
The feed concentration of ammonia is assumed to be 0 
x1 = 0        (6.22) 
Zeng et al, 1998 provided a coefficient of ammonia production to glutamine 
conversion of 0.8. 
€ 
ka =UTR* AGR       (6.23) 
This can thus be related to glucose consumption rate 
€ 
AGR =GGR*0.8      (6.24) 
and substituted into the mass balance, which may be rearranged. 
€ 
x4F +UTR*GGR*0.8*N = 0     (6.25) 
 
€ 
x4 =
UTR*GGR*0.8*N
F      (6.26) 
 
€ 
F ≥ 0.8*UTR*GGR*Nxmin
     (6.27) 
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As a range of values exists for possible consumption rates of glutamine and ammonia 
is a product of its breakdown a number of possible values also exist for the production 
rate of ammonia. 
 
Figure 6.4 Window of operation for ammonia concentration 0-6mmol.L-1 
The minimum feed flow rate required is directly proportional to the cell number within the 
alginate scaffold. This log graph demonstrates the possible feed flow rates for a given cell 
number for a range of glutamine to ammonia conversion ratios. Control action must take place 
at a value equal to or exceeding the curve. 
 
 
The minimum flow rates required to ensure the ammonia concentration is between 0 
and 6mmol.L-1 are much lower than for any of the three other considered metabolites. 
It can be said with reasonable certainty that ammonia can be neglected in terms of the 
eventual overall control strategy, as other metabolites will have to be very far out of 
specification before ammonia exceeds 6mmol.L-1 in concentration. 
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6.5 Combination of metabolic windows of operation 
 
Combining figures 6.1-6.4 provides an overall metabolic window of operation taking 
into account glutamine, glucose, lactate and ammonia concentrations within the bulk 
flow. This window shown in Fig. 6.5 show that the waste products lactate and 
ammonia may be ignored as the flow rates required to ensure they remain within 
acceptable concentration limits are much lower than those required to maintain 
glucose and glutamine.  
 
 
Figure 6.5  Overall metabolic window of operation 
Combination of windows of operation for the two substrates, glucose and glutamine, and the 
two metabolic waste products, ammonia and lactate demonstrates that where glucose is 
controlled the other three will also be controlled indirectly with the exception of low cell 
numbers where glutamine control will be dominated. The error bars shown indicate the range 
of ammonia and glutamine based upon the ranges indicated in figures 6.3 and 6.4. 
 
The flow rate window of operation is dictated by glucose or glutamine concentration 
which itself depends upon cell number as at low concentrations within the scaffold 
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thermal degradation rate of glutamine becomes significant when compared with the 
consumption rate by the mesenchymal stem cells. Figure 6.6 demonstrates that this 
cross over takes place at a very low cell concentration not much higher than that at the 
time of seeding, where the GGR is taken to be 0.35 (the middle of the suggested range, 
Zeng et al (1998), below this cell concentration glutamine dominates and above this 
glucose concentration dominates. For this reason it can be assumed that only glucose 
requires to be controlled to maintain the concentrations of the two substrates: glucose 
and glutamine and the two metabolites: lactate and ammonia. For any minimum flow 
rate to maintain glucose, lactate and ammonia concentrations will be below specified 
limits. 
 
 
Figure 6.6  Glutamine vs. Glucose domination on window of operation 
The importance of considering glutamine control and glucose control only applies at low cell 
cocentrations. When the average ratio of glucose uptake to glutamine uptake is assumed, 
glutamine control is not of concern. Thus, in this work glutamine control is neglected. 
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6.6 Process control 
 
Using the windows of operation process control loops can be set up to control the 
metabolite concentrations within the bulk flow. It has already been determined that if 
glucose is controlled, glutamine, lactate and ammonia concentrations may be 
neglected and assumed to be controlled within specifications. The oxygen was 
considered to be controlled effectively at 0.079mmol.L-1 and not vary on entry to the 
bioreactor.  
 
Work on developing a controller to maintain the oxygen concentration in solution has 
demonstrated that two-step controllers are inappropriate for use within this system as 
due to the delays inherent in the system the response is too slow to prevent large 
oscillations.  For this reason proportional integral (PI) control was tested from the 
outset. Indications were that irrespective of the value assigned to the gain, control of 
this nature was quite unstable.  
 
The solution was to use a gain that was proportional to the cell number estimated by 
the oxygen uptake rate as stated in the previous section and thus varied in time. Gains 
above 2.9 were unstable so the gain was specified as 2.9 divided by the maximum cell 
number to give a gain value of 2.519x10-8 X where X is the estimated cell number 
based upon oxygen consumption rates (outlined in Chapter 3). By dividing the 
maximum stable gain by the maximum cell number, the risk of instability was 
minimised, as the overall gain cannot exceed 2.9. Integral control was estimated at 
0.1*Proportional gain. As with the model of oxygen control in Chapter 4, a model of 
control of substrate concentrations was created in Simulink. This model is outlined in 
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Appendix 2. The results of the controller within the model are shown in Fig. 6.7 and 
6.8. Fig. 6.7 shows that this proportional integral controller leads to good maintenance 
of the glucose concentration. However, there is considerable offset. The associated 
fresh feed rate responsible for controlling this DOT is shown in Fig. 6.8 and has a 
sigmoidal shape. This is expected as the gain varies in a sigmoidal shape due to its 
relation to the estimated cell number. The offset indicates that further tuning of the 
controller is required. Final results were obtained for a controller with a proportional 
gain of 1*10-3 and an integral time of 1*10-5 (see Fig. 6.9 and 6.10). Although the 
response of the system still has offset, increasing the gain further results in instability 
of the type characterised in Fig. 6.11.  
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The strength of this control system at maintaining concentration well within the 
specified boundaries, despite the offset means that attempts to improve this controller 
further will not be made. The next stage in the process will be integrating this 
proportional controller with the Proportional Integral (PI) controller developed in 
Chapter 4 to maintain dissolved oxygen tension.  
 
6.7 Conclusions 
 
The work contained within this chapter has demonstrated that of the four key 
metabolites under consideration, merely controlling one (glucose) with the specified 
boundaries will ensure the other three (lactate, ammonia and glutamine) remain within 
specifications. The only exception to this relationship is at low concentrations close to 
the seeding number 106 cell.ml-1 where glutamine dominates, rather than glucose. 
Given that this only takes place at the outset of the graft development this has been 
neglected. A control model has thus, been created for glucose based on measurement 
of glucose in the exit concentration of the purge stream being compared to a set point 
and the resulting error being processed by a proportional integral (PI) controller.  
 
After early difficulties with the stability of the controller, a solution was found that 
linked an estimated cell number to the gain which changed in time rather than being 
constant. The results of this controller although showing a small offset as is 
characteristic of a proportional controller have sufficient stability that no further 
improvement is needed prior to its unification with the oxygen control model.  
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Chapter 7  Overall Process Control 
 
 
In this chapter a possible technique for integrating the previously developed control 
systems for the dissolved concentrations of three key substrates and two metabolites in 
the process of creating a tissue engineered artery; glucose, glutamine, oxygen, lactate 
and ammonium is presented. Appropriate modifications to inlet conditions are 
performed and an overall strategy is implemented that will maintain the ranges of all 
five compounds within physiological boundaries. 
 
7.1 Introduction 
 
 
In Chapter 4, a control strategy using the flow rate of culture medium within the 
recycle loop was demonstrated that would maintain dissolved oxygen tension within 
the physiological range of mesenchymal stem cells. This control system made no 
consideration of any other parameters within the system with the exception that 
temperature remained constant at the physiological 37oC. All feed substrates and 
metabolites were considered to be in excess and the feed flow rate was maintained as a 
constant. In Chapter 6 a similar approach was taken and the concentration of two key 
substrates and two metabolites was considered, feed components glucose and 
glutamine and their resepective waste products lactate and ammonia. For this control 
system the oxygen concentration was assumed to be controlled at 0.079mmol.L-1. 
Although the model was not constructed independently of oxygen dependence it took 
no account of the effect a variation in oxygen concentration would have on metabolite 
consumption or production. To determine whether the environmental conditions of the 
vascular tissue engineering bioreactor (VTEB) in its current incarnation may be 
effectively controlled these two separate and distinct systems must be combined and 
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integrated to determine if further strategy modifications are necessary. An additional 
window was constructed for pH. The minimum flow rates required by the pH window 
(Chapter 5) are much lower that those required to keep the concentrations of glucose 
and glutamine within specification and can thus be neglected.  
 
7.2 Comparing windows of operation 
 
A window of operation has been derived for the fresh-feed and recycle streams’ flow 
rates so as to maintain a DOT of 0.079mmol.L-1 (see Fig 4.9) at the exit of the 
bioreactor. The fresh feed rates are low due to the absence of oxygen within the 
culture medium; higher flow rates would result in the oxygen concentration falling 
below 0.079mmo.L-1. 
 
Separately Fig. 6.5 provides the lower limit of a window of operation representing the 
minimum permissible feed flow rate for the four feed metabolites against cell number 
for each of the four chemicals.  
 
It is clear from examining these two figures that the two separate control systems, 
developed independently, for oxygen and feed substrates cannot be integrated. The 
fresh feed rates required to maintain the feed substrate concentrations are far in excess 
of the maximum permissible flow rates that will maintain the DOT without violating 
the limits placed upon the recycle loop flow rate by the windows of operation derived 
in Chapter 4. The conclusion must be that the current operating conditions require that 
a decision be made whether either the concentration of oxygen or the feed substrates 
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are controlled within the physiological limits. It is not possible to maintain conditions 
within all specified tolerances hence the operating conditions must be modified. 
 
7.3 Modification of operating conditions 
 
A number of opportunities for modifying the operating conditions exist including 
increasing the limit upon the recycle flow rate, increasing the concentration of the 
substrates within the feed and increasing the dissolved oxygen concentration within 
the feed. 
 
Increasing the permitted range of the recycle rate and thus expanding the window of 
operation is not possible, as stated in Chapter 4 higher shear rates have been shown to 
lead to the formation of osteoblasts, progenitors of bone cells (Portner et al, 2005). 
Formation of such cells would render any tissue-engineered graft useless and thus 
cannot be allowed. 
 
Increasing the concentration of the glucose and glutamine within the feed is a potential 
solution, as lower fresh feed rates would then be required to maintain specified 
tolerances for these substrates. By increasing feed concentration of glucose from 
6mmol.L-1 to 12mmol.L-1 and glutamine from 4mmol.L-1 to 8mmol.L-1 (assuming a 
ratio of glutamine uptake to glucose uptake of 1:0.35 moles) the required feed rate 
drops dramatically (see Fig. 7.1). 
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Figure 7.1 Minimum fresh feed rates required to maintain glucose and 
glutamine concentrations for feed composed of 12mmol.L-1 glucose and 8mmol.L-
1 glucose within specification. 
 
Although these flow rates are not sufficient to allow the maintenance of the dissolved 
oxygen concentration within acceptable parameters (see Fig. 4.9), they do indicate that 
a small concentration adjustment can bring about a change in required feed rate 
equivalent to an order of magnitude. Unfortunately the effect these reduced feed flow 
rates have upon the concentration of one of the waste products, lactate is prohibitive.  
 
Figure 7.2 shows that for the reduced fresh feed flow rates, lactate concentration will 
significantly exceed the specified limit of 3mmol.L-1. Ammonia is unlikely to breach 
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its upper limit of 6mmol.L-1 under these conditions, but potentially could if the ratio of 
glucose uptake rate to the ammonia production rate is high.  
 
 
Figure 7.2 Concentration of lactate and ammonia for decreased feed rates  
Blue represents desired concentration, red represents specified maximum concentration, error 
bars on ammonia represent maximum and minimum ratio for glucose uptake rate to ammonia 
production rate. 
 
Given that the feed rates were not reduced sufficiently to allow oxygen concentration 
to be maintained and the concentration of lactate began to limit, it is clear that 
increasing the concentration of the feed is not sufficient to solve the problem. Any 
method that requires reduction of the fresh feed rate is not appropriate as the 
concentration of the waste products lactate and ammonia will always exceed 
specifications. The curve of feed flow-rate against cell number for lactate shown in 
Fig. 6.2 represents the absolute minimum feed flow rates that may be achieved by 
modulating the concentrations of the fresh feed metabolites. If the concentration of 
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glucose is increased to 8.5mmol.L-1 the minimum flow rates required to maintain 
glucose concentration can be reduced to those required for lactate. Fig. 7.3 shows the 
minimum glutamine concentrations required to allow operation equivalent to the 
lactate window. The error bars represent variation in the ratio of the glucose uptake 
rate to the ammonia production rate. 
 
Figure 7.3 Minimum concentration of glutamine required in the fresh feed  
This concentration ensures fresh feed/purge flow rates that maintain both lactate and 
glutamine within specified levels. 
 
By using a fresh feed composed of 6mmol.L-1 glutamine and 8.5mmol.L-1 glucose 
rather than the originally specified recipe containing 4mmol.L-1 and 6mmol.L-1, the 
trend of minimum values for fresh feed against cell number changes to that shown in 
Fig. 7.4. 
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Figure 7.4 Minimum flow rate required to maintain concentration restraints 
for richer culture medium. 
This curve represents the minimum fresh feed flow rates of the new media composition to 
ensure the two substrates, glucose and glutamine, and the two metabolite, lactate and 
ammonia, remain within specifications. 
 
This new window shown in Fig. 7.4 although sufficient to maintain fresh feed 
metabolites still does not allow for operation of the bioreactor at that will maintain the 
oxygen concentration.  
 
The remaining option to achieve this integrated control is to increase the concentration 
of dissolved oxygen within the fresh feed, this has the advantage of permitting higher 
fresh feed rates that can supply sufficient glucose and glutamine, purge excessive 
ammonia and lactate and not dilute the oxygen concentration below physiological 
limits. By varying the oxygen concentration it is possible to determine what oxygen 
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feed concentration is required to permit operation within the same range of fresh feed 
flow rates specified by the feed metabolite windows of operation. For fresh feed 
containing a range of oxygen concentrations Fig. 7.5 shows the windows of possible 
feed rates for varying recycle rate. 
 
 
Figure 7.5 Windows of Operations (WOOs) relating recycle rate to feed flow 
rate for a variety of oxygen concentration. 
A series of WOOs show how the range of acceptable fresh feed flow rates increases with the 
oxygen concentration of the fresh feed.  
 
 
The Windows of Operation (WOOs) in Fig. 7.5 represent systems where the fresh feed 
stream contains a range of dissolved oxygen tensions. Together, Fig. 7.5 and 7.4 
demonstrate that the fresh feed rate in an integrated system may be controlled in a way 
that maintains both the specified oxygen and feed metabolite concentrations. Table 7.1 
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summarises the changes made in operating conditions to allow an integrated control 
model to be created. 
Table 7.1 Modifications to system operating conditions to allow models 
developed in chapters 4 and 6 to be integrated. 
Changing the properties of the feed stream allows the windows of operation for the substrates 
and oxygen to overlap permitting a unified control system to be developed. 
 
Metabolite 
Previous concentration in 
fresh feed (mmol.L-1) 
Revised concentration in 
fresh feed (mmol.L-1) 
Glutamine 4 6 
Glucose 6 8.5 
Oxygen 0 0.054 
 
 
7.4 Integrated Control Model 
 
 
Using the new operating conditions (see table 7.1) that have been demonstrated to 
allow integrated control, the first stage of creating a unified model is to determine 
which parameters are cross-linked, so that results obtained are truly representative of 
the process system in its entirety. A new Simulink model was created for this 
simulation, combining the models developed in Chapter 4, for oxygen, and in Chapter 
6, for the respiratory metabolites. This combined model is outlined in Appendix 3. 
 
Fig. 7.6 represents the inputs and outputs of the two models and how these should be 
cross-linked to combine the oxygen model (see chapter 4) and the feed metabolite 
model (see chapter 6). The oxygen control loop controls the recycle loop rate to 
maintain the oxygen concentration within the bioreactor and the value this controller 
take within the metabolite system.  
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The fresh feed rate will also affect the recycle rate controller within the oxygen system 
although this effect is indirect as the effect of the feed rate on the dissolved oxygen 
tension (DOT) requires the recycle rate to rise to compensate. The oxygen 
concentration at any time is required by the metabolite control model to determine the 
consumption rate by the cells as the metabolic reactions are all cross-related. 
 
The interaction of these variables requires some new terms to be included within the 
integrated model that were not part of either of the two constituent parts.  
 
This combined model must take account of the interaction of the glucose and oxygen 
consumption, as at any given time either substrate may be responsible for limiting the 
cell growth rate. Equation 7.1 represents the Verhulst equation for cell growth and 
equation 7.2 shows how the growth rate is dependant upon the concentration of a 
limiting substrate, both of these equations were implemented in Chapter 4.  
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€ 
dX
dt = µX 1−
X
Xmax
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟      (7.1) 
Where X is the cell concentration (.ml-1), µ is the specific growth rate (s-1) and Xmax is 
the maximum cell concentration (.ml-1), 
€ 
µ = µmax
S
KS + S
     (7.2) 
Where S is the substrate concentration (mM),  KS is the  half saturation constant for 
the substrate (mmol.L-1), µ is the maximum specific growth rate (s-1). 
 
In a situation where there are two limiting substrates such as in this integrated model 
equation 7.3 applies. 
 
€ 
µ = µmax
CG
KG + CG
* CO2KO2 + CO2
    (7.3) 
 
Where CG is the glucose concentration (mM), KG is the half saturation constant for 
glucose (mM), µ is the maximum specific growth rate (s-1). CO2 is the oxygen 
concentration (mM) and KO2 is he half saturation constant for oxygen. 
 
Zeng et al (1998) stated that the ratio of consumption of glucose to oxygen is 
1mol.mol-1 hence the uptake rates should be equivalent. 
 
Equation 7.3 has been implemented within the unified model to simultaneously model 
the effect of glucose and oxygen concentrations on the cell growth rate. A further term 
is included in the integrated model to acknowledge that it is not possible to pre-gas the 
media with oxygen to a high accuracy. This variation in accuracy introduces noise into 
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the system and was represented within the integrated model by a term for random 
variation in oxygen concentration between 0.044 and 0.064mmol.L-1 (the desired 
value is 0.054mmol.L-1).  
 
Testing the unified model including these new terms provides the control trends for 
the recycle loop flow rate and fresh feed rate and the measured values of oxygen and 
glucose are shown in Fig. 7.7-7.10. These figures show that the changes in the 
operating conditions have been sufficient to allow both systems to work in unison 
without further tuning being required. The unified model of the bioreactor has 
successfully demonstrated that both the glucose and the oxygen concentration in 
solution may be controlled by modulated changes in the feed and recycle loop flow 
rates. 
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7.5 Conclusions 
The aim of this chapter was to bring together the separate models derived for oxygen, 
substrates and waste products and pH. Earlier work has shown that lactate, glutamine 
and ammonia could be neglected where glucose was controlled successfully and the 
same was also true for pH. This meant that the final unified system was only required 
to maintain control of two substrates, oxygen and glucose.  
 
The windows of operation developed for these two substrates in earlier chapters were 
shown to be incompatible and changes in the operating conditions were required to 
overcome this. The feed concentrations of oxygen, glucose and glutamine were 
increased. These increases enabled the creation of a window within which all five 
substrates could be controlled within specified ranges. 
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Control was possible with the two systems unified as shown in Fig. 7.6 and the results 
in Fig. 7.7 - 7.10 show that although there are oscillations within the system glucose 
and oxygen concentrations are broadly controlled.  Given the complex inter- 
relationship between all the parameters this must be considered a successful outcome. 
A unified model for the control of a bioreactor containing cells developing into the 
first stage of a tissue engineered bypass graft has been proposed.  
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Chapter 8  Conclusions and Further Work 
 
 
A model for the control of a bioreactor system designed to produce tissue engineered 
arterial grafts has been developed in this work. The model has been used to control the 
oxygen, substrate and waste levels within the system. 
 
8.1 Bioreactor system 
 
Using a combination of scientific literary sources and empirical data, a model was 
developed to describe the dynamics of the bioreactor system. 
 
The model was divided into subsystems: oxygenator, bioreactor, recycle loop, feed 
and purge. These subsystems were subsequently integrated together. This unification 
provided a representation of the dynamic system suitable for modelling changes in the 
dissolved concentrations of substrates and waste products and was suitable for 
determining the possibilities for environmental control. 
 
One of the key issues with the design of the bioreactor system was an inability to 
determine cell number online for any given time. This coupled with the variability of 
the oxygen uptake rate depending upon cell density provided a considerable obstacle 
to predicting the cell number in real time. 
 
Yeast cells which grew rapidly compared with mammalian cells were utilised as an 
example of a eukaryote cell to determine how oxygen uptake rate decreases as the cell 
density increases and how oxygen uptake rate is related to the cell number in this 
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work. This relationship provided crucial information for the control of the bioreactor 
system. This had the secondary benefit of allowing cell number to be estimated online 
from the oxygen consumption rate. Estimation of cell number online allows the health 
of the graft to be estimated. If oxygen uptake rate falls unexpectedly potential 
problems with the graft may be detected. Delivery time of a developing artery may 
also be determined, this allows scheduling of surgery for a recipient of the graft. 
 
8.2 Dissolved oxygen tension (DOT) process control 
 
Control of the flow rate within the recycle loop, containing the membrane oxygenator, 
was utilised to maintain oxygen tension within the alginate scaffold. Oxygen tension 
was maintained at a value analogous to the in-vivo concentration within the bone 
marrow regions where mesenchymal stem cells may be isolated. 
 
A computational fluid dynamics (CFD) software package was used to determine the 
minimum flow rate within the recycle loop to ensure that the oxygen tension within 
the scaffold remained at physiological concentrations. This minimum flow rate varied 
with cell number and increased as the graft developed, at any given time it represented 
the minimum possible rate at which the controller could instruct the recycle rate to 
operate. 
 
A window of operation for the bioreactor was formed using this minimum flow rate 
coupled with shear stress limitations. This window provided the maximum and 
minimum flow rates that could be implemented by the controller. The simplest form of 
controller, the two-step, was insufficient for maintenance of DOT. Thus, a 
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Proportional and Integral (PI) controller was investigated using the software package, 
Simulink. For the development of these controllers it was assumed that all other 
substrates were in excess and oxygen was the only limiting factor. A transfer function 
was formed using a mass balance and linearisation of the non-linear terms to describe 
the input-output relationship between the recycle flow rate and the oxygen 
concentration at the exit of the bioreactor. This transfer function provided a first 
approximation of the system and by using online Ziegler-Nichols techniques and 
finally trial and error the PI controller’s parameters were selected. This control was 
capable of ensuring DOT remained within a physiological range. Thus, it is 
demonstrated that recycle loop control is sufficient to control DOT when oxygen is the 
only variable requiring control. 
 
8.3 Metabolic compound process control 
 
Key substrates within the cell culture medium were identified as glucose and 
glutamine. The key waste products were the by-products of their breakdown, lactate 
and ammonia. Approximate relationships between these four components of cellular 
metabolism were obtained from Zeng et al (1998). The fresh feed flow rate was 
chosen as the control parameter for maintenance of the four components. Windows of 
Operation were determined for each component using similar methods to those used 
for the control of the oxygen concentration. The combination of the four resultant 
Windows of Operation demonstrated that, with the exception of at very low cell 
numbers, glucose control would simultaneously ensure that glutamine, lactate and 
ammonia would also be controlled appropriately. Under the assumption that oxygen 
was controlled at a constant level of 0.079mmol.L-1, a gain that incorporated a term for 
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cell number was used. A proportional controller was used to achieve glucose control. 
Cell number was estimated using the model for cell growth. Dissolved oxygen tension 
was maintained constant at 0.079mmol.L-1. The output from the cell growth model fed 
directly into the proportional controller. Changes in the cell growth model output led 
to a change in the value of the controller gain as the graft developed and allowed 
superior control to be achieved. 
 
Simulations were performed using Simulink and it was demonstrated that it is viable 
to use control of the fresh feed flow rate by proportional control to maintain glucose 
within specified boundaries and thus, also the glucose, glutamine, and lactate 
concentrations when the oxygen concentration is maintained at 0.079mmol.L-1. 
 
8.4 Overall system control model 
 
Combining the oxygen and metabolite models without prior modification was not 
possible. The fresh feed flow rates required by the metabolic control system, 
particularly at higher cell numbers, required recycle rates far in excess of those 
permitted by the Window of Operation for the dissolved oxygen concentration. The 
solution was to use pre-gassed rather than sparged fresh medium and also to increase 
feed concentrations of glucose and glutamine. The oxygen concentration selected was 
0.054mmol.L-1. However a lack of possible accuracy in the gassing of cell culture 
media ensures that there would be considerable variation and as such a term was 
included within the model to set the value randomly within the range 0.044-
0.064mmol.L-1. This variation introduced noise into the system but did not prevent 
successful control of the dissolved oxygen by the PI controller. Glucose and glutamine 
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concentrations within the fresh feed were increased from 4 to 6 and 6 to 8.5 mmol.L-1, 
respectively. Combination of the two models, with these new parameters, permitted 
simultaneous control of the concentrations of glucose, glutamine, lactate, ammonia 
and oxygen.   
 
Although this model has demonstrated a possible theoretical strategy for the control of 
a number of environmental parameters within a tissue engineering bioreactor, the 
solution is far from comprehensive. This model contains a number of limitations. It is 
based upon a set obtained from empirical data and peer reviewed literature and it 
involves a number of assumptions. Stem cell biology remains in its infancy, since 
tissue engineering was first coined as a phrase, only very simple materials, such as 
skin, have been approved by the US FDA (Food and Drug Administration) for use as a 
treatment in humans. The exact definitions of stem cell sub-populations, such as 
mesenchymal stem cells (MSC), remain controversial and the methods used to isolate 
such populations are ill defined and require much further development. This lack of 
definition ensures that assumed values for metabolic and growth rates of such cells are 
merely estimates and are subject to revision as the field advances. However, the 
shortage of viable alternatives that are capable of matching the effectiveness of the 
organs and tissues that we are born with, ensure that this field will move forwards. To 
achieve the production scale of tissues and organs required to meet the demand of an 
ageing population demands that methods of production be considered in parallel as the 
biological knowledge advances. Tissue engineered material designed for use in human 
patients will need to be produced in a regulated, controlled and replicable manner. 
This type of process will be demanded by government regulatory agencies to ensure 
the safety of patients. It is thus, vital that control engineering is explored within the 
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context of tissue engineering and this thesis provides a first step. Concerns of scale 
have been considered and methods that provide solutions to these problems have been 
explored. A solution to controlling a number of biological parameters within a 
bioreactor for the development of a tissue engineered blood vessel has been 
demonstrated. 
 
8.5 Future Work 
 
As a first step this body of work provides numerous opportunities for further work and 
investigation. One key area is how process control can be designed to accommodate 
changes in cellular metabolic demand as immature cell types differentiate into more 
mature cell types. Environmental conditions responsible for causing stem cell 
populations to differentiate down particular pathways require much further research 
before this will be possible. However once the biology is better understood, the 
creation of sophisticated mathematical models will be possible. Such models, likely 
based around non-linear dynamics and population modelling, will provide powerful 
tools for the development of a wide variety of control systems that can both drive 
development of tissues and organs and allow their healthy development prior to 
implantation within patients. Ultimately bioreactors for use in tissue engineering are 
likely to have two distinct stages of production. In the case of a tissue engineered 
blood vessel, the first will be the proliferation of an immature cell type such as MSC 
throughout the scaffold, allowing the initial formation of a tube structure. It is a 
control system for this stage, that this thesis has focused upon. The second stage will 
expose the MSC cells to controlled environmental conditions that encourage the 
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conditions that lead to the development of a healthy artery composed of three distinct 
layers of connective tissue, muscle, and a lining of endothelial cells. 
 
For the development of a control system used within this thesis many of the required 
values have been obtained from literature in good faith and are normally founded upon 
in-vivo conditions. Further research is required to determine if in-vivo conditions are 
indeed truly the most appropriate.  
 
With regard to the design of the vascular tissue engineering bioreactor (VTEB) used 
within this work, it requires further improvement before it can become an effective 
method of producing tissue engineered arterial grafts. Sterility remains a large issue, 
the use of antibiotics being unsuitable to tissue engineered materials due to the risk of 
allergic or idiosyncratic responses, the masking of cryptic infections that can become 
resistant later and because of possible effects upon cell growth and/or proliferation. 
Full automation of the system requires incorporation of steps such as cell handling and 
tube extrusion although such concerns remain low priority for the foreseeable future. 
 
The work performed in this thesis demonstrates the possibility and the complexities in 
developing environmental control of bioreactors used for tissue engineering. As a 
greater understanding of the biology of stem cells is attained the control methods 
discussed here may be implemented to allow the production of arterial grafts for use in 
the treatment of a variety of medical conditions. The advancement of stem cell biology 
will allow tissue engineering and cell therapy to realise the hope of curing underlying 
disease rather than merely treating the symptoms. 
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Appendices 
These Appendices include the Simulink models used to produce the results presented 
and discussed within the main thesis. Appendix 1 incorporates the two levels of the 
model used to develop oxygen control for the bioreactor (See chapter 4). Appendix 2 
incorporates the two levels of the model used to develop substrate control for the 
bioreactor (see chapter 6). Finally, Appendix 3 shows how these two models interacted 
to model the overall control system developed for the bioreactor (see Chapter 7). 
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